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ABSTRACT 
 
Cancer is a growing health concern world-wide and is the second most common cause of 
death after heart diseases. Current treatment strategies such as surgery, chemotherapy 
and radiation provide some relief to cancer patients but the toxic side effects associated 
with chemotherapy and radiation often lead to further adverse health effects. Hence there 
is a need for drugs with better safety profile and improved efficacy. 
 
Cannabinoids are a group of compounds with several therapeutic properties and besides 
their appetite stimulant, anti-emetic and analgesic effects, cannabinoids can inhibit 
tumor growth, survival and metastasis. The mechanisms of action of cannabinoids as 
anticancer agents are highly complex and not completely understood. Studies from our 
laboratory indicate that the specificity protein (Sp) transcription factors, Sp1, Sp3 and 
Sp4 that belong to the Sp/KLF family of transcription factors are overexpressed in many 
tumors and regulate critical factors responsible for cancer cell proliferation, growth, 
angiogenesis and survival. Hence, we hypothesized that cannabinoids elicit their 
responses on cancer cells by downregulating the expression of Sp proteins and Sp-
regulated gene products. Treatment of colon and prostate cancer cells with the 
cannabinoids WIN and cannabidiol (CBD) inhibited cancer cell proliferation, induced 
apoptosis and downregulated Sp proteins and Sp-dependent genes. Furthermore, we 
demonstrated that WIN and CBD-mediated induction of apoptosis and repression of Sp 
proteins were mediated by phosphatases and that the phosphatase involved in WIN-
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dependent downregulation of Sp proteins was protein phosphatase 2A (PP2a). In 
addition WIN induced expression of ZBTB-10, an Sp repressor and downregulated 
microRNA-27a (miR27a) and these effects were PP2a-dependent indicating that WIN 
transcriptionally represses Sp protein expression by activating the phosphatase, PP2a. 
 
We also investigated the effects of 1,1-bis(3'-indolyl)-1-(p-bromophenyl)methane (DIM-
C-pPhBr) and the 2,2'-dimethyl analog (2,2'-diMeDIM-C-pPhBr), on survivin 
expression in colon and pancreatic cancer cells. Survivin is an anti-apoptotic protein 
associated with cancer cell survival and confers radiation-resistance in patients receiving 
radiotherapy. In addition radiation induces survivin, leading to radioresistance in tumors.  
In this study we demonstrated that DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr inhibit 
cell proliferation and induce apoptosis in colon and pancreatic cancer cells and in 
combination with radiotherapy, these drugs suppress radioresistance by inhibiting 
radiation induced survivin.  
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CHAPTER I  
INTRODUCTION 
 
CANCER A HISTORICAL PERSPECTIVE 
Paleo-oncological studies have revealed cancers in several prehistoric animals that 
existed before man (1). The first evidence of cancer (chondrosarcoma) was found in 
Utah in the fossilized remains of a theropod dinosaur (Allosaurus fragilis) from the 
Jurassic epochs (1, 2). Several ancient scriptures and manuscripts provide sufficient 
evidence to suggest that man had a basic knowledge of cancer at least 5000 years ago, 
although it was never recognized as a distinct disease entity until recently (1). Edwin 
Smith Papyrus, an ancient Egyptian medical text, which dates back to 3000 BC, contains 
one of the earliest mentions of cancers of the head and breast, which are described as 
bulging growths with no known remedy (3, 4). Another medical manuscript that records 
soft-tissue tumors and osteolytic lesions of the metastatic cancer in humans is the Ebers 
Papyrus written in 1500 BC (Figure 1) (4, 5). Susrutha Samhitā, one of the foundational 
works of Indian medicine (Ayurveda) records tumors affecting various parts of the body 
and discusses the pathogenesis and management of these conditions (6). The Babylonian 
Talmud (central text of mainstream Judaism) mentions a 7 year headache that Titus 
suffered as a curse for destroying the temple of Jerusalem, which eventually after an 
autopsy was found to be due to a tumor in the brain (possibly a meningioma or 
hemangioma) (1, 7).  
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Although ancient manuscripts provide descriptive evidence of this long existent disease, 
there is no mention of the term cancer in any of these available medical documents. It 
was the Greek physician Hippocrates (460-370 BC), the father of medicine who used the 
term “karkinos”, the Greek word for crab to describe the growths found in patients that 
he examined (1). It was speculated that the tough surface of the tumor resembling the 
hard shell of the crab or the shape of the tumor with the blood vessels around it 
resembling a crab with claws could be the reason why he chose the term. The term 
“karkinos” was later translated to “cancer” derived from the Latin word “cancrum” 
meaning crab by the Roman encyclopaedist Aulus Cornelius Celsus (ca 25 BC - ca 50) 
(3, 8). The term “oncology” which is used to describe the branch of medicine which 
deals with the study of the development, diagnosis and treatment of cancer, is derived 
from the Greek word “onkos” meaning bulk mass or tumor growth and “logy” meaning 
study, and its coinage is credited to the Roman physician Claudius Galen (130-200 AD) 
(9). Galen is also known to have coined the word “sarcoma” which was used to refer to 
tumors with a “fleshy” appearance in cross-section (3, 10). 
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Figure 1.The Egyptian medical texts Edwin and Ebers papyri. 
 
 
“What causes cancer?”- It is a question that has baffled physicians since the beginning of 
time. Several theories were put forth to explain the etiology of cancer. In ancient Egypt 
where magic and religion dominated medical practices, the cause of cancer was 
attributed to evil gods and demons and any disease was believed to be a consequence of 
“the will of the Gods” (3, 11). The classical period or the Greco-Roman era (500 BCE – 
500 CE) witnessed a shift in the approach to understanding the cause of a disease. The 
influence of religion and the occult declined and made way for a naturalistic 
understanding of the pathology of illness (12). The humoral theory of disease proposed 
by Hippocrates suggested that an imbalance in the levels of 4 humors (body fluids) 
namely phlegm, blood, bile and urine caused diseases, with an excess of black bile being 
responsible for cancer. Galen who was a patron of the humoral theory performed 
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anatomical experiments on animals and classified tumors into different types (10, 13).   
The humoral theory prevailed for over 1300 years until the Renaissance, when the works 
of Andreas Vesalius (1514-1564) and Theophrastus Paracelsus (1493-1541), undermined 
the long existent Galenic principles of humoral theory. The humoral theory was 
superseded by the lymph theory proposed by the French physician René Descartes 
(1596-1650), who stated that cancer was the result of degenerating and fermenting 
lymph. The Age of Rationalism, brought in new proponents of the lymph theory such as 
Henry François le Dran (1685-1770), who further elaborated that tumors grew in 
localized areas and then spread to different parts of the body via the lymphatic system 
(3).  
 
The eighteenth century marked the beginning of cancer epidemiology with physicians 
forming links between occupational and lifestyle choices and the occurrence of cancer. 
Bernardini Ramazzini documented an increase in the incidence of breast cancer and 
lower rates of cervical cancer in nuns (14). Snuff users’ predisposition to developing 
nasal cancer observed by the English physician John Hill (1714-1775) is considered to 
be the first acknowledgement of carcinogenesis induced by external factors (15) while 
the first documented case of occupational cancer was recorded by Percival Pott (1714-
1788), who observed an increased incidence of scrotal cancer in chimney-sweeps (3, 16). 
With the Roman law prohibiting human dissection owing to religious reasons, the field 
of cancer pathology suffered severely until the eighteenth century. A lift on this ban 
initiated a new dawn in the field cancer research. Giovanni Battista Morgagni (1682-
 5 
 
1771) gave birth to the field of scientific oncology with his compilations of 700 
autopsies describing different cancers in his publication “On the Sites and Causes of 
Disease”. His efforts and findings disproved the Cartesian lymph theory (17, 18) and led 
to the establishment of the first cancer hospital, LaLutte Contre Le Cancer, in Rheims, 
France, and the first cancer institute in Middlesex, England (19).   
 
Cancer began to be recognized as an independent disease with its own symptoms and 
treatment.  With the invention of the light microscope by H. Jansen during the 19th 
century, scientists switched their focus to cells (20). The German physiologist Johannes 
Müller (1801-1858), was one of the first individuals to visualize cancerous tissue under 
the microscope and confirmed that cancer was not made up of lymph or black bile but 
instead was composed of cells. However, Müller erroneously proposed that cancer cells 
did not arise from normal cells and instead were a result of plastic exudates or budding 
elements called blastema in between normal cells (1, 3, 21).  Later it was Muller’s 
student Rudolf Virchow (1821-1902) who discovered that cancer cells and normal cells 
arose from the same source. Virchow popularized the maxim Omnis cellula e cellula 
("every cell originates from another existing cell like it.") thus disproving the blastema 
theory (22, 23). He also speculated that tumors formed either due to hereditary 
predisposition or by chronic irritation (17). His theory of cancer spreading by a liquid 
was disproven in 1865 by the German surgeon, Karl Theirsch (1822-1925), who 
hypothesized that cancer cells reached secondary sites by cellular embolism. He studied 
metastasizing epithelial tumors of skin with the help of serial sectioning techniques and 
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established that malignant cells were ultimately responsible for the spread of the disease 
(24).  
 
The foundation for the modern classification of tumors was laid due to the work of 
Muller, Virchow and Karl von Rokitansky (1804-1878). Rokitansky identified the two 
components of cancer, the parenchyma forming the cancer mass composed of cancer 
cells and the stroma that formed the supportive framework composed of connective 
tissue. This later formed the basis for classification of tumors into different types 
(epithelial or mesenchymal, benign or malignant) (25). During the late 19th century, the 
works of Robert Koch and Louis Pasteur brought to light a number of infectious agents 
that were responsible for a variety of diseases. The advocates of the infectious theory 
believed that cancer was also an infectious disease. Experiments were conducted in 
Russia, wherein tumors were surgically transplanted from one dog to another. The 
appearance of tumors in the latter after several weeks fueled the idea that cancer was 
infectious and transmissible (26). Similar experiments were conducted by two Danish 
researchers in 1908 using chicken leukemia cells. Their work was later followed up by 
Peyton Rous in 1910, whose experiments led to the discovery of the chicken Rous-
sarcoma virus and laid the foundations for the field of tumor virology (24). Although, 
the infectious theory of cancer began to fade away with no evidence of tumors spreading 
through viruses in humans (with few exceptions), the initial discoveries of Rous and 
Howard Temin led to the understanding of the genetic nature of the disease. The works 
of these two researchers were critical in unveiling the role of certain genes that were 
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responsible for the cancerous phenotype, and these cancer causing genes later came to be 
known as “oncogenes”. The concept of genes promoting growth of cells stimulated 
speculation on the existence of genes that could inhibit the growth of cells as well, to 
balance the biological system (27). This hypothesis was confirmed by Stephen Friend in 
1986, when he isolated the first “tumor suppressor” gene, Rb (retinoblastoma), 
associated with a familial form of eye cancer (28). 
 
The long and tortuous route towards understanding cancer often involved long 
deviations and frequent mis-steps that in hindsight appear misguided or even far-fetched. 
However, as a wise man once said, “We can see so far because we stand on the shoulder 
of giants”. 
 
CANCER STATISTICS AND GLOBAL HEALTH 
Cancer is a global health problem and it is estimated that one in eight deaths worldwide 
are caused by cancer which is higher than deaths from infectious diseases, AIDS, 
tuberculosis and malaria combined. The World Cancer Report of 2008 documents 12.6 
million cases of cancer, 7.5 million mortalities from cancer and 28 million individuals 
alive with cancer within five years from the initial diagnosis (29). The most frequently 
diagnosed and preeminent cause of deaths from cancer in both developed and 
developing countries are lung cancer in males and breast cancer in females. Prostate, 
colorectal, stomach and bladder cancer in men and colorectal, corpus uteri and ovarian 
cancers in women are the more frequently diagnosed cancers in developed nations. 
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Prostate cancer is observed to be the most frequently diagnosed cancer in men in the 
developed regions of the world with an incident rate of 21.7 %. This was followed by 
lung and colorectal cancer with 16.2 % and 13.2 % incident rates respectively. Lung 
cancer however has the highest mortality rate (26.9%) in men from the developed 
regions of the world. Colorectal and prostate cancers have a mortality rate of 10.9 % and 
8.9 % respectively and stomach and bladder cancer have similar incidence rates in men 
however the mortality rate of stomach cancer is higher than bladder cancer (Figure 2). 
Women from economically more developed regions exhibit a higher incidence (26.7%) 
and mortality rate (15.5%) of breast cancer. The incidence rate of colorectal cancer in 
women is similar to the rates found in men from developed countries and the number of 
deaths caused due to lung cancer is almost equal to that of breast cancer in women from 
the developed nations (Figure 3).  
 
It is estimated that less developed nations contributed over 50% of the cases of cancer in 
2008 and two thirds of the cancer related deaths world-wide occur in less developed 
nations (29). Men in the less developed nations are commonly affected by cancers of the 
stomach, liver, colorectum, prostate and esophagus, while women exhibit increased 
incidence of cancers of the cervix uteri, stomach, colorectum and liver. Lung cancer 
represents 16.8% of all cancers in men but only 7.9% of all cancers in woman in less 
developed countries. Breast cancer and cancer of the cervix uteri are high in women 
from the economically less developed nations and constitute 20.0 % and 13.1% of all 
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cancer cases respectively. The mortality rates of breast, cervix uteri and lung cancer in 
women are all approximately 11.8 % (30).  
 
 
 
Figure 2. Total number of cancer cases and cancer mortality in men worldwide (30) 
 
 
COLON CANCER 
Colorectal cancer is the third most diagnosed cancer in men and second most frequently 
observed cancer in women worldwide according to the IARC report of 2008 (29-31). 
Over 1 million cases of colon cancer were diagnosed across the globe in the year 2008  
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Figure 3. Total number of cancer cases and mortality in women worldwide (30) 
 
 
and the number of deaths due to colorectal cancer is estimated to be more than half a 
million. This accounts for 8% of all cancer deaths, making it the fourth most leading 
cause of cancer death. Colon cancer incidence is higher in the more developed countries 
with 0.7 million cases compared to the less developed nations with 0.5 million cases in 
2008 (30). Although, the prevalence rates for colorectal cancer are higher in individuals 
from the developed and industrialized nations, western lifestyles in less developed 
countries are resulting in increasing incidence rates (32). Individuals that migrate to an 
industrialized country with high incidence of colon cancer exhibit higher incidence rates 
compared to individuals residing in their native countries (33).  
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Colon cancer incidence is high in Australia, New Zealand, Europe and North America in 
both men and women, whereas the incidence is lower in Central, Northern, Eastern, 
South-Central and Middle African countries (Figure 4) (30, 31). International trends in 
incidence rate of colorectal cancer were examined by Center et. al. based on the 
Globocan 2008 report from IARC. Countries such as Slovenia, Slovakia and the Czech 
Republic exhibited the highest increase in colorectal cancer incidence from 1983-87 to 
1998-2002 with more than 45% increase in men and 25% in women (34). This increase 
is attributed to the high prevalence of obesity owing to the increased availability and 
consumption of food products due to an improved economy and diets high in fat and low 
in fiber (35). Obesity coupled with increased exposure to tobacco (evident from high 
incidence of lung cancer) is thought to contribute to the increased rate of colorectal 
cancer in men in these parts of Europe (34, 36). 
 
In Spain there was an, 87% increase in colon cancer rates in men and 35% increase in 
women and these increases also correlated with increased westernization in Spain which 
was delayed until the mid-1970s (34). Among other developed nations, Japan recorded a 
large increase in the incidence rate (>90%) of colorectal cancer during the past several 
decades in males and the fecal occult blood test for screening colorectal cancer that was 
implemented during the 1990s in Japan is believed to be a reason for the increase in the 
incidence rates (37, 38). In addition, an increase in obesity due to higher intakes of fat-
rich food also contributed to the increase in colorectal cancer in Japan (34, 39, 40).  
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Figure 4. Colorectal cancer cases and cancer mortality worldwide in 2008 (30) 
 
 
Two countries that shared changes in colorectal cancer incidence rates due to the ethnic 
and cultural differences in their populations were Singapore and Israel. Jews and non-
Jews that comprise the Israeli population exhibited differences in the incidence of colon 
cancer due to a combination of environmental and genetic factors. Westernized lifestyle 
and other high risk factors such as genetic mutations resulting in the Lynch syndrome 
(HNPCC) increases colorectal cancer rates in Jews compared to non-Jews (34, 41) . In 
contrast, non-Jews in Israel, the majority of whom are Arabs practice a traditional 
lifestyle with a diet rich in fruits, vegetables and olive oil have a lower incidence of 
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colon cancer compared to Jews (42). The lowest rate (per 100,000 individuals) of colon 
cancer in the world was observed in India with an average of 5.8 and 4.35 in males and 
females respectively from 1998-2002, however recent trends indicates a slow rise in the 
rates of colon cancer (30).  
 
The only countries that showed an exception to the increase in cancer incidence were the 
United States, Canada and New Zealand. There was a statistically significant decrease in 
the incidence of colon cancer in US men and women according to the nine SEER 
registries and similarly there was a decrease in the incidence rate in women from Canada 
and New Zealand. Canada and New Zealand showed stable incidence rates for colorectal 
cancer in men from 1983-87 to 1998-2002 (30, 34).  
 
Besides the influence of diet and lifestyle choices, colorectal cancer screening can also 
contribute to the variation in the rates observed worldwide. Previously undetected cases 
can be diagnosed with the implementation of stool blood tests such as fecal occult blood 
test and other invasive screening tests like sigmoidoscopy and colonoscopy and this 
elevates the incidence rate. However, removal of precancerous polyps detected by 
colonoscopy can also decrease the number of colon cancer cases and this may explain 
the drop in the colon cancer rates in the US. However, in Canada and New Zealand 
national guidelines recommending colorectal cancer screening had been introduced only 
recently and due to lower screening rates its influence on the low cancer incidence is 
minimal (43-45). 
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Diet and Colon Cancer 
Risk factors for colon cancer include obesity, increased alcohol intake, smoking, 
increased consumption of red meat, processed meats, highly refined grains, starch and 
low intakes of fruits and vegetables. The consumption of white meat such as poultry and 
fish, plant-based food sources of protein, substitution of saturated with unsaturated fats 
and incorporating legumes, sugars and unrefined grains as the major source of 
carbohydrates are known to reduce the risk of colon cancer (34, 46).  
 
Fiber 
The debate surrounding the fiber content in the diet and its role in reducing the risk of 
colon cancer has been in existence since the proposal of the dietary fiber theory by Denis 
Parsons Burkitt. According to Burkitt, the low incidence of colon cancer in certain 
African nations compared to western countries was due to the high content of fiber in 
their diet (46, 47). Fiber has multiple effects on the human colon such as increased fecal 
weight, which has been proposed to have an inverse relationship with colon cancer 
incidence (48). However, several studies comparing populations with similar fecal bulk 
and intestinal transit time have shown a difference in the incidence of colon cancer (48). 
In addition some studies show similar colon cancer incidence rates in populations with 
differences in stool weight and intestinal transit (49, 50). Fiber in the diet alters the 
metabolism of bile acids and increased concentration of bile acids in the feces are 
consistently observed in populations with high incidence of colon cancer (48, 51). The 
pH of the colon also contributes to colon carcinogenesis, with a low pH favoring 
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decreased development of colon cancer (52). Butyric acid (short-chain fatty acid), a 
degradation product of dietary fiber is one of the key anions contributing to a low pH 
environment of the colon. Butyrate is known to play a crucial role in controlling cell 
growth, suppressing DNA synthesis and reversing virus-induced cellular differentiation 
in vitro. Hence, butyrate may be essential for maintaining normal colonic mucosa and 
inhibiting transformation (48, 53, 54). The relationship between high dietary fiber and 
colon cancer has been examined in several case controlled and cohort studies. Although 
most case-control studies indicate a strong inverse correlation between intake of 
vegetables, fruits and fiber and risk of colorectal cancer, prospective cohort studies do 
not show that a high fiber diet protects against colon cancer. The inconsistencies 
between results from case-control and prospective cohort studies are unclear. However, 
according to Chan et. al. (46) cancer patients in case control studies are likely to recall 
unhealthy dietary behaviors since the information is collected after diagnosis of cancer 
and this can increase the chance of bias. A recent survey of 10 European populations 
showed that there was a 40% decrease in the risk of colorectal cancer in individuals with 
diets high in fiber, vegetables and fruits. This disparity may also be due to differences in 
levels of other nutrients in the diet such as folate, which has anti-cancer properties. 
High-fiber fruits and vegetables are the major source of folates in the European diet 
whereas folate-fortified flour and breakfast cereal are major sources in the US and 
consumption of large quantities of high-fiber fruits and vegetables may not prevent 
colorectal cancers in the US since the food products are already enriched with nutrients 
such as folates and other protective dietary factors (46). 
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Red Meat 
Red meat is another dietary risk factor that has been associated with colorectal cancer. 
Most epidemiological studies show a clear association between increased risk of 
colorectal cancer and high intake of red meat (55-62). However, some studies do not 
show this correlation (63-65). Several theories have been postulated to explain the 
poorly understood association between red meat consumption and colorectal cancer. Red 
meat is believed to stimulate the secretion of the hormone insulin, which in turn binds to 
insulin receptors and insulin-like growth factor 1 (IGF-1) receptors to increase cell 
proliferation and inhibit apoptosis (66). Fat present in red meat is also hypothesized to 
contribute to colorectal carcinogenesis and studies in humans and laboratory animals 
show that high fat diets increase bile acid excretion (67-69). Experiments in rat and 
mouse models suggest that bile acids function as tumor promoters by increasing turnover 
of intestinal mucosal cells (55, 70-72). In addition, dietary fat also plays a role in 
modifying the intestinal microflora leading to transformation of bile acids into potential 
carcinogenic substances (69, 73). High levels of iron stores is thought to be a cancer risk 
factor in Western populations and heme iron is present in significant quantities in red 
meat and promotes growth of transformed cells and increases DNA damage by acting as 
a pro-oxidant and generating oxidative stress in cells (74, 75). Several studies have also 
examined the relationship between colorectal cancer risk and cooking of meat. 
Consumption of meat cooked at high temperatures for long durations leading to heavy 
browning of the surface of the meat increases the risk of colorectal cancer (76). Meat 
that is subjected to high temperatures generates mutagenic heterocyclic amines (HCA) 
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from creatinine, which are subsequently metabolized to N-hydroxylamines. These 
metabolites are further metabolized into N-OH esters by acetyltransferases and 
sulfonyltransferases which form DNA adducts primarily at guanine bases (77). Studies 
investigating the interactions between meat consumption, cooking (i.e. degree of 
“doneness” and genetic polymorphisms that affect the metabolism of these HCAs have 
shown an association between these carcinogens and colorectal neoplasia (78-80). In one 
such study women with genotypes that caused rapid acetylation of meat-related 
carcinogens had a higher risk of colorectal cancer with increased red meat intake in 
comparison to women who consumed large amounts of red meat and had a genotype 
associated with slower acetylation of meat-related HCAs (81). Avoiding the 
consumption of meat cooked at high temperatures for long durations and substituting red 
meat in the diet with alternative protein sources such as fish or poultry are effective 
means of reducing the risk of colon cancer (46).  
 
Calcium 
Calcium intake is hypothesized to be advantageous for reducing the risk of colon cancer. 
Dietary calcium is believed to form insoluble calcium soaps with toxic secondary bile 
acids and free ionized fatty acids in the lumen of the colon, thereby protecting the colon 
cells against their toxic effects (82). Calcium also plays a more direct role in reducing 
the risk of colorectal cancer by inhibiting proliferation and inducing apoptosis in colon 
cells (83, 84). Analysis of colon cancer cases from various studies evaluating the effects 
of dietary calcium suggests a decrease in the risk of distal colon but not proximal colon 
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cancer and most of the protective effects were seen with an intake of calcium within the 
range of 700-800 mg/day (85).  
 
Vitamin D 
Besides calcium, several studies have recorded the benefits of Vitamin D as an anti-
proliferative, anti-angiogenic and pro-apoptotic agent in colon cancer cells (83, 86, 87). 
Results from a placebo-controlled randomized clinical trial indicate that the protective 
effects of calcium were observed entirely in individuals with high levels of 25-hydroxy-
vitamin D in their circulation. This suggests that calcium supplementation and vitamin D 
levels act in conjunction and not separately in reducing the risk of colon cancer (88).  
 
Vitamin B9 (Folic acid) 
B vitamins are essential components of the diet that affect processes such as DNA 
synthesis repair and methylation. Of all the B vitamins, folate has been the most studied 
in respect to the risk of colon cancer (46). Chronic folate deficiency is thought to result 
in hypomethylation of p53 and also DNA strand breaks of the p53 tumor suppressor 
gene, all of which can predispose a person to colon cancer (89, 90). A large prospective 
cohort study of women examining the effects of dietary folate on colorectal cancer 
showed decreased p53 mutations in subjects consuming 300-399 µg/day of folate; the 
beneficial effects of folate were not observed in women with tumors overexpressing 
wild-type p53 (91). Levels of folate and alcohol intake have also been associated with 
the enzyme methylenetetrahydrofolate reductase (MTHFR). MTHFR catalyzes the 
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conversion of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF), 
which is a methyl donor for remethylation of homocysteine to methionine. A diet low in 
folate or depletion of methyl groups due to alcohol consumption can affect individuals 
expressing a functionally variant MTFHR that lacks the ability to effectively convert 5, 
10-MTHF to 5-MTHF. Impaired methyl stores and insufficient dietary supplementation 
affect DNA methylation leading to dysregulation of gene expression (46, 92). Animal 
studies indicate that the dose as well as timing of folate administration can have a 
differential effect on colon cancer since administering high levels of folate at later stages 
of carcinogenesis can promote tumor growth (93). In addition, evidence from clinical 
studies suggests a possible detrimental effect of folate supplementation in patients with a 
recent history of colorectal adenoma (94). 
 
Lifestyle and Colon Cancer  
Lifestyle factors such as alcohol consumption, smoking and physical exercise also 
influence the risk of cancer.  
 
Alcohol 
The causal relationship between alcohol and colorectal cancer has long been debated, 
however most studies suggest only a modest correlation between these factors (95). The 
Pooling Project of Prospective Studies combined data from eight large prospective 
studies conducted in 5 countries and compared individuals who did not consume alcohol 
to those who had an alcohol intake of about 30 to <45 g/day. A multivariate relative risk 
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of 1.16 was associated with alcohol consumption and individuals consuming alcohol >45 
g/day had a multivariate relative risk of 1.42 (96). Although, most case controlled and 
prospective cohort studies have indicated an increased risk of colorectal cancer in 
individuals consuming alcohol, some studies have failed to show this correlation (97-
102). Various mechanisms have been proposed to explain how alcohol promotes 
colorectal carcinogenesis. Based on evidence from studies investigating folate status and 
colorectal cancer risk  and the antagonistic effects of alcohol, it is plausible that the 
increased risks due to alcohol may be related to the effects on folate (92, 103). In 
addition, alcohol-induced immunodepression, changes in bile acid composition and 
activation of liver carcinogens via induction of cytochrome p450 enzymes may also 
contribute to the procarcinogenic effects of alcohol (46, 104).  
 
Cigarette Smoking 
Studies in the 1950s, examining the effects of cigarette smoking on colorectal cancer 
risk did not yield any positive correlation due to the lack of knowledge of the long gap 
between exposure and tumor development. However, with the discovery of colorectal 
adenomas and the early stages of colon cancer, a strong causal relationship was observed 
between smoking and increased risk of colorectal cancer. Smoking generates several 
genotoxic compounds including aromatic amines, polynuclear aromatic hydrocarbons, 
heterocyclic amines and nitrosamines. These carcinogens can irreversibly damage DNA 
and several meta-analyses of case-controlled and prospective cohort studies have 
demonstrated the relationship between tobacco smoking and increased risk of colorectal 
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cancer (46, 105-108). Meta-analyses revealed that past smokers were found to have a 
higher incidence of colorectal cancer than the current smokers, which is consistent with 
the time-lag between initiation and tumor development. In addition, the risk was 
elevated more for rectal than colon cancers and in the colon smoking increase tumors in 
proximal more than the distal region (106, 108, 109). Although, past smokers have a 
higher risk, a recent prospective study indicates that cessation of smoking for at least 31 
years can reduce the risk of colorectal cancer (110). 
 
Body Weight and Physical Inactivity 
Excessive body weight or body mass index (BMI) is another risk factor for colorectal 
cancer in both men and women (111, 112). Meta-analysis of prospective studies showed 
that an increase in waist circumference (10-cm increment) elevated the risk of colorectal 
cancer by 33% and 16% in men and women respectively (113). Obesity related 
hyperinsulinemia may also promote cancer growth by increasing the levels of IGF 1, or 
binding to IGF- binding proteins and thus increasing the levels of free IGF1 (66). An 
insulin sensitizing adipokine (cytokines secreted by adipose tissue), adiponectin, exhibits 
an inverse correlation with adenoma and colon cancer risk in men in some studies (114, 
115). Physical inactivity, which can lead to insulin resistance, is also a major colon 
cancer risk factor and prospective cohort and case-control studies have demonstrated an 
association between increased physical activity and reduced risk of colorectal cancer in 
both men and women. (116-118). The reasons for decreased risk of colon cancer in 
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physically active individuals is associated with low insulin levels, reduced systemic 
inflammation and decrease in abdominal adiposity due to physical exercise (46).  
 
PROSTATE CANCER 
Prostate cancer is the second most commonly diagnosed cancer accounting for 27.9 % of 
all cancers and sixth leading cause of cancer related deaths in men world-wide with 6.1 
% of cancer mortality (30, 119). North America, Oceania and Northern and Western 
Europe display highest incidence rates, while the lowest rates of prostate cancer are 
observed in Asia and North Africa. Recent studies indicate that 23 % - 42 % of the cases 
of prostate cancer in high incidence areas such as Europe and U.S might be a result of 
over-diagnosis due to PSA (Prostate Specific Antigen) screening. Over-diagnosis could 
also be a confounding factor for the low mortality estimates due to prostate cancer in 
U.S Caucasian males and some Europeans where PSA screening is very common (120, 
121). Low mortality rates from prostate cancer in most western countries including the 
U.S, Canada, Finland, France, Italy, Israel, the Netherlands, Norway, Portugal, Sweden 
and Australia have been attributed to the improved therapies and early detection (122-
124). Certain Asian and East European countries such as Japan, Singapore and Poland, 
where PSA testing has been limited show a rise in prostate cancer incidence and 
mortality rates and this may be due to changing to diets rich in animal fat, physical 
inactivity and increased obesity (Figure 5) (122).  
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 Figure 5. Prostate cancer cases and mortality worldwide in 2008 (30) 
 
 
Genetic Predisposition 
Risk factors associated with prostate cancer include old age, ethnicity and family history 
(125). Men below 40 years of age are seldom diagnosed with prostate cancer and death 
due to prostate cancer is a rarity in individuals who are less than 50 years of age. In the 
United States, African-American men are at a higher risk than individuals from other 
races and their mortality rate is 2.4 times higher than that of Caucasian men. Other 
ethnic populations such as Asian/Pacific-Islanders, Native Americans and Hispanic men 
have a lower than average risk for prostate cancer (125, 126).  Family history of prostate 
cancer is an important risk factor and a 2 fold increase in risk is observed in individuals 
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with a paternal family history of prostate cancer and the risk increases by >3-fold if a 
brother has been diagnosed with prostate cancer. If both the brother and father are 
diagnosed with prostate cancer then the individual’s risk for the disease is increased 
almost nine-fold (125, 127). Similarly, family history is also a contributor to prostate 
cancer mortality. Individuals with a father and brother who died of prostate cancer have 
a twofold higher risk for death resulting from prostate cancer compared to men without a 
family history of prostate cancer (125, 128).  
 
Obesity  
Most studies indicate that obesity in adulthood increases the risk for developing 
advanced stage prostate cancer and is accompanied by increased cancer recurrence and 
cancer-related mortality. A meta-analysis of 6 cohort studies reported that for every 5 kg 
m-2 increase in BMI there was a 15 % increased risk of prostate cancer death in initially 
cancer-free individuals and a 20 % increase in prostate cancer-specific mortality. 
Similarly, a 5 kgm-2 increase in BMI also elevated the risk for increased PSA levels by 
21% (129). Evidence from several studies suggested that PSA concentrations in obese 
men tend to be low due to a larger blood volume, and PSA screening in obese men may 
be less accurate than in non-obese individuals (130, 131). 
 
The mechanisms proposed for obesity-induced prostate cancer growth and progression 
are similar to that of colon carcinogenesis and include impaired functioning of multiple 
hormonal pathways and increasing levels of insulin and inflammatory cytokines, and 
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decreased levels of adiponectin, all of which can contribute to prostate cancer 
progression (132-134). The Physicians’ Health Study reported an association between 
levels of C-peptide, a circulating marker for insulin secretion with the increased prostate 
cancer-related mortality. An increased risk was observed in obese individuals with high 
levels of insulin compared to obese men with lower C-peptide levels, suggesting that 
BMI and C-peptide levels together may be a better prognostic indicator for prostate 
cancer (125, 132). Results from the large (150,000 men) European Prospective 
Investigation into Cancer and Nutrition (EPIC) showed that risk of advanced prostate 
cancer was related to measures of central obesity, waist circumference (WC) and waist 
to hip ratio (WHR). A 6% increase risk of advanced prostate cancer was observed with a 
5 cm increase in WC in men and a 21% increased risk was observed for every 0.1 units 
of increased WHR (135).   
 
The effects of weight change in the time period before or after diagnosis of prostate 
cancer has not been extensively investigated; studies examining weight gain from early 
adulthood (18 or 21 years) to mid-life have produced mixed results concerning risk of 
prostate cancer. Some studies failed to show any significant correlation with prostate 
cancer incidence (136-139), while others (140, 141) such as the AARP-NIH Diet and 
Health Study observed that weight gain from adolescence to mid-life resulted in an 
increased risk for prostate cancer mortality but not for total, local or extra-prostatic 
disease (142) . The only study to investigate effects of weight change on prostate cancer 
in the period shortly before and after diagnosis observed that weight gained 5 years prior 
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to treatment with radical prostatectomy and 1 year post-treatment increased the 
recurrence of prostate cancer, whereas the effects of weight loss were not significant 
(143).  Studies on the effect of weight loss or gain before or after diagnosis of prostate 
cancer are important and represent a modifiable risk factor that can be used in preventing 
recurrence of prostate cancer in diagnosed/affected individuals (125).  
 
Physical Activity 
Several cohort studies have shown a strong correlation between physical activity and 
aggressive or advanced prostate cancer risk and data from the Health Professionals 
Follow-up Study (HPFS) found a lower risk for the incidence and mortality from 
advanced prostate cancer in men 65 years or older. However, no such associations were 
observed in younger individuals (144). Men from the American Cancer Society Cancer 
Prevention Study II Nutrition Cohort (CPS II) who performed the highest level of 
physical recreational activity and those who did not engage in any physical activity 
showed no difference in risk of prostate cancer. However, those individuals who were 
engaged in >35 metabolic equivalent-hours/week of recreational physical activity 
exhibited a lower risk for aggressive prostate cancer compared to subjects who were not 
involved in any recreational physical activity (145). The effects of post-diagnosis 
exercise on prostate cancer recurrence or mortality gave encouraging results; there was a 
61% decrease in cancer-specific mortality in individuals exercising ≥3 hours per week, 
and brisk walking for 3 or more hours per week also decreased the incidence of prostate 
cancer recurrence (146, 147).  
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Smoking 
Smoking has been consistently associated with higher risk for prostate cancer and results 
from a prospective cohort study showed a 1.6 relative risk for prostate cancer mortality 
for current smokers compared to non-smokers (148). Smoking earlier than 10 years prior 
to diagnosis and total life time smoking have not been linked to increased risk, however 
recent smoking i.e. within 10 years before diagnosis of the disease is associated with 
increased risk for advanced and aggressive prostate cancer (149). Smokers undergoing 
radiation, androgen-deprivation therapy and radical prostatectomy exhibit more severe 
outcomes compared to non-smokers undergoing similar treatment regimes, suggesting 
that smoking can also impair the beneficial therapeutic effects of prostate cancer 
treatment (150-152). The mechanisms of smoking-enhanced prostate cancer are not well 
understood but it has been suggested that cigarette smoking may increase plasma levels 
of total and free testosterone (153, 154) and carcinogens such as N-nitroso compounds 
and cadmium, which are present in cigarette smoke initiate prostate cancer (155, 156). 
Tobacco smoke may influence development of prostate cancer by enhancing cancer 
growth, angiogenesis and invasion which will be discussed later sections. Several studies 
show that nicotine enhances neovascularization, capillary growth and tumor growth 
associated with enhanced vascularity (157-159). Smoking may also induce certain 
epigenetic modifications since aberrant CpG hypermethylation of adenomatous 
polyposis coli (APC), glutathione S-transferase pi (GSTP1), and multidrug resistance 
one (MDR1) genes was observed in smokers and these genes are prognostic markers for 
advanced prostate cancer (160).    
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Oxidative Stress and Antioxidants 
Oxidative stress is known to damage DNA and protein and hence contribute to 
carcinogenesis and the inhibitory effects of dietary antioxidants such as vitamin E, 
selenium and lycopenes on prostate cancer growth and progression have been 
investigated (125).  
 
Vitamin E 
Various cancer prevention trials such as the Alpha-Tocopherol Beta-Carotene Cancer 
Prevention (ATBC) study, have demonstrated a statistically significant reduction in the 
cancer risk and prostate cancer-specific mortality in men assigned to -tocopherol 
(vitamin E) supplementation (161-163). In addition laboratory studies using 
experimental models show that vitamin E and its derivatives decrease DNA damage, 
inhibit malignant cellular transformation, suppress tumor growth and induce apoptosis in 
human prostate cancer cells (164-167). Nevertheless, the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) and the Physician’s Health Study II (PHS II) failed 
to show any significant reduction in the risk of prostate cancer in men receiving 400 IU 
day-1 of -tocopherol. Interestingly, a significant increase in the prostate cancer risk was 
observed due to vitamin E intake in the SELECT study (168, 169). The reasons for such 
variations observed in these studies are not clear. Examination of data from 
epidemiological studies indicates no overall association between prostate cancer risk and 
vitamin E alone but was observed in smokers with advanced prostate cancer risk (170, 
171). Similarly, prospective studies demonstrate a protective effect of vitamin E and -
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tocopherol against prostate cancer in ever smokers and against lethal and aggressive 
prostate cancer in the general population (172-174).  
 
Selenium 
 Selenium is an essential micronutrient required for the proper functioning of the 
antioxidant enzyme glutathione peroxidase. The amount of selenium in food depends on 
the soil in which it is grown in and hence can influence the amount of dietary intake of 
selenium. Ecological studies have indicated an inverse correlation between selenium 
content in the soil and prostate cancer incidence (175, 176). However, studies 
investigating the chemopreventive effects of selenium against prostate cancer have 
yielded ambiguous results. Although, some randomized trials and cohort studies indicate 
a decreased risk of prostate cancer among men taking selenium supplements, other 
studies has shown no significant correlation between selenium and prostate cancer (177-
180). 
 
Lycopene 
Lycopene, a phytochemical and carotenoid pigment found in tomatoes and other fruits 
and vegetables has long been studied for its prevention of prostate cancer. Consumption 
of tomatoes, especially cooked tomatoes (processing increases the concentration of 
bioavailable lycopene) decreases prostate cancer risk, however this association was not 
observed in 11 case-control and 10 prospective cohort studies subjected to meta-
analysis. A 25%-30% reduction in the risk of prostate cancer was observed in cohort 
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studies but dietary based case-controlled studies failed to show any correlation. (181, 
182). Meta-analysis showed an inverse relation between plasma lycopene levels and 
prostate cancer risk with a relative risk of 0.55 in case-control studies and 0.78 for cohort 
studies (182). In an another nested case-control study there was a non-statistically 
significant inverse relationship between lycopene (OR, 0.66; 95% CI, 0.38–1.13) and 
risk of prostate cancer among men over 65 years, without a family history of prostate 
cancer (183). However, other studies show no significant association between lycopene 
and tomato consumption on prostate cancer risk (184-187). Most data suggest that 
consumption of lycopene and tomato-based products do protect against advanced stage 
prostate cancer if not the indolent disease (125). 
 
Calcium 
Calcium intake is another risk factor for prostate cancer due to its suppressive effects on 
the levels of the active metabolite of vitamin D, dihydroxyvitamin D [1,25(OH)2D] 
which are involved in regulating differentiation and proliferation of the prostate 
epithelium (125, 188). Evidence suggesting an increased risk of aggressive prostate 
cancer with high intake of calcium has been reported in several studies (189-191). A 
recent study of African-American men in California, found a significantly lower risk of 
advanced prostate cancer in men who were poor absorbers of dietary calcium with the 
vitamin D receptor Cdx2 GG genotype. Those individuals with an AA genotype and 
higher amounts of calcium in the diet were at an increased risk for advanced prostate 
cancer (192). The association between serum calcium levels and risk of prostate cancer 
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has been investigated in three prospective cohort studies, the National Health and 
Nutrition Examination Survey (NHANES I), the NHANES Epidemiologic Follow-up 
Study and NHANES III.  A 2.5 fold increase for cancer risk was observed for men in the 
highest tertile of serum calcium levels from the NHANES I and NHANES follow-up 
studies and similar trends were observed in the NHANES III follow-up study, suggesting 
that serum calcium can be used as a prospective biomarker of fatal prostate cancer (193, 
194). 
 
Coffee Intake 
Lower risk of prostate cancer mortality due to coffee consumption has been reported in 
observational and animal studies. Improved glucose metabolism and insulin secretion is 
associated with long-term coffee drinking and coffee contains antioxidants that may 
protect against prostate cancer (195-197). Of the three studies that have examined the 
effects of coffee on prostate cancer mortality, two studies report no association of cancer 
mortality and coffee consumption. However, data from the Health Professionals Follow-
up Study indicates an 18% lower risk for prostate cancer overall and 60% lower risk for 
prostate cancer mortality in men consuming six or more cups of coffee per day 
compared to non-coffee drinkers. Regular and decaffeinated coffee had a similar effect 
on the risk for cancer mortality in this study, indicating that active components other 
than caffeine might be responsible for the protective effects of coffee (198). 
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In summary environmental and lifestyle factors play a pivotal role in deciding the course 
of prostate cancer both before and after diagnosis. Well-designed prospective cohort 
studies and long-term follow ups can improve our understanding of the interaction 
between lifestyle factors and cancer outcomes and identify important prognostic risk 
factors, which in turn can facilitate diagnosis and improve the quality of life after 
prostate cancer has been diagnosed.  
 
CANCER CLASSIFICATION 
The discovery of the microscope and histopathological analyses of tumor sections 
coupled with the idea that cancer cells and normal cells arise from the same source led to 
the classification of neoplasms (27).   
 
Classification Based on Histopathology 
The human body is composed of four basic types of tissues namely, epithelial, 
connective, muscle and nervous tissues, and a combination of these tissues gives rise to 
the organs and organ systems of the body. The epithelium is made up of cells that are in 
close proximity to one another and rests on a thin filmy basement membrane which acts 
as a scaffold and a platform for their normal growth and regrowth after injury (199). 
Some epithelial tissues form sheets and layers that line the body cavities and protect the 
organs and blood vessels, while others give rise to specialized glands that secrete mucus 
to protect the cells and tissues from the caustic effects of acids and other substances. 
Epithelial tissues lack their own blood supply and hence are sustained by a supply of 
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essential nutrients from the underlying connective tissue also known as the stroma (200). 
“Carcinoma” is the term given to all cancers of epithelial origin and they account for 
90% of all human cancers (201). Epithelial cells that specialize in protection give rise to 
“squamous cell carcinomas” and are frequently observed in locations such as the skin, 
nasal cavity, oropharynx, larynx, lung, esophagus and cervix. The cancers of the 
glandular epithelium that serve a secretory function are called “adenocarcinomas” and 
are commonly found at tissue sites such as the lung, colon, breast, pancreas, stomach, 
esophagus, prostate, endometrium and ovary (27).  
 
Connective tissue, derived from the embryonic mesodermal layer form structures that 
contribute to the supportive framework of the body. Mesenchymal tissue is a type of 
embryonic connective tissue that gives rise to the extracellular matrix of tendons, skin, 
adipocytes, osteoblasts and myocytes. Cancers that arise from the mesenchymal tissues 
are termed “sarcomas” and account for only 10% of all cancers (202). The sarcomas are 
further classified into specific types depending on the site of the body that it affects. If 
the smooth muscle is involved then it is referred to as a leiomyosarcoma, similarly if the 
fat cells are affected it is termed a liposarcoma. Chondrosarcoma and osteosarcoma are 
the cancers of the cartilage and bone respectively (27). 
 
Specialized connective tissues, namely blood, bone marrow and lymph nodes, give rise 
to hematological malignancies and are broadly divided into leukemias and lymphomas. 
Any myeloid or lymphoid malignancy that involves peripheral blood and bone marrow 
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is termed leukemia. Cells from the myeloid lineage include erythrocytes, granulocytes, 
platelets, macrophages and mast cells while the lymphoid lineage produces monocytes, 
lymphocytes and plasma cells. Leukemias are classified into acute and chronic based on 
the maturity of cells that are involved in the formation of the cancer. An increase in the 
number of immature blast cells is termed acute, whereas an elevation in levels of a more 
mature population of cells is referred to as a chronic condition. The terms “acute” and 
“chronic” can also reflect the time period required for the progression of the disease. The 
second criterion used to classify leukemia is the cell lineage. If the cancer forming cell 
population comprises of cells from the bone marrow that proceed to form lymphocytes 
then the term used is lymphoblastic or lymphocytic leukemia, while the term 
myelogenous leukemia is used when the cells involved in the malignancy are precursors 
of red blood cells, some types of white blood cells and platelets. Hence, this 
classification system gives rise to 4 major kinds of leukemia namely, acute 
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute 
myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). A lymphoma 
on the other hand is a lymphoid malignancy that affects the lymph nodes and 
extramedullary sites, and is classified into Hodgkin’s and non-Hodgkin’s lymphomas 
(27, 29, 203, 204).  
 
Neurons are involved in transmitting signals and impulses while the neuroglial cells 
protect, repair and support neurons. The nervous tissue gives rise to neuroectodermal 
tumors and account for less than 2% of all malignancies world-wide. Cancers of the glial 
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cells are called gliomas and are further categorized into low grade tumors called 
astrocytomas and high grade tumors termed as glioblastomas. The nerve sheath is lined 
by myelin producing cells known as Schwann cells and the neoplasms affecting them are 
termed schwannomas or neurilemomas (27, 29). 
 
Classification Based on Invasive Ability 
Besides tissue of origin, invasive ability is another measure used to classify neoplasms. 
Neoplasms that exhibit a slow and localized growth are called benign (Figure 6). They 
are commonly encapsulated by a fibrous connective tissue capsule and do not infiltrate 
adjacent tissues. Benign neoplasms are composed of cells that are well differentiated 
with low numbers of mitotic figures (205). A large proportion of neoplasms that occur in 
the body are benign and do not pose a threat to the individual However, in certain cases 
when the growth is on a vital organ, the resulting pressure on the organ can impair its 
normal functioning (27). Infarctions and obstructions caused as a result of benign 
growths on organs depending on the location can be life threatening to the host. Benign 
tumors may also have adverse consequences when present on endocrine glands due to 
secretion of enormous amounts of hormones into the circulation (27, 205).  
 
Tumors that are not self-limiting in their growth and are potentially a threat to an 
individual’s life are referred to as malignant neoplasms. A distinct feature of malignant 
tumors that sets it apart from benign growths is the ability to invade adjacent tissues and 
vasculature, and spread to distant sites, a process known as metastasis. Malignant 
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neoplasms grow rapidly and contain large numbers of cells with varying degrees of loss 
of differentiation  (Figure 6) (27, 205). In contrast to benign tumors, they often outgrow 
their own blood supply causing tissue necrosis and host tissue damage (206). Their 
ability to metastasize to distant tissues also makes them sites of ectopic hormone 
production (205). 
  
Figure 6. Histopathological representation of benign and malignant neoplasia (27) 
 
 
Benign tumors are usually named using a prefix designating the specific tissue where the 
tumor originated followed by a suffix “–oma”, for example Lipoma, chondroma etc. The 
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term malignant neoplasm is synonymous with cancer and the specific designation is 
based on the tissue of origin followed by addition of the term “carcin” (for epithelial 
tissues) or “sarc” (for mesenchymal tissues) to the suffix “-oma”. Hence, a neoplasia of 
the bone is termed osteoma if it is benign and osteosarcoma if it is malignant. Similarly, 
a benign tumor of the glandular epithelium is called adenoma and its malignant 
counterpart adenocarcinoma (27, 205).  
 
Classification Based on Morphology and Behavior 
Neoplasms can be grouped into various categories based on the morphological and 
behavioral alterations they undergo prior to achieving a state of malignancy (Figure 7).  
 
Hyperplasia 
Cells that replicate at a far greater rate than the normal cells are termed hyperplastic. 
These cells have an abnormal proliferation rate; however, they resemble normal cells in 
morphology and are capable of assembling themselves into tissues like normal cells (27, 
205). Besides physiological liver hyperplasia that is observed after partial hepatectomy, 
pathological increases in hormonal levels such as estrogen and progesterone can result in 
endometrial hyperplasia; similarly excessive production of adrenocorticotrophic 
hormone (ACTH) can lead to bilateral adrenocortical hyperplasia (205).  
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Figure 7. Histopathological representation of hyperplasia, dysplasia, metaplasia and anaplasia (205) 
 
 
Metaplasia 
Metaplasia is a condition where the cells of a particular region are replaced by another 
set of adult differentiated cells that are not normally encountered in that area. This is 
usually triggered in response to an adverse condition, as a protective mechanism. 
Metaplasia is frequently observed in the epithelial transition zones such as the regions 
between the cervix and the uterus or the esophagus and the stomach where the squamous 
epithelial cells get replaced by mucus secreting columnar epithelium (27, 205). Another 
example is the bronchial epithelium which is, lined by ciliated pseudostratified columnar 
epithelium that changes to stratified squamous epithelium as a result of chronic cigarette 
smoking. Similarly, squamous metaplasia is also encountered in the gall bladder due to 
chronic irritation from gall stones leading to a shift in the columnar or cuboidal 
epithelium to stratified squamous epithelium. Besides, epithelial tissues, connective 
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tissues such as tendons also undergo metaplastic changes and transform into cartilage or 
bone tissue (205). 
 
Dysplasia 
In case of dysplasia cells undergo atypical or irregular proliferative changes as a result of 
chronic irritation or inflammation (207). Some of the changes observed are variations in 
the size and shape of the nucleus, increased nuclear staining by dyes, increased ratios of 
nuclear versus cytoplasmic size, increased mitotic activity and absence of characteristics 
associated with the normal differentiated cells (27). Dysplasia is commonly encountered 
in the squamous epithelium of the bronchi of chronic cigarette smokers and in post-
hepatitic form of human liver cirrhosis associated with hepatitis B virus (HBV) (208, 
209). Although these growth adaptive changes (hyperplasia, metaplasia and anaplasia) 
generally disappear when the stimulus is removed, they can be highly significant since 
these changes are the early steps in the development of neoplasia. 
 
Anaplasia 
Anaplasia is characteristic of a malignant neoplasm and literally means “to form 
backward” or “without form”. It is a term describing cells that have shed all their tissue-
specific properties and are de-differentiated, making it impossible to trace them back to 
their tissue of origin. Anaplasia is characterized by two levels of disorganization namely 
cytologic and positional. The cytologic alterations include changes in the nucleus to 
cytoplasm ratio, an increase in the size of the nuclei and nucleoli, hyperchromatic nuclei, 
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increased cytoplasmic basophilia, an increase in the number of mitosis, atypical mitotic 
figures, formation of tumor giant cells and cellular pleomorphism. Positional anaplasia is 
characterized by loss of architecture and disordered cellular interrelations between the 
component cells of the neoplasm (27, 205).  
 
CARCINOGENESIS 
Cancer can be best defined as normal cells that have gone awry. The replicative potential 
of the cellular machinery that the metazoans are endowed with is highly complex and 
designed for highly ordered development and maintenance of adult tissue by repair of 
wounds and replacement of worn out cells. However, this finely tuned system is 
vulnerable to dysregulation by alterations of genes that maintain homeostasis and this 
results in uncontrolled cell growth and division. Oncogenes and tumor-suppressor genes 
are two classes of genes that are subjected to genetic alterations and this facilitates the 
process of carcinogenesis. 
 
Oncogenes and Mechanisms of Activation 
Genes that regulate cell proliferation, growth and differentiation in all multicellular 
organisms have an inherent potential to induce cancer and are called proto-oncogenes. 
These proto-oncogenes are precursors of oncogenes and are activated by mutations, gene 
translocations and gene amplifications (210, 211). 
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Mutations 
Single point mutations of genes can often lead to alterations in the encoded protein 
structure as a result of amino acid substitution. These modified proteins in turn can 
contribute to the transformation of normal cells into a malignant phenotype (27, 205, 
212). Structural alteration of the ras proteins (HRAS, NRAS and 2 types of KRAS 
species) encoded by the members of the ras family of oncogenes is a classic example of 
oncogene activation through mutations. Ras, a G-protein, is an important regulator of 
cell shape, motility and growth with an intrinsic guanosine-nucleotide binding activity 
and guanosine triphosphatase activity (213). Mis-sense mutations in the 12th, 61st and 
less frequently 13th codon leads to the substitution of amino acid residues glycine (G12) 
and glutamine (Q61) to valine resulting in an oncogenic form of ras protein that has an 
enhanced GTP binding and GTPase activity essential for its transforming ability (214-
216). Twenty to thirty percent of all human tumors have mutations in the ras family of 
oncogenes, with the highest incidence in adenocarcinomas of the pancreas, colon, lung, 
thyroid and myeloid leukemia (217). KRAS mutations are commonly found in 
carcinomas of the lung, colon and pancreas, while NRAS mutations are frequently 
encountered in acute myelogenous leukemia and myelodysplastic syndrome (212, 218, 
219). Mutations in another gene, BRAF, results in a structurally altered, constitutively 
active  serine threonine kinase, B-Raf (220). The amino acid substitution of valine at 
position 599 to glutamic acid modifies the kinase domain of the protein that 
uncontrollably triggers the MAP kinase signaling cascade, which regulates cell 
proliferation, differentiation and survival. BRAF mutations are frequently observed in 
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melanomas, colorectal cancers, hepatocellular carcinomas and gliomas (221, 222). 
Similary, Src, a tyrosine kinase, encoded by the SRC gene is another oncoprotein that is 
constitutively active due to a mutation in the 527th codon, which replaces tyrosine with 
an unrelated amino acid (27, 223). 
 
Chromosomal Translocations 
Chromosomal translocations are commonly observed in hematological malignancies 
such as Burkitt’s lymphomas and chronic myelogenous leukemias (224). In some cases, 
certain sections of the chromosome carrying an oncogene break off and get 
juxtapositioned adjacent to a highly active transcriptional promoter or otherwise get 
fused with a section of a chromosome containing another oncogene. Activation of the c-
myc proto-oncogene proceeds via insertional mutagenesis. A section of chromosome 8 
containing the myc gene is reciprocally translocated to a region on chromosome 14 
containing the transcriptional regulator for the immunoglobulin gene, thereby producing 
enormous amounts of growth promoting signals under the influence of a highly active 
promoter. Besides the t(8;14) translocation encountered in Burkitt’s lymphoma, 
chromosomes 2 and 22 also undergo reciprocal translocation with c-myc containing 
chromosome 8 (27, 225-227).   Philadelphia chromosome is a condition that is invariably 
observed in all cases of chronic myelogenous leukemia (205). Unlike Burkitt’s 
lymphoma reciprocal translocation in CML results in the fusion of two sections of 
chromosome 9 and 22 each containing the genes abl and bcr respectively (224, 228, 
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229). The resulting fused genes synthesize a hybrid Bcr-Abl protein that exhibits 
elevated tyrosine kinase activity that enhances cell transformation (230). 
 
Gene Amplifications 
Growth factors and cell cycle related proteins are highly regulated under normal 
conditions. However, during cancer progression the increasing demand for these growth 
promoting factors is met by producing multiple copies of their corresponding genes via 
gene amplification. Cytogenetic findings from examination of tumors provide evidence 
for gene amplification in the form of abnormal karyotypic markers such as 
homogenously staining regions, double minutes, and abnormally banded regions (231-
234). Oncogenes from the MYC, cyclin D1, EGFR and RAS families are frequently 
amplified (212). The first evidence of gene amplification was found in the human 
promyelocytic leukemia cell line HL-60, with a 16-32 fold amplification of the c-myc 
locus (235, 236). C-myc amplification is also observed in colon carcinoma, small cell 
lung carcinoma and non-small cell lung carcinoma (237-239). A closely related gene, N-
myc is frequently amplified in neuroblastomas and is associated with advanced tumor 
stage, aggressive tumor histology and clinical behavior (237, 240, 241). Amplification of 
EGFR (ERBB1) is observed in glioblastomas and cancer of the head and neck. 
ERBB2/HER2/neu is most often amplified in  primary breast cancer and is associated 
with poor prognosis (242). Similarly, the abl proto-oncogene is also amplified in cell 
lines derived from patients with chronic myelogenous leukemia (243).  
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Oncogene Products 
Products of oncogenes can be grouped into transcription factors, chromatin remodelers, 
signal transducers, growth factors, growth factor receptors and apoptosis regulators 
(212). 
 
Transcription Factors 
These are proteins that bind to short DNA sequences (cis-elements) to regulate 
transcription of genes positively or negatively (244). Most transcription factors share 
common structural domains such as, basic DNA binding domains, zinc fingers, 
homeobox etc. and interact with each other to regulate gene expression. Products of 
immediate early genes myc, fos and jun are frequently overexpressed in cancers (235, 
239, 240, 245-247).  The transcription factors Fos and Jun dimerize to form the AP1, 
which is a heterodimeric transcription factor often found in a hyperactivated state in 
cancer cells and regulates processes such as cell proliferation, differentiation and 
apoptosis (248). Stat3 of the STAT (signal tranducers and activators of transcription) 
family of transcription factors is also constitutively activated in a number of human 
cancers. Stat 3 homodimerizes by binding to phosphotyrosine residues within their SH2 
domains and migrate to the nucleus to regulate gene expression. Deactivation of Stat3 in 
breast cancer and melanoma cells triggers apoptosis and growth inhibition indicating its 
significance in cancer cell survival (249, 250). Prostate cancers commonly show fusion 
of an androgen responsive promoter element containing gene, TMPR552 with ERG1 or 
ETV1 genes from the ETS family of transcription factors that regulate cell proliferation, 
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differentiation and apoptosis. The resulting fusion products activate transcription factors 
that facilitate transformation of cells in the prostate gland into cancer cells by increasing 
proliferation and inhibiting apoptosis (251). Gli, Notch and NF-B are other 
transcription factors that function as oncoproteins (27). 
 
Growth Factors   
These are a group of polypeptides essential for cell growth and proliferation. However, a 
surge in levels of growth factors through constitutive activation of a growth factor gene 
can facilitate malignant transformation of cells (212). Under normal conditions growth 
factors are rate limiting components for cell proliferation. However, cancer cells have a 
diminished requirement for specific growth factors, which is achieved by autocrine 
activation, synthesis of essential growth factors, structural alterations in the growth 
factor receptors or switching to alternate pathways that obviate the need for a growth 
factor receptor (252-254). Members of the epidermal growth factor (EGF) family bind to 
receptor tyrosine kinases ErbB-1-4 to initiate various signal transduction cascades. 
Cancer cells hijack these signaling pathways to promote processes such as cell 
proliferation, differentiation and survival (255, 256). Transforming growth factor beta 
(TGF-) is a cytokine that under normal conditions stimulates apoptosis and 
differentiation. However, during cancer TGF-can act as a tumor promoter and 
increases epithelia-mesenchymal transitioning, which contributes to metastasis, 
stimulates angiogenesis resulting in increased vasculature in the tumor tissue and 
uncontrolled proliferation of cancer cells (256, 257). The VEGF (vascular endothelial 
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growth factor) family of growth factors consists of five proteins, VEGFA, VEGFB, 
VEGFC, VEGFD and PIGF (placenta growth factor) that bind to one of the three 
receptors VEGFR-1-3 to regulate angiogenesis and vasculogenesis. In addition, VEGF 
exerts certain autocrine responses on tumor cells and these include survival, migration 
and invasion (256). PDGF (platelet derived growth factor) is another growth factor that 
is involved in coagulation and wound healing and is capable of transforming fibroblasts 
containing PDGF receptors in vitro and inducing proliferation of various cancer cell 
types (212).  
 
Growth Factor Receptors 
Modified growth factor receptors are commonly observed in various types of cancers 
and contribute to pro-oncogenic pathways (258). Deletion of the ligand binding domain 
of EGFR can result in a constitutively active tyrosine kinase receptor that undergoes 
phosphorylation and transfers signals to downstream effectors even in the absence of a 
ligand bound to the receptor (259). Activating mutations of EGFR are found in at least 
10% of non-small cell lung carcinoma patients (260, 261). Similarly, activating 
mutations are also observed in other members of EGR family- ERBB3, ERBB4 and less 
frequently in ERBB2 (212, 262). ErbB-2/HER2 is more often amplified at the 
corresponding portion of chromosome 17 to produce multiple copies of the receptors, a 
common feature observed in 20-25% of metastatic breast cancers (263).  ErbB-2 is also 
overexpressed in stomach, ovarian and aggressive forms of endometrial tumors and 
ErbB-4 mutations are commonly observed in 19% of melanomas. IGF1R signaling 
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activates pro-survival pathways and is frequently amplified in breast cancer, melanoma 
and pediatric cancers. Translocations, mutations and amplifications of the PDGFR 
gene are observed in gastrointestinal stromal tumors, glioblastoma, and chronic 
myelomonocytic leukemia (256). 
 
Signal Transducers 
Non receptor protein kinases and guanosine-triphosphate-binding proteins are two 
classes of signal transducers that participate in several cell signaling pathways essential 
for various physiological processes. Non receptor protein kinases are categorized into 
tyrosine kinases and serine threonine kinases depending on the amino acid residues 
phosphorylated by these kinases (264, 265). Mutations of signaling molecules including 
AKT, SRC, ABL, and RAF1, can also dysregulate the pathways and facilitate cancer 
progression and survival. 
 
Apoptosis Regulators 
Programmed cell death is a process by which, unhealthy or unnecessary cells are cleared 
from the body and it plays a vital role in development and maintenance of health. 
However, cancer cells express mutated genes that encode for proteins that inhibit the 
process of apoptosis thus providing a favorable environment for cancer cells to survive. 
The inhibitors of apoptosis (IAP) family of proteins are one such group of molecules that 
interfere with the process of programmed cell death and are frequently overexpressed in 
cancers. Members of IAP suppress apoptosis in cancer cells by inhibition of cysteine 
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proteases called caspases and pro-caspases. (266). Survivin, the key player of this 
family, is overexpressed in cancers of the lung, colon, breast, prostate, pancreas, 
stomach, high-grade lymphomas and neuroblastomas (267-270) and confers drug 
resistance in multiple cancer types (271, 272)  Bcl2 family proteins are another group of 
apoptosis regulators with pro-apoptotic and anti-apoptotic abilities. Anti-apoptotic 
members of this family include Bcl2, Bcl-xL, Bcl-wl proteins and are commonly 
overexpressed in large B-cell lymphoma, chronic lymphocytic leukemia and lung cancer 
(212, 273-275). 
 
MicroRNAs 
In contrast to other oncogenes, genes that encode microRNAs give rise to single 
stranded non-coding RNAs 21-23 nucleotide in length. They act as negative regulators 
of protein expression at the post-transcriptional level by binding to 3’UTRs of the target 
mRNA to inhibit translation. MicroRNAs can act as oncogenes as well as tumor 
suppressors (276-278) 
 
Tumor Suppressors  
Tumor suppressor genes (TSG) encode a class of proteins that safeguard the cells from 
mutations and maintain the integrity of the genome thus preventing development of 
cancer. In contrast to oncogenes that are distinguished by their gain-of-function 
mutations, tumor suppressor genes acquire mutations that result in loss-of-function 
(213). 
 49 
 
The existence of TSGs was not known until cell fusion experiments conducted by Harris 
and colleagues using normal and malignant cells demonstrated growth inhibition of 
murine tumor cells in syngeneic animals (279, 280). Results from this experiment 
suggested that malignancy was a recessive trait that can be suppressed by the presence of 
hypothetical wild-type alleles on a pair of chromosomes from the normal cells (280-
282). In addition, tumorigenicity in the hybrid cells could be abolished despite the 
presence of activated oncogenes such as RAS (283). Since, these wild-type genes 
inhibited the tumor forming abilities in the normal-cancer hybrid cells they were referred 
to as tumor suppressor genes.  
 
In spite of the evidence from the cell fusion experiments, the existence of TSGs was 
questioned by many for several reasons. Normal cell phenotype was considered to be a 
dominant trait and malignancy could be achieved only by mutating both the alleles of a 
tumor suppressor gene. The probability of inactivating both the copies of a gene per cell 
generation was estimated to be around 10-12 which was considered to be highly 
improbable. However, this conundrum was solved by the combined efforts of Carl O. 
Nordling and Alfred G. Knudson, who proposed the “two-hit hypothesis” (27, 284, 285). 
 
Knudson’s “Two Hit Hypothesis” 
The proof that cancer can arise in two steps with each step occurring at a rate within the 
accepted range of mutation rates came from the epidemiological studies conducted on a 
rare childhood eye tumor, retinoblastoma. Knudson observed two forms of 
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retinoblastoma, a familial form, characterized by bilateral lesions (presence of tumors in 
both eyes) with an early age of onset and a sporadic form of the disease with tumors 
affecting only one eye. Based on these observations he proposed the two-hit model for 
development of retinoblastoma. In case of the hereditary form of the disease, the first hit 
(mutation) is already present in the germ line, inherited from one of the parents. The 
germ line mutation on one allele is not sufficient for tumor development; hence a 
subsequent hit is required to inactivate the second copy of the wild-type gene. The 
second hit, which is invariably a somatic mutation, inactivates the remaining copy of the 
gene driving the retinal cells to proliferate uncontrollably. Since, all the cells have the 
germ line mutation in the retinoblastoma gene (Rb), retinal cells are highly vulnerable, 
and a single somatic mutation can result in tumor development, this explains the 
increased frequency of bilateral tumors in the familial form of the disease. On the other 
hand the sporadic form of the disease requires two successive somatic mutations in the 
retinal cells for the formation of retinoblastoma. Individuals affected with the sporadic 
form of the disease initially inherit two copies of wild-type alleles from their parents and 
hence require two sets of mutations to inactivate both the copies of the genes. The rarity 
with which two successive mutations occur at the same locus inactivating both the 
alleles explains the unilateral occurrence of the tumors in case of the sporadic form of 
the disease (284, 285).  
 
Although, the two-hit hypothesis was successful in elucidating the mechanism by which 
inherited and somatic mutations cooperatively initiate the cancer development process it 
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failed to explain the highly improbable successive mutation events that are required for 
causing the non-inherited form of retinoblastoma (27). 
 
“Loss of Heterozygosity” 
Homologous recombination of chromosomal arms occurs during the process of gamete 
formation (meiosis). Chromosomal crossover is observed between the sister chromatids 
of the homologous chromosomes and is a process that ensures genetic diversity. Besides 
meiosis, sharing of genetic information between the chromosomes also occurs during 
active somatic cell division and is termed mitotic recombination (286-289). The 
inactivation of the second Rb allele was proposed to occur through the process of mitotic 
recombination. 
 
It was hypothesized that inactivation of the first copy of the Rb gene takes place through 
a somatic mutation at a frequency (10-6 per generation) that was considered well within 
the limits of accepted values of mutation rates. This mutation results in a heterozygous 
condition (Rb+/-) with one copy of the wild type Rb gene and a mutated copy of the 
inactive Rb allele. The second copy of the gene with a wild type configuration however 
is not inactivated by a mutational event but is replaced by a defective allele from the 
homologous chromosome that is formed during replication. Segregation of the 
chromatids at the end of mitosis can result in either retention of heterozygosity (Rb+/- 
and Rb-/+) with one defective allele and one normal allele in the chromosome pair or loss 
of heterozygosity (LOH) resulting in an Rb-/- and Rb+/+ genotype in the daughter cells. 
 52 
 
LOH occurs at a frequency of 10-5 to 10-4 per cell generation, a far more probable event 
than somatic mutation, and is a more plausible explanation for the inactivation of the 
second copy of the gene in retinoblastoma. Since, the probability of occurrence of LOH 
is greater than somatic mutations, it is suggested that inactivation of the first copy of the 
gene might also go through LOH (27, 290).  These postulations were later confirmed 
through LOH studies on the gene for esterase D that is closely located to the RB1 locus 
(291). 
 
Most tumor suppressor genes can be classified into three groups: Caretakers, 
Gatekeepers and Landscapers. 
 
Caretaker Genes 
As discussed above the probability of multiple mutations occurring in a single cancer 
cell is low; however inactivation of certain specific genes called the caretaker genes can 
breach the genome’s defense making it vulnerable to mutations. (292). The caretaker 
genes do not directly suppress tumor growth, instead they maintain the integrity of the 
genome by keeping it stable and free from mutations. Silencing of caretaker genes alone 
is not sufficient for tumor development instead the initiating event has to be followed by 
subsequent mutations in other tumor suppressor genes and oncogenes that precipitate 
transformation of a normal cell into a neoplastic state. In autosomal dominant diseases 
such as hereditary nonpolyposis colorectal cancer (HNPCC) only a single mutant allele 
of the caretaker gene is inherited and a somatic mutation of the second allele is required 
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to increase the mutation rate to inactivate the gatekeeper genes. However, in case of 
autosomal recessive syndromes such as xeroderma pigmentosum (XP), a condition that 
predisposes an individual to sunlight induced cancer, both alleles of the caretaker gene 
must be inherited in the mutated form (213). Germ line mutations of caretaker genes 
such as MLH1, MLH2, PMS1 or PMS2 that are involved in DNA mismatch repair are 
frequently observed in HNPCC. Similarly, nucleotide-excision repair genes, human 
excision repair cross complementing (ERCC) genes ERCC2 and 5 undergo mutations in 
case of xeroderma pigmentosum (293). Ataxia telangiectasia is a neurodegenerative 
disorder that is associated with a mutation in the caretaker gene, ATM, which plays a role 
in DNA repair.  Under normal conditions the ATM protein senses double-stranded DNA 
breaks and relays signals by activating p53 to arrest cell cycle for the repair of damaged 
DNA, however the defective protein fails to halt the cell cycle leading to faulty repair of 
DNA and increased cancer risk  (213, 293). Although inactivation of caretaker genes 
ultimately lead to cancer, restoration of these gene functions in a cancer cell will not 
affect its growth. Since these indirectly acting caretaker genes are not required for 
neoplasia, most nonhereditary, sporadically occurring tumors will develop without them 
(294) 
 
Gatekeeper Genes 
Unlike caretakers, gatekeepers are directly involved in control of tumor growth. These 
genes protect the cells from malignancy by inhibiting undue cell proliferation and 
inducing apoptosis. The gatekeeper genes ensure an added level of protection against 
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cancer in cells. When the genetic material is subjected to an insult that results in DNA 
damage, the caretaker genes are responsible for initiating the DNA repair process. 
However, in scenarios where the caretaker genes fail to carry out the DNA repair 
process, the gatekeepers trigger events to either stop further cell proliferation, to prevent 
mis-repaired DNA from replicating or to activate the programmed cell death machinery 
which eliminates the precancerous cells. If the gatekeepers fail to prevent damaged DNA 
from replicating, defective genetic material accumulates leading to malignant 
transformation of cells (295). The adenomatous polyposis coli (APC) gene functions as a 
gatekeeper gene in colon tissue. Truncating mutations of the APC gene leads to a 
condition called familial adenomatous polyposis (FAP) which is characterized by the 
presence of benign colorectal growths in the colon, which can progress to form 
malignant tumors. The gatekeeper genes have tissue-dependent functions and 
inactivation of a certain gene results in susceptibility to a specific cancer type. For 
example APC mutation predisposes an individual to tumors in the colon but not kidneys. 
Similarly, mutations in the Von Hippel–Lindau (VHL) gene lead to cancers of the kidney 
and not colon (213). 
 
Some TSGs exhibit overlapping roles as both a caretaker and gatekeeper. For example 
the breast cancer susceptibility genes BRCA1 and BRCA2, encode proteins that are 
involved in DNA repair and clearly conform to the class of caretakers. Several model 
systems exhibit global genome instability when BRACA1/2 genes are functionally 
inactivated. It has been reported that BRCA1/2 also regulates a wide range of genes 
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required for cell cycle control, cell proliferation and differentiation. These results 
indicate that BRCA1/2 can take on the role as a gatekeeper gene in addition their 
involvement in maintaining genomic stability as a caretaker (296). Similarly, the P53 
gene exhibits some level of duality in its function as a tumor suppressor. Silencing p53 
leads to dysregulation of several genes controlling pathways involved in cell 
proliferation, growth and survival (297-299). Although p53 functions as a classical 
gatekeeper, evidence suggests a caretaker role with germ line mutations in the P53gene 
resulting in genome instability and tumor formation (300).  
 
Landscaper Genes 
This class of indirectly acting tumor suppressor genes was discovered following the 
histopathological analysis and observation of initiating lesions in juvenile polyposis 
syndrome (JPS).  JPS is characterized by the presence of hamaratomatous polyps in the 
colon and have a low potential for developing into colorectal cancer. These polyps are 
composed of mesenchymal and inflammatory cells unlike the adenomatous polyps that 
give rise to colorectal cancers, which are rich in epithelial cells. The few epithelial cells 
within and around the hamaratomatous polyps do not exhibit any signs of neoplasia and 
are not at an increased risk of progressing towards malignancy. JPS can advance to a 
state of neoplasia by mutations in the mesenchymal cells that give rise to a defective 
stromal environment which in turn drives proliferation of epithelial cells and this is 
described as a landscaper effect.  The mutations in the landscaper genes are predicted to 
affect various components of the tumor microenvironment including extracellular matrix 
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proteins, adhesion proteins, or secreted growth/survival factors, unlike the mutations in 
the other two classes of genes which directly influence the tumor cells (301). Recent 
studies investigating the molecular genetic basis of JPS, have localized the genetic 
defects to PTEN and SMAD4 genes (302, 303). PTEN gene gives rise to PTEN 
(phosphatase and tensin homolog) a dual specificity phosphatase that regulates the cell 
cycle and controls growth while SMAD4 codes for a protein that is involved in the TGF-
 signaling pathway. Further genetic evaluation of the stromal and epithelial cell 
population of the JPS polyps has revealed that the clonal alterations of PTEN and 
SMAD4 are located in the stromal cells and not the epithelial cells (304). These 
observations in addition to the presence of a significant population of mesenchymal cells 
in polyps concur with the idea that the stromal cells are neoplastic and exert a landscape 
effect on the adjacent epithelial cells (305). 
 
The Non-oncogenic Addiction Phenomenon (NOA) 
In addition to oncogenes, there are many other genes that are essential for the 
maintenance of the cancer phenotype in cells; however they do not undergo any 
oncogenic mutations or alterations to their function. This heightened dependence of 
tumors on several pathways driven by a set of genes that are not classical oncogenes is 
termed non-oncogenic addiction. Since these genes are rate-limiting for oncogenic 
pathways, they can be potential targets for cancer therapy (306). The genes of the NOA 
can be classified into two groups namely, intrinsic and extrinsic. The tumor-intrinsic 
NOA genes function within the tumor cell in a cell-autonomous manner while the 
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extrinsic NOA genes operate in the stromal and vascular cells that support the tumor 
(307). The heat shock factor 1 (HSF1) is a well-studied non-oncogene and a definitive 
example of the non-oncogene addiction phenomenon. HSF1 is a transcription factor that 
is activated in response to proteotoxic stresses such as heat and hypoxia. HSF1 mediates 
its effects via heat-shock proteins that are involved in refolding of proteins, inhibiting 
protein aggregation and directing misfolded proteins to the ubiquitin proteasome 
pathway for degradation. Studies conducted in HSF1 deficient mice demonstrate a lower 
incidence of tumors, reduced tumor burden, and increased survival when compared to 
their wild-type littermates. Similarly, knockdown of HSF1 employing small hairpin 
RNAs (shRNAs) decreased the viability of multiple cancer cell lines with minimal 
effects on normal cells, suggesting a higher dependence of cancer cells on HSF-1 
compared to normal cells (307, 308). However, HSF1 does not show any somatic 
mutations and overexpression of HSF1 fails to transform immortalized mouse 
embryonic fibroblasts (MEF). In addition, MEFs devoid of HSF1 are resistant to 
transformation by either oncogenic H-RASV12D or PDGF-B. It is hypothesized that HSF1 
induces heat-shock protein 90 (HSP90) which forms a complex with its substrate 
targeting unit, Cdc37 and this complex stabilizes numerous proteins such as Cdk4, 
HER2/ErbB2, Akt that are involved in cell proliferation and survival (306, 309).  
 
Other examples of non-oncogenic addiction include increased dependency of BRCA-2 
deficient cancer cells on the DNA stress protein poly ADP-ribose polymerase (PARP), 
tumor cell mediated suppression of immune surveillance by downregulation of major 
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histocompatibility complex (MHC) and synthesis of chemokines (e.g., CCL2), cytokines 
(e.g., IL6 and IL10), and prostaglandins to suppress activation of cytotoxic T cells (307, 
310, 311). 
 
Normalcy to Malignancy 
Genetic changes caused by the action of carcinogens in normal cells leads to 
transformation of the cell into a cancerous phenotype. In addition recent studies indicate 
that epigenetic changes, such as those caused by methylation of gene promoters and 
histones are also crucial events required for development of cancer. However, it is still 
not clear if epigenetic changes are caused by chemical carcinogens or occur 
spontaneously due to dysregulation of proteins involved in promoter and histone 
methylation. The stages involved in the transition of a normal cell into a cancer cell 
include initiation, promotion, malignant conversion and tumor progression (Figure 8). 
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Figure 8. Schematic representation of processes involved in tumor development 
 
 
Tumor Initiation 
Tumor initiation is the first step in multistage carcinogenesis and is characterized by 
genetic alterations that result in dysregulation of the physiological control mechanisms 
in an initiated cell. Chemical carcinogens damage genetic material by forming adducts 
with nucleotides of DNA which can eventually lead to mutations, if left unrepaired 
(312). Most of these chemicals do not readily interact with biological molecules, but are 
metabolized into mutagenic electrophiles by drug metabolizing enzymes that are 
involved in metabolizing and eliminating endogenous and exogenous substances. The 
 60 
 
electrophilic metabolites react with nucleophiles such as DNA and protein to form 
covalent adducts which can lead to irreversible damage. The ability to detoxify 
carcinogens or repair the damaged DNA depends on the gene-environment interactions 
which in turn determines the cancer risk of the exposed individual (313).  Carcinogens 
such as X-rays can ionize water molecules in the cell to generate aqueous free radicals, 
which react with DNA strands to form double-strand breaks leading to loss of genetic 
material (314). Changes which include genetic damage that activates proto-oncogenes 
and inactivate tumor suppressor genes result in an undue growth and survival advantage 
for these cells and this can be categorized as a tumor-initiating event (315). Recent 
evidence suggests that epigenetic changes such as DNA methylation, histone 
modifications, nucleosome positioning and non-coding RNAs may also play a key role 
in initiating tumorigenesis in some forms of cancer (316, 317). For example colon, lung, 
lymphoid and other tumors display de novo hypermethylation of the CpG islands in the 
promoter of the DNA repair gene MGMT leading to aberrant DNA repair and increased 
G to A mutations (318-320). Similarly, spontaneous hydrolytic deamination of 
hypermethylated cytosine can cause C to T transition mutations (321). 
 
Tumor Promotion 
Normal cells undergo a series of mutations in order to achieve a state of complete 
malignancy.  Since the accumulation of mutations is dependent on the rate of cell 
proliferation, the initiated cells undergo rigorous cell division with no effect on the 
adjacent uninitiated cells. This process known as clonal expansion is dependent on 
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promoting agents that generate a population of cells that are predisposed to further 
genetic alterations and malignant transformation (322, 323). 
 
Most tumor promoters elicit their biological responses without metabolic activation and 
they are primarily involved in facilitating formation of tumors in initiated cells. 
Promoters are generally not mutagenic and cannot function alone as a carcinogen but act 
in concert with the initiator. Chemicals that exhibit tumor-promoting effects include 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), benzoyl peroxide, macrocyclic lactones, 
bromomethylbenzanthracene, anthralin, phenol, tryptophan, 
dichlorodiphenyltrichloroethane (DDT), phenobarbital, cigarette smoking condensate, 
polychlorinated biphenyls (PCBs), teleocidins, cyclamates, estrogens and other 
hormones, bile acids, ultraviolet light, wounding, abrasion, and other chronic irritation 
(312). Some agents such as benzo[a]pyrene and 4 aminobiphenyl function as both tumor 
initiators and tumor promoters and hence are termed complete carcinogens.  
 
Malignant Conversion 
Cells can undergo further genetic changes which transform them from a preneoplastic 
state to a malignant phenotype. Conversion of cells into a malignant form is achieved by 
repeated exposures to a tumor promoter. Since the rate of cell division influences the risk 
of conversion into malignant cells, clonal expansion facilitated by tumor promoters 
enhances conversion of cells into a malignant phenotype which is also paralleled by 
further genetic changes. The genetic alterations that occur can be attributed, in part, to 
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faulty DNA synthesis and repair mechanisms leading to activation of oncogenes and 
inactivation of tumor suppressors (324). In addition exposure of preneoplastic cells to 
DNA-damaging agents greatly increase the odds of malignant conversion (312). 
 
Tumor Progression 
The malignant cells acquire more aggressive traits such as the ability to invade adjacent 
cells and tissues. Further genetic and epigenetic changes lead to increased genomic 
instability and uncontrolled cell proliferation favoring tumor progression (325). Some of 
the changes observed during this stage are activation of proto-oncogenes such as ras, 
myc, raf, HER2 and jun through point mutations, gene amplifications and chromosomal 
translocations. Similarly, loss of functional tumor suppressors occurs via deletion, 
chromosomal recombination and disjunction. These changes enhance the ability of cells 
to metastasize into distant tissues and establish secondary tumors at these sites by 
uncontrolled proliferation (315). Although there is evidence for different stages of 
cancer cell progression, the corresponding mutations acquired by cells to achieve a state 
of malignancy results from the accumulation of these genetic changes and not the order 
or the stage in which they occur.  
 
The effects of tumor initiators and promoters on normal cells and the various steps 
involved in multistage carcinogenesis have been observed in a skin cancer model. The 
role of non-mutagenic agents in tumor formation and growth came to light during 
attempts to effectively induce skin tumors in mice (326, 327). The mouse skin tumor 
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model involves application of chemicals such as benzo[a]pyrene (BP), 7, 12-
dimethylbenz[a]thracene (DMBA), or 3-methylcholanthracene (3-MC) on a patch of 
skin and after several months of treatment skin carcinomas are formed. Modifying this 
approach to a single application of DMBA and repeated administration of a skin irritant 
TPA (12-O-tetradecanoylphorbol-13-acetate), active ingredient of croton oil, to the same 
area of skin led to growth of papillomas after 4-8 weeks (328, 329). TPA application was 
essential for the formation of papillomas and discontinuing the application of TPA 
caused the papillomas to regress. DMBA application was critical for papilloma 
formation and repeated treatment with TPA alone did not result in papilloma formation. 
In addition treatment with DMBA followed by delayed (one year) administration of TPA 
resulted in formation of skin tumors. These observations lead to the conclusion that 
DMBA serves as a tumor initiator that results in an irreversible long-lived genetic 
alteration, evident from the fact that skin tumors form even if promotion with TPA is 
begun one year post DMBA treatment. TPA, on the other hand functions as a non-
genotoxic tumor promoting agent. Thus DMBA initiated cells when subjected to 
repeated exposure to a promoter (TPA) undergoes clonal expansion essential for 
transforming initiated cells into a preneoplastic state. Certain papillomas exhibit TPA 
independence following several TPA treatments and these tumors continue to grow and 
develop into carcinomas even after TPA treatments are discontinued. This phenomenon 
suggests a second genetic alteration which facilitates acquisition of aggressive traits 
resulting in cell transformation. An identical effect is observed when the cells are 
subjected to a second application of the initiator. This phenomenon involving a second 
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genetic event pushing the benign growth to an aggressive phenotype is called tumor 
progression (330-332).  
 
DMBA is a known mutagen and generates mutations in exposed cells and skin tumors 
invariably contain point mutations in the H-ras oncogenes and experimentally 
transfected skin cells expressing H-ras oncogenes closely resemble DMBA initiated 
cells.  DMBA treatment also converts the ras proto-oncogene to an active oncogene 
(333). However, this mutation alone does not enhance cell proliferation and promotion 
with TPA gives rise to a papilloma. Exposing this papilloma to a mutagenic agent results 
in mutation of the p53 tumor suppressor gene, which functions in concert with the ras 
oncogene to form carcinomas (334). TPA activates the serine threonine kinase, protein 
kinase-Cα (PKCα), which subsequently activates several downstream genes such as NF-
kB, Fos, Jun and MAPK which cooperate with H-ras oncogene to enhance proliferation 
(335-337).  
 
Cytotoxic agents can also function as tumor promoters. For example cigarette smoking 
and frequent consumption of alcohol increase the risk of certain head and neck cancers 
(338, 339). Various mutagenic carcinogens that are present in cigarette smoke can 
initiate cells present in the epithelium lining throat and mouth. Consumption of large 
quantities of alcohol can cause cellular toxicity and although alcohol is a weak mutagen 
it is capable of causing cell death due to its toxic effects. This toxic effect on the 
mucosal cells in turn stimulates the underlying stem cells to divide in order to restore the 
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epithelial cell layers. Under normal conditions these stem cells proliferate at a slow and 
steady rate, however, to compensate for the damage sustained the cells divide at a faster 
pace resulting in clonal expansion of the initiated cells. This rapid proliferation of cells 
helps in gaining other mutations that eventually lead to head-and-neck cancers (27, 338, 
340). 
 
Molecular Genetics of Colon Cancer 
Studies on the development and progression of colorectal cancer suggest that colon cells 
pass through various stages prior to formation of a carcinoma; the individual stages are 
not readily observed in every tissue however, sequencing experiments reveal genetic 
alterations corresponding to all stages of tumor development (Figure 9). Human aberrant 
crypt foci (ACF) are flat colonic epithelial lesions characterized by altered glandular 
architecture with the absence of dysplasia (341). ACF are considered to be the precursor 
lesion which gives rise to colon cancer. Any growth that is found above the mucosal 
layers is termed a polyp and colorectal polyps that measure less than 5 mm in size are 
hyperplastic in nature and hyperplastic polyps are not precursors of colorectal cancers 
(342). In contrast adenomatous polyps that are formed from the glandular epithelium 
exhibit high degrees of dysplasia with varying levels of differentiation in the epithelial 
cells and there is evidence that adenomatous polyps develop into colorectal carcinomas 
(343). 
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Figure 9. Genetic model of colorectal cancer (344) 
 
 
Adenomatous Polyposis Coli Gene (APC), Loss of 5q 
The adenomatous polyposis coli tumor suppressor gene (APC) is frequently found 
defective in various familial syndromes such as familial adenomatous polyposis (FAP), 
Gardner syndrome and Turcort’s syndrome that predispose individuals to colorectal 
cancer. Besides familial syndromes APC is inactivated by somatic mutations in 70-80% 
of sporadic colorectal adenomas and carcinomas and are considered to be an early event 
in the formation of adenomas (345-347). Studies show that the frequency of APC gene 
mutations does not vary among small adenomas, advanced adenomas and carcinomas, 
unlike other somatically mutated genes found in colon cancer (347, 348). In addition the 
earliest lesions such as microscopic adenomas exhibit somatic mutations in the APC 
gene and both the alleles of the APC gene are inactivated in adenomas and carcinomas 
found in FAP patients and sporadic colorectal cancer patients in accordance to the 
Knudson’s two hit model (344, 346). Hence, it is hypothesized that loss or inactivation 
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of the APC gene located on chromosome 5q induces proliferation of colon cells and 
these cells may then undergo clonal expansion to give rise to an adenoma (348).  The 
most well studied function of the APC protein is regulation of β-catenin in the canonical 
Wnt signaling pathway. Wnt ligands bind to their cognate receptor complex of Frizzled 
proteins and inhibit the function of proteins such as glycogen synthase kinase 3β 
(GSK3β) and Axin thus stabilizing the β-catenin levels in the cell (347, 349). β-Catenin 
interacts with certain DNA-binding proteins such as the TCF/LEF (T-cell 
factor/lymphoid enhancer family) in the nucleus where it serves as transcriptional 
coactivator of several genes including cyclin D1, CMYC, matrix metalloproteinase 7 
(MMP7) and growth factors FGF20 and FGF9 (350). In the absence of the Wnt ligand 
APC binds to Axin and facilitates phosphorylation of β-catenin by two kinases namely 
casein kinase 1 and GSK3β. Phosphorylation of β-catenin targets it for ubiquitination 
and subsequent proteasomal degradation. However, inactivation or loss of APC 
increases -catenin levels, which transcriptionally activate several proto-oncogenes that 
encode for cell cycle proteins and growth factors (347, 349). 
 
DNA Hypomethylation 
An overall decrease in DNA methylation is observed in colon cancer cells compared to 
adjacent normal cells and this is also observed in early stages of colorectal cancer. DNA 
from small adenomas indicate hypomethylation in one-third of the DNA that was 
analyzed (351, 352). The loss of DNA methylation especially in pericentromeric 
sequences prevents chromosome condensation and can result in mitotic non-disjunction 
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leading to loss or gain of chromosomes (353). Sequences such as the long interspersed 
nucleotide element 1 are affected by the global decrease in methylation which can 
potentially activate some elements to transpose (354-356). In addition hypomethylation 
also alters genomic imprinting resulting in the loss of imprinting of regulators of cell 
proliferation and apoptosis (357). Lastly, epigenetic changes such as hypomethylation 
can predispose cells to aneuploidy causing instability in the genome leading to genetic 
alterations such as allelic losses of tumor suppressor genes (348).  
 
KRAS Mutations 
Mutations in the ras gene in an early adenoma triggers clonal expansion resulting in the 
formation of dysplastic tumors (348). The 3 important members of the ras sub-family 
KRAS, HRAS and NRAS are frequently found mutated in several human cancers with 
40% of colon cancer cases containing KRAS somatic mutation (358). The ras genes 
encode a family of small-G proteins that operate downstream of receptor tyrosine 
kinases such as epidermal growth factor receptor (EGFR). Ras plays a role in activating 
mitogen activated protein kinase (MAPK) and PI3K signaling pathways involved in cell 
growth, proliferation and survival.  Mutations affecting KRAS are commonly found on 
codons 12 and 13, while mutations affecting codon 61 are rare (344). These mutations in 
the KRAS alleles are believed to be responsible for the tumorigenic properties of 
advanced colon cancer cells. Moreover, inactivation of the mutated KRAS alleles in 
advanced cancer cells inhibits their tumor forming abilities both in vitro and in vivo 
(359). Although, KRAS mutations are considered to be an event that transitions an 
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adenomatous polyp into a state of dysplasia, evidence from several studies indicate the 
presence of KRAS mutations in colon polyps that do not exhibit any malignant potential. 
In addition KRAS mutations are frequently observed in non-dysplastic lesions such as 
the aberrant crypt foci and hyperplastic polyps that may not develop into a carcinoma 
(341, 360, 361). 
 
LOH of Chromosome 18q 
A majority of colon carcinomas (70%) exhibit loss of heterozygosity on the long arm of 
chromosome 18. Of the 70% of colon cancers exhibiting LOH at chromosome 18, 50% 
are large and late-stage adenomas and less than 10% are early and small adenomas 
suggesting that loss of 18q may be responsible for progression rather than initiation of 
colorectal carcinomas. (348, 360). SMAD2 and SMAD4 are two tumor suppressor genes 
that are located on chromosome 18q and these genes are found mutated in 5% and 10-
15% of colon carcinomas respectively (344, 362, 363). In addition, SMAD4 undergoes 
biallelic loss in one-third of metastatic colon tumors. These genes encode proteins that 
play a vital role in the transforming growth factor-beta (TGF-β) receptor dependent 
growth inhibitory signaling pathways. Binding of TGF-β ligand to the TGF-β type II 
receptors leads to phosphorylation of the type I TGF-β receptors, which in turn 
phosphorylates members of the Smad family of transcription factors. Phosphorylated 
Smad 2/3 complexes interact with Smad4 to give rise to hetero-oligomeric complexes 
which translocate into the nucleus to modulate transcription of genes such as such as 
p300/CBP, TFE3, Ski and c-jun (364-366). TGF-β mediated growth arrest is 
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accomplished by two mechanisms namely, induction of p15 and p21, inhibition of 
cdc25A and downregulation of c-myc (366). SMAD2 and SMAD4 genes are inactivated 
by mutations (frameshift, missense or non-sense) or loss of an entire region of a 
chromosome or small deletions (366). Deleted in colorectal cancer (DCC) is another 
gene found on chromosome 18 and DCC is deleted in 70% of colorectal cancers. It is 
present in the region of allelic loss of more than 90% of colon cancers with LOH of 
chromosome 18q (367, 368). DCC functions as a part of a receptor complex for netrin-1, 
which is a lamin-related secreted protein that plays a critical role in cell migration and 
axonal outgrowth in developing nervous tissues (369-371). DCC exerts pro-apoptotic 
effects by activation of cysteine aspartic protease caspases. When DCC is unbound to its 
ligand, netrin-1, it is cleaved at its intracellular domain by an unknown caspase (372). 
The cleavage exposes an upstream addiction/dependence domain (ADD) and releases 
the inhibitory C-terminal domain. The ADD then interacts with the initiator caspase-9 
and triggers the apoptosis cascade (373). However, when DCC is bound to netrin-1 
ERK1/2 MAPK and small GTPases are activated (374, 375). In mice overexpression of 
netrin-1 generates hyperplastic and neoplastic lesions and inhibition of cell death in the 
gastrointestinal tract. The dual functions of DCC classify this gene as a conditional 
tumor suppressor (376).  
 
Loss of 17p, p53 
Loss of p53 function is considered to be a key step in the transformation from an 
adenoma to a carcinoma and. 70% of all colon cancers show LOH on 17p and most 
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adenomas lack 17p LOH and exhibit p53 mutations on the remaining p53 allele (348, 
360) (377). p53 has an active role in transcriptional regulation of genes that encode 
factors that participate in cell-cycle checkpoints, promote apoptosis and inhibit 
angiogenesis (378). The adenoma-carcinoma transition process can impose tremendous 
amounts of stress on cells which may be counter-productive to cancer cells. During 
conversion from adenoma to carcinoma stresses such as DNA strand breakage, telomere 
erosion, hypoxia and reduced nutrient exposure can activate cell-cycle arrest and 
apoptosis by means of wild-type p53 functions. However, p53 mutations enable tumor 
cells to survive unfavorable environments and facilitate cancer cells to progress to the 
carcinoma stage (344). In addition p53 mutants with missense mutations retain the 
ability to inhibit autophagy in the cytoplasm similar to its wild-type counterpart but are 
unable to transcriptionally activate autophagy in the nucleus thus deregulating this cell 
death pathway (379-381). 
 
In addition to these changes other gene defects including mutations in TCF4, AXIN1&2, 
PI3K, BRAF, CDK8, PTEN are also observed in different subsets of colon cancers (344). 
KRAS mutations and the absence of APC mutations have been reported in most ACF 
from sporadic cancers while ACF from familial adenomatous polyposis patients exhibit 
APC mutations with no KRAS mutations indicating that the molecular mechanisms 
operating in sporadic and familial forms of colon carcinomas are different (382). 
Similarly, demonstration of mutational events such as loss of 17p and other genes in 
both carcinomas and in some very small adenomas suggest that although there is a 
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preferred sequence for genetic events during colon carcinogenesis, the accumulation of 
these events may be more critical than their order of occurrence (348).  
 
Molecular Mechanisms: Prostate Cancer 
Prostatic intraepithelial neoplasia (PIN) is considered to be the first step in development 
of prostate cancer and the precursor lesions are localized in the pre-existing duct acinar 
system (383). Based on the extent of cytological abnormalities PIN is classified from 
low to high grade.  The distinguishing features of PIN include increased cell crowding, 
luminal epithelial hyperplasia, fewer numbers of basal cells, enlarged and atypical 
nuclei, anisonucleosis and cytoplasmic hyperchromasia with minimal basal cell layer 
disruption (384). Although, PIN is widely accepted as the precursor for prostate cancer, 
recent evidence suggest an early inflammatory lesion that precedes PIN as the precursor 
for prostate cancer. These studies propose that infectious agents, dietary carcinogens and 
hormonal imbalances lead to prostate tissue damage, chronic inflammation and 
regenerative lesions termed as proliferative inflammatory atrophy (PIA). Such areas of 
focal atrophic prostate epithelium characterized by increased epithelial proliferation are 
often observed in ageing men and are frequently found near PIN and adenocarcinoma. In 
addition some evidence indicates that certain high-grade prostatic intraepithelial 
neoplasias (PIN) and early adenocarcinomas appear to arise from PIA, however, further 
studies employing molecular pathological techniques and animal models are required to 
determine if PIA is indeed the driving force for prostate cancer (385-389). PIN then 
progresses to latent adenocarcinoma, clinical adenocarcinoma and eventually 
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metastasizes to lung, liver, pleura and invariably the bone where it results in 
characteristic osteoblastic lesions (390-392).  
 
Prostate cancer development is associated with a series of genetic changes that facilitate 
cells to progress through different stages of prostate cancer. The basis for the sequence 
of these molecular events is derived from patient studies however; it is unclear if the 
genetic alterations need to occur in a well-defined temporal order (Figure 10).  
 
 
 
Figure 10. Genetic model of prostate cancer (392) 
 
 
NKX3.1, 8p21 LOH  
Prostate cancer initiation is strongly associated with downregulation of NKX3.1 
homeobox gene and is proposed to occur through multiple mechanisms (393). LOH of 
8p21 is a common occurrence in 85% of high-grade PIN and adenocarcinomas and 
NKX3.1 gene is localized within a 150-Mb minimal deleted region of chromosome 
8p21.2 (394-397). Downregulation of NKX3.1 occurs through epigenetic mechanisms, 
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possibly due to promoter methylation, in cases where 8p21 LOH is not observed (398). 
Contrary to the earlier belief that all advanced cancers lose NKX3.1 expression, recent 
studies demonstrate low levels of NKX3.1 expression in all types of prostate cancer 
suggesting that decreased and not total loss of NKX3.1 expression occurs during prostate 
cancer progression (392, 399, 400). NKX3.1 is the earliest known marker for prostate 
epithelium and the absence of NKX3.1 during development can decrease synthesis of 
secretory proteins and prostatic ductal branching (401-403). Mice that are heterozygous 
and homozygous mutants of NKX3.1 display prostatic hyperplasia and dysplasia and 
tend to develop PIN (401, 404). In addition mice with inactivated NKX3.1 exhibit 
deregulated expression of several antioxidant and prooxidant enzymes, including 
glutathione peroxidase 2 and 3 (GPx2 and GPx3), peroxiredoxin 6 (Prdx6), and 
sulfyhydryl oxidase Q6 (Qscn6) making them susceptible to oxidative damage (405). 
Restoration of NKX3.1 function in human prostate cancer cell lines promotes 
phosphorylation of H2AX and recruitment of phosphorylated ATM  for activation of 
DNA damage checkpoints, cell cycle arrest, DNA repair or apoptosis (406).  
 
Up-regulation of Myc 
The transcription factor Myc is an oncoprotein involved in processes such as cell 
proliferation, protein synthesis, metabolism and stem cell renewal. The MYC oncogene 
is localized on the 8p24 chromosomal region and since a subset of advanced prostate 
cancers display amplification of this region it was assumed that Myc played a role only 
in advanced stage prostate cancer (392, 407). However results from overexpression of 
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Myc protein in luminal cells of PIN, primary carcinomas and metastatic disease 
suggesting that Myc alterations might be an early event in prostate carcinogenesis (407). 
Forced expression of MYC immortalize nontumorigenic human prostate cells and 
transgenic expression of human c-Myc in the mouse prostate can give rise to PIN 
followed by invasive adenocarcinoma demonstrating the oncogenic potential of Myc in 
intiating prostate cancer (408, 409). In addition downregulation of NKX3.1 was 
observed in Myc-induced prostate tumors in mice implying that loss of NX3.1 
complements elevated Myc expression to facilitate the PIN to cancer progression (408). 
 
TMPRSS2-ERG Fusion Gene 
Activation of the ETS (E26 transformation-specific) family of transcription factors ERG, 
ETV1 by chromosomal rearrangements is frequently observed in most prostate cancers. 
The TMPRSS2-ERG created as a result of chromosomal rearrangement expresses an N-
terminally truncated ERG protein under the control of an androgen-responsive promoter 
of TMPRSS2 (251, 410). The chromosomal rearrangement occurs either through an 
interstitial deletion due to the close proximity of both genes on chromosome 21q or 
through a less frequent unbalanced chromosomal translocation (411, 412). Chromosomal 
rearrangements due to interstitial deletion are  hypothesized to be an indirect effect of 
androgen receptor (AR) binding resulting in chromosomal proximity between TMPRSS2 
and ERG loci leading to formation of the fusion gene following DNA strand breakage 
(413, 414). TMPRSS2-ERG fusions occur at 15% rate in high-grade PIN and 50% rate 
in prostate cancer indicating that the chromosomal rearrangement might be an event that 
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occurs after cancer initiation (415, 416). Evidence from whole-genome chromatin 
immunoprecipitation assays and massively parallel sequencing studies reveal that ERG 
can block AR signaling by binding to AR target genes and inducing repressive 
epigenetic programs via activation of H3K27 methyltransferase EZH2, a Polycomb 
group protein which in turn disrupt lineage-specific differentiation of prostate epithelial 
cells (417).  Cell culture assays and studies in transgenic mice demonstrate that 
activation of the ETS gene has a moderate effect on promotion of epithelial-
mesenchymal transistion and tumor-invasive properties (418, 419) .  In addition, 
expression of truncated ERG cooperates with loss of PTEN synergistically to facilitate 
development of high-grade PIN and carcinoma in mice. Evidence from these studies 
indicates that ETS chromosomal rearrangements inhibit differentiation programs and 
promote prostate carcinogenesis by cooperating with other transforming events (420, 
421).    
 
PTEN Inactivation 
PTEN, encodes a dual-specificity phosphatase localized on chromosome 10q23, which 
frequently displays allelic loss in prostate cancer (422, 423). PTEN copy number loss is 
observed as an early event in cancer and is associated with progression to advanced or 
aggressive, castration-resistant disease.  Studies investigating the loss of PTEN also 
suggest that complete loss of PTEN does not occur in prostate cancer, and that low 
levels of PTEN activity are retained (393). Conditional deletion of PTEN in the prostate 
epithelium or germline loss of PTEN in heterozygous mutants results in PIN or 
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adenocarcinoma (424-426). PTEN loss along with inactivation of NKX3.1, upregulation 
of MYC and the TMPRSS-EGR fusion gene are required for cancer progression (420, 
421). Cellular senescence is observed in prostate tumors due to complete loss of PTEN 
in mouse models indicating avenues for therapeutic intervention by selective knockdown 
of PTEN in prostate cancer cells to promote senescence (427, 428). Data from cell 
culture and mouse studies show that decrease or loss of PTEN predisposes to castration-
resistant form of prostate cancer however, the mechanism of this response is not clear, 
but suggests a possible interaction between PTEN and androgen receptor (429-431). 
 
ERK/MAPK Activation 
ERK/(p42/44) MAPK is often activated along with Akt signaling in advanced prostate 
cancer. These pathways jointly promote tumor progression and result in castration 
resistance in prostate cancer cell lines and mouse models (431-434). However, the 
events leading to activation of ERK/MAPK signaling are not well defined and defective 
growth factor signaling may play a role (435). RAS and RAF mutations are uncommon in 
early stage prostate cancer whereas deregulation of these oncogenes are more frequently 
observed in advanced prostate cancer (436). Expression of activated forms of RAF 
(BRAFV600E) or RAS (K-ras [+/V12]) in mice leads to development of prostate gland 
hyperplasia which progresses to rapidly growing invasive adenocarcinomas (437, 438). 
Dysregulation of the RAS and RAF signaling pathways can also occur since a small 
subset of aggressive prostate cancers exhibit translocation of B-RAF or C-RAF (439). 
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Ezh2 
The gene enhancer of zeste homologue 2 (EZH2) gene is part of the Polycomb repressor 
complex and encodes for a histone lysine methyltransferase that is upregulated in 
hormone-refractory and metastatic prostate cancer (440, 441) . EZH2 represses the 
prostate-specific tumor suppressor gene NKX3.1 through ERG (442). In addition EZH2 
targets other genes associated with metastasis such as E-cadherin and DAB21P that 
actively promote prostate cancer metastasis through NF-B and Ras signaling pathways 
(443-445). 
 
Oncogenic tyrosine kinases such as Her2/Neu and Src tyrosine kinases play important 
roles in aggressive disease, progression to metastasis and castration resistance and are as 
therapeutic targets in patients with advanced disease (446, 447). AR signaling results in 
Src activation which in turn leads to AR phosphorylation, castration-resistance, 
increased cell proliferation and heightened invasive properties (448-450). Similarly, 
developmental signaling such as Hedgehog pathway has a substantial role in prostate 
cancer progression through autocrine and paracrine mechanisms in epithelial and stromal 
cells respectively (451-454). FGF signaling through activation of FGFR1 or 
overexpression of FGF10 to drive the ERK MAPK pathway is also involved in prostate 
carcinogenesis. MicroRNAs have specific roles in pathogenic processes concerned with 
cancer growth and development and miR profiling studies of human prostate tumors and 
xenografts indicate distinct microRNA expression patterns for indolent and aggressive 
prostate tumors (455, 456) (457). Tumor suppressor microRNAs such as miR-101 can 
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suffer loss of alleles and upregulate oncogene EZH2 while the oncogenic microRNAs 
such as miR-106b-25 cluster can negatively regulate the tumor suppressor PTEN (458, 
459).  
 
Hallmarks of Cancer 
During the process of multistage carcinogenesis cancer cells acquire certain traits that 
allow them to function autonomously and progress to a state of malignancy. The six 
traits listed in the seminal article “The Hallmarks of Cancer” published by Hanahan and 
Weinberg include sustaining proliferative signaling, resistance to anti-growth signals, 
evading cell death, unlimited replicative potential, sustained angiogenesis and activation 
of tissue invasion and metastasis (Figure 11) (460). Advances in the field of molecular 
biology and development of better tools in the past decade have improved our 
understanding of cancer biology.  The “Hallmarks of cancer” since has had four more 
additions that are categorized as “emerging hallmarks”- namely deregulation of cellular 
energetics and evasion of the immune system and “enabling characteristics”- which 
include genomic instability and tumor-promoting inflammation (461).  
 
Sustaining Proliferative Signaling  
The production and secretion of growth signals that facilitate cell growth and division in 
normal cells is highly regulated and tightly controlled whereas cancer cells can 
circumvent these finely tuned mitogenic signaling pathways to gain control over the 
proliferative machinery. The mechanisms governing these signaling cascades are highly  
 80 
 
 
 
Figure 11. Hallmarks of cancer. Reprinted from “Hallmarks of Cancer: The Next Generation”, Vol. 144/ 
Issue 5, Douglas Hanahan,Robert A. Weinberg, Copyright (2013), with permission from Elsevier (461). 
 
 
complex in normal cells and are poorly understood on the other hand these signaling 
pathways in cancer cells are more defined (256, 462-464).   Cancer cells acquire the 
ability to sustain proliferative signaling in multiple ways. They synthesize growth factor 
receptor ligands to activate cognate receptors expressed on the cell surface initiating 
autocrine signaling loops to stimulate proliferation. Growth factors from normal cells in 
the tumor associated stroma also enhance tumor cell growth. In addition, increased 
expression of cell surface receptors sensitize cancer cells to limiting amounts of growth 
factor ligands present in the environment. Cancer cells also deregulate growth signaling 
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pathways by expressing constitutively active receptors that are capable of conveying 
signals downstream in the absence of ligand (461). The B-Raf protein is constitutively 
activated by a mutation in 40% of melanoma patients resulting in stimulation of the 
downstream MAPK pathway (465). Negative feedback loops serve as an effective 
mechanism to ensure that growth signal transmission is transitory.  An example of a 
defective negative feedback loop is the Ras oncoprotein signaling. The oncogenic 
mutation compromises the Ras GTPase binary signaling activity thus preventing the 
ability of the protein from switching to an “off” state to arrest the signaling process. 
Similarly, the effector of PI3K signaling, phosphatidylinositol (3,4,5) trisphosphate 
(PIP3) is degraded by the phosphatase PTEN as a part of the regulatory feedback 
mechanism. However, PTEN is absent in most tumors due to promoter methylation 
resulting in increased PI3K signaling which contributes to tumorigenesis (466, 467). 
Although, cancer cells elevate growth factor levels to boost their replicative potential 
recent studies conclude that excessive growth factor signaling can be detrimental to cells 
due to triggering of cellular senescence or induction of apoptosis and these responses 
represent an intrinsic cellular defense mechanism against excessive signaling.(468-470). 
 
Resistance to Anti-growth Signals 
Growth inhibitory effects in cells are mediated by tumor suppressor genes and Rb 
(retinoblastoma-associated) and p53 are two tumor suppressors that are frequently found 
inactivated in several cancers.  The Rb protein serves as a gatekeeper by preventing or 
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permitting cells to progress through its growth and division cycle based on the 
extracellular and intracellular stimuli that it receives (471-473). 
 
The absence of Rb permits cells to proceed through various phases of the cell cycle 
without any checks and facilitates their proliferation. In contrast p53 functions as an 
internal sensor to various stresses such as genomic damage, suboptimal levels of 
nucleotides, growth promoting signals, glucose or oxygenation. In such scenarios p53 
transmits signals to halt cell-cycle progression until cells attain homeostasis (461). 
Contact inhibition is another mechanism that exists in the cells to limit unnecessary cell 
proliferation and maintain tissue homeostasis. Loss of contact inhibition is a common 
phenomenon observed in many cancer cells and facilitates their ability to maintain 
uncontrolled growth. Merlin, the product of a tumor suppressor gene NF2 mediates 
contact inhibition by tethering cell-surface adhesion molecules such as E-cadherin to 
transmembrane receptor tyrosine kinases such as the EGF receptor. Coupling E-cadherin 
to EGF receptors not only reinforces cell-cell adhesion but also restricts growth factor 
signaling due to sequestration of the receptor tyrosine kinases (461, 474, 475). Another 
well-known antiproliferative factor is TGF-β which in early stages of cancer acts as a 
tumor suppressor by inhibiting cell proliferation, but can function as a tumor promoter 
by activating the epithelia-mesenchymal transmission (EMT) in the late-stage cancers 
(476-478).  
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Evading Cell Death 
Apoptosis or programmed cell death is a natural barrier to cancer formation and is 
disabled in several cancers (470, 479). Apoptosis can proceed through intrinsic and 
extrinsic pathways and what sets these pathways apart are the regulators involved in 
each of these mechanisms. The extrinsic pathway receives and processes extracellular 
death-inducing signals through the extracellular Fas ligand and Fas receptor and other 
death receptors and their ligands. The intrinsic pathway consists of regulators that 
respond to intracellular signals and both these pathways converge on common effectors 
termed as caspases, which are cysteine aspartic acid dependent proteases. The signals 
from the intrinsic and extrinsic pathways travel through a group of initiator caspases 
(caspases 2, 8, 9 and 10) that in turn relay signals to executioner caspases (caspases 3, 6 
and 7). These executioner caspases are the final effectors of apoptosis leading to 
digestion and disassembly of cellular components and phagocytosis by neighboring 
cells.  Cancer cells employ several schemes to evade apoptosis. The “guardian of the 
genome”, p53 can sense DNA strand breaks and chromosomal abnormalities in cells and 
induces apoptosis by increasing the expression of proteins Noxa and Puma. Loss of p53 
activity renders the cells ineffective in checking for DNA damage and the ability to filter 
defective cells through apoptosis (480). Tumors can also resist cell death by upregulating 
antiapoptotic factors such as Bcl-2 and Bcl-xL. These proteins bind the pro-apoptotic 
factors Bax and Bak localized in the mitochondrial membrane and prevent them from 
disrupting the integrity of the mitochondrial membrane. Disruption of the mitochondrial 
membrane is essential for the release of pro-apoptotic factors such as cytochrome-c into 
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the cytoplasm to activate caspases and induce apoptosis. Alternatively, cancer cells can 
downregulate expression of pro-apoptotic factors such as Bax, Bak and Bim to inhibit 
apoptosis (479).  
 
Autophagy is a physiological reaction that occurs in the cell in response to cellular stress 
(e.g. deprivation of nutrients) and mediates both tumor cell survival and death. During 
autophagy cellular structures and organelles are broken down and engulfed by 
intracellular vesicles termed autophagosomes which fuse with lysosomes for activating 
degradation. The catabolic products formed as a result are used for biosynthesis and 
energy metabolism to support the cells under extremely stressful conditions (481, 482). 
Regulators that govern apoptosis also play a role in autophagy. PI3K, Akt and mTOR 
(mammalian target of rapamycin) kinases inhibit autophagy when activated by survival 
signals and the absence of survival signals can decrease PI3K signaling and initiate 
apoptosis or autophagy (481-484). In contrast several studies demonstrate that conditions 
such as nutrient deprivation, radiotherapy and chemotherapy with certain cytotoxic drugs 
that induce autophagy can be cytoprotective to cancer cells (484-487). In addition, 
cancer cells that are subjected to stress can shrink by means of autophagy to a dormant 
state and return to full functionality when the environment is more favorable (485, 488). 
These contradictory findings demonstrate that autophagy can serve as a tumor 
suppressor and a tumor promoter and function “as a double-edged sword”. 
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Unlimited Replicative Potential 
Cancer cells are able to undergo limitless replication cycles unlike normal cells which 
cease to divide and grow after a limited number of cell growth and division cycles. This 
unlimited replicative potential of cancer cells is associated with structures called 
telomeres that are hexanucleotide repeats present in tandem on the ends of every 
chromosome. Every cell growth and division cycle progressively erodes and shortens the 
telomeres on the chromosome. Complete loss of telomeres after several proliferation 
cycles leaves the ends of chromosomes unprotected predisposing the DNA to form end-
to-end fusions with other chromosomes leading to genomic instability and cell death. 
Hence, the length of the telomeres on the chromosome dictates the number of cell 
divisions the cells can pass through before entering a state of senescence or crisis (489, 
490). On the other hand cancer cells are not restricted by the limited replication cycles 
resulting from telomere shortening. Cancer cells express high levels of a DNA 
polymerase, telomerase that adds telomere repeat segments to the ends of DNA after 
each replicative cycle gifting the cells with the power of immortality. Studies in 
telomerase null mice demonstrate that telomere shortening induces senescence or 
apoptosis in premalignant cells which otherwise would have developed to form tumors 
(491). In addition evidence from studies on mice indicate that absence of telomerase 
function in certain cases can be beneficial for cancer progression and development.  Loss 
of p53 can allows cells to undergo unchecked replication even after complete telomere 
loss which can lead to breakage-fusion-bridge (BFB) cycles. BFB cycles can accelerate 
the rate at which cells acquire mutations or undergo genomic alterations such as 
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activation of oncogenes or inactivation of tumor suppressors. The presence of telomerase 
function in this scenario might prove to be disadvantageous since restoring telomere 
length can prevent BFB cycles limiting the rate at which the cells acquire mutations 
(491, 492). However there is no conclusive evidence to suggest the possibility of p53 
and telomerase loss cooperating to promote tumor formation in humans (461).  
 
Sustained Angiogenesis 
Angiogenesis is the process of sprouting new vessels required for the supply of nutrients 
and oxygen and in normal cells angiogenesis is typically functional only during 
embryogenesis, wound healing and female reproductive cycling. However, cancer cells 
demand a greater supply of oxygen and nutrients which is met by processes such as 
angiogenesis and vasculogenesis. In contrast to normal cells where angiogenic signaling 
pathways operate transiently, the “angiogenic switch” in cancer cells is always turned on 
(493). Factors regulating angiogenesis can be stimulatory or inhibitory. Vascular 
endothelial growth factor (VEGF) is a well-studied angiogenesis inducer that is involved 
in blood vessel formation during embryonic and post natal development as well as in 
physiological and pathological conditions. The VEGF family of growth factors include 
VEGF ligands A, B, C and D and Placental Growth Factor (PIGF) which form homo- or 
hetero-dimers with each other and interact with receptor tyrosine kinases VEGFR 1-3 
and co-receptors Neutrophilin1 and 2 to elicit their responses in cells (494). Regulation 
of VEGF gene expression is controlled by many factors such as fibroblast growth factor, 
interleukin-1 and TGF-β in both normal and tumor cells (495-497). In addition, muscle 
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contraction, hypoxia and inflammation contribute to regulation of VEGF gene 
expression (498-500). Cells that are transformed by oncogenes may express VEGF 
family members and control expression of VEGF through transcription factors such as 
hypoxia inducible factors (HIF1 and HIF2), Ap-1, NF-B, E2F1 and ZNF24 (501-503). 
Moreover, the extracellular matrix serves as a storehouse for VEGF ligands that are 
sequestered in its inactive forms and are released following proteolytic cleavage by 
extracellular matrix degrading proteases (504). The angiogenic machinery in the cell is 
balanced by endogenous angiogenesis inhibitors that serve as a natural barrier for 
tumorigenesis. Thrombospondins are a family of proteins that play a role in tissue 
remodeling, embryonic development, wound healing, synaptogenesis and neoplasia. 
Thrombospondin-1 (TSP-1), is a well characterized member of the family and inhibits 
angiogenesis by affecting endothelial cell migration, survival and VEGF bioavailability. 
It can also suppress tumor growth by activating TGF-, interacting with cell surface 
receptors and regulation of extracellular proteases (505). In addition to TSP-1, 
endostatin, a type 18 collagen, and angiostatin also function as endogenous angiogenesis 
inhibitors (505-507).   
 
Activation of Tissue Invasion and Metastasis 
The invasion-metastasis cascade is a multistep process involving a sequence of events 
that is initiated when cancer cells invade local tissues (508, 509). Epithelial-
Mesenchymal transition (EMT) is a phenomenon that is closely associated with cancer 
cell invasion and metastasis and is commonly observed during embryogenesis and 
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wound healing. EMT enables transformed epithelial cells to invade and metastasize to 
distant tissues and at the same time resist cell death by evading the apoptotic machinery 
(510, 511). Transcription factors such as Snail, Slug, Twist and Zeb1/2 are reported to 
mediate EMT in cancer cells. During EMT epithelial cells undergo alterations such as 
conversion from a polygonal/epithelial to a spindly/fibroblastic morphology, acquire 
traits such as increased motility, increased expression of matrix metalloproteinases to 
digest extracellular matrix and the ability to resist apoptosis (508, 512). The transcription 
factor involved in initiating EMT can directly repress a critical component of the cell-
cell junction complexes, E-cadherin (513). This cell adhesion molecule is involved in the 
assembly of epithelial cells into sheets and ensures that cells within tissues are bound 
together by forming adherens junctions. Loss or mutational inactivation of E-cadherin is 
often associated with a cell phenotype that is highly invasive and metastatic and 
overexpression of E-cadherin is reported to have tumor suppressor effects (514, 515). On 
the other hand cell adhesion factors such as N-cadherin that facilitate cell migration and 
motility in neurons and some mesenchymal cells are commonly overexpressed in several 
aggressive carcinomas (515). Recent studies indicate that cross talk between the 
neoplastic cells and stromal cells is necessary for invasion and metastasis and it is more 
obvious that the epithelial cells do not function autonomously (516). Cancer cells relay 
stimulatory signals to the adjoining tumor stroma and the mesenchymal stem cells 
located in the stroma secrete chemokines such as  CCL5 (Chemokine [C-C motif] ligand 
5) in response to signals that stimulate invasive behavior in cancer cells (517). Similarly, 
activation of macrophages confined to tumor periphery by IL4 secretion from cancer 
 89 
 
cells is reciprocated by supply of metalloproteinases and cysteine cathepsin proteases 
from activated macrophages to allow cancer cells acquire invasive abilities (518). 
Following invasion cancer cells undergo intravasation in to adjacent blood and lymph 
vessels and are transported through the lymphatic and hematogenous routes to distant 
tissue sites. Experimental models of metastatic breast cancer demonstrate activation of 
cancer cells by EGF released from tumor associated macrophages (TAM) followed by 
release of  colony stimulating factor-1 (CSF-1) by activated cancer cells to reciprocally 
stimulate TAMs, which in turn mediated cancer cell intravasation into the blood vessels 
and dissemination to distant sites (519). The next step in the invasion-metastasis cascade 
is extravasation of cancer cells from the blood and lymph vessels into tissue sites. 
During the process of dissemination cancer cells are drawn farther away from the source 
of EMT-inducing signals hence diminishing the effects of these signals on the cancer 
cells. As a result cancer cells that have experienced EMT and acquired invasive and 
metastatic properties may revert back to a form that is histopathologically identical to the 
primary tumor from which they arose and this phenomenon is termed as mesechymal-
epithelial transition (MET) (520). Formation of micrometastases (small nodules of 
cancer cells) at foreign tissue locations and successful development of macroscopic 
lesions from the established micrometastases is referred to as colonization (508, 509). 
Cancer cells that arrive at a distal tissue have poor adaptive capabilities initially and 
employ several strategies to thrive in the foreign tissue. In some cases the 
micrometastases may remain dormant due to the influence of systemic suppressors that 
primary tumors release and may abruptly arise as metastatic growths when the supply of 
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suppressors cease as in case of resection of the primary tumor (521, 522). Similarly, 
metastatic growths seen decades after surgical removal of primary tumors from breast 
cancer and melanoma patients is attributed to the ability of the micrometastases to finally 
adapt to the foreign environment and establish as macroscopic lesions after years of trial 
and error (523-525). Other mechanisms of micrometastases dormancy  and survival in 
the new unfavorable environment may include anti-growth signals sequestered in the 
extracellular matrix of normal tissue and tumor suppressor effects of the immune system 
(523, 524, 526).  
 
Enabling Characteristics and Emerging Hallmarks 
The hallmarks of cancer described above are acquired in tumor cells through multiple 
mechanism, however two important characteristics that enable these cells to be 
transformed include, genomic instability and tumor-promoting inflammation (Figure 12) 
(461). 
 
Genomic Instability  
The genome maintenance system detects and corrects defects in genetic material of the 
cell and ensures that the mutation rates are kept low during each cell-growth-division 
cycle. Moreover, the surveillance system also keeps a check on the genomic integrity of 
cell by eliminating cells carrying any genetic defects or mutations (527-529). Defects in 
the maintenance machinery impairing any of its functions including ability to detect 
DNA damage and activate the repair mechanism or ability to directly repair damaged 
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Figure 12. Emerging hallmarks and enabling characteristics of cancer. Reprinted from “Hallmarks of 
Cancer: The Next Generation”, Vol. 144/ Issue 5, Douglas Hanahan,Robert A. Weinberg, Copyright 
(2013), with permission from Elsevier (461). 
 
 
DNA or ability to inactivate mutagenic molecules before it damages DNA can culminate 
in genomic instability and facilitate cancer development and progression (527, 528, 530-
533).  
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Tumor-Promoting Inflammation 
It is evident from several studies that inflammation also plays a crucial role in promoting 
tumorigenesis (534-537). Inflammation can enrich the tumor microenvironment with 
growth factors that can ensure continuous proliferation of tumor cells. Similarly, a 
constant flow of survival factors can make the cells resistant to anti-growth signals. In 
addition inflammation can provide cells with proangiogenic factors and matrix 
metalloproteinases that facilitate processes such as EMT, tumor invasion and metastasis. 
Activated inflammatory cells can generate reactive oxygen species (ROS) and reactive 
nitrogen intermediates (RNI) that are capable of inducing mutations leading to genomic 
instability. 
 
The emerging hallmarks of cancer are suggested to be functionally important for the 
development of cancer and also include deregulation of cellular energetics and evasion 
of the immune system (307, 530, 537). 
 
Deregulation of Cellular Energetics 
The uncontrolled proliferation of cancer cells can result in an excessive demand for 
energy and nutrients and these additional requirements are typically met by 
modifications in metabolic pathways operating in these cancer cells. Normal cells under 
aerobic conditions breakdown glucose to pyruvate via glycolysis and the pyruvate 
subsequently enters the citric acid cycle to generate NADPH, which then undergoes 
oxidative phosphorylation in the mitochondria to generate ATP. However, under 
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anaerobic conditions the cells produce lactate via glycolysis using lactate dehydrogenase 
which consumes NADPH for re-use in glycolysis. Notably cancer cells even under 
normoxic conditions utilize the latter (lactic acid fermentation) pathway for generating 
energy which proceeds rapidly but results in generation of fewer ATP/cycle and this is 
termed as the Warburg effect, named, Otto Warburg, who first described this 
phenomenon (538-540). Hypoxic conditions and hypoxia regulators such as HIF1α and 
HIF2α transcription factors activate the aerobic glycolytic pathway in cancer cells and 
oncogenes such as RAS and MYC and mutated tumor suppressors such as TP53 are 
associated with aerobic glycolysis (541, 542). Ras oncoprotein and hypoxia can increase 
the levels of HIF1α and HIF2α, which can in turn upregulate aerobic glycolysis (543-
545). In addition isocitrate dehydrogenase1/2 (IDH) is also reported to be activated by 
gain in function mutations in gliomas and other tumors (546). Glucose transporter, 
GLUT1 is another factor that is upregulated in cancer cells to increase the import of 
glucose into the cytoplasm to compensate for the 18-fold lower energy that is generated 
under anaerobic conditions (541, 542, 547). Although, aerobic glycolysis produces less 
energy compared to mitochondrial oxidative phosphorylation cancer cells prefer 
glycolysis even when there is sufficient quantities of oxygen. Vander Heiden et al. 
postulated that glycolysis generates various intermediates that can be shuttled into 
several pathways important for biosynthesis of macromolecules and cytoplasmic 
organelles (548, 549).   
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Evading the Immune System 
Recent studies suggest an important role for the immune system in serving as a natural 
barrier against tumorigenesis. Genetically engineered mice devoid of CD8+ cytotoxic T 
lymphocytes (CTLs), CD4+ Th1 helper T cells, or natural killer (NK) cells exhibit an 
increased tumor incidence and higher cancer susceptibility in mice with combined 
deficiencies of T cells and NK cells. This suggests that both innate and adaptive immune 
systems have a substantial role to play in immune system mediated tumor inhibition 
(526, 550). Furthermore results from transplantation experiments conducted in mice 
corroborate the role of immune system in cancer inhibition. Cancer cells that arise in 
immunodeficient mice are unable to form secondary tumors in syngeneic or 
immunocompetent hosts; on the other hand cancer cells from tumors that are formed in 
immunocompetent hosts are fully capable of forming secondary tumors in both hosts. 
This suggests that highly immunogenic cancer cells are eradicated in the 
immunocompetent host leaving behind only weakly immunogenic cancer cells which 
can form tumors in both types of hosts. In contrast cancer cells in an 
immunocompromised host do not undergo the process of immunoediting to eliminate the 
strongly immunogenic cancer cells. As a result when these cells are transferred to an 
immunocompetent host the immune system eradicates the immunogenic cancer cells 
(526, 550, 551). Epidemiology studies on colon and ovarian cancer patients with tumors 
heavily infiltrated with CTLs and NK cells exhibit better prognosis than patients 
expressing lower levels of these lymphocytes (552-555). In addition some cancers may 
be held in a dormant state as a result of the immune system and these individuals do not 
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show any signs of cancer. However, when these “so-called” tumor-free individuals 
donate organs, immunosuppressed organ recipients develop donor-derived cancers 
confirming an important role for the immune systems in tumorigenesis (556).  
 
CANCER THERAPY 
Therapeutic measures employed to treat cancer have changed over time with increased 
understanding of cancer biology. Targeted therapies and sophisticated surgical 
techniques have replaced archaic medical practices that were once the only available 
methods for treatment for cancer. Clinicians now have the option to choose from a wide 
range of treatment methods that are best suited for the patient depending on the location, 
grade and stage of the tumor and the general condition of the patient. Surgery, 
chemotherapy and radiation are the most commonly practiced treatment interventions 
against cancer and more advanced treatment strategies such as targeted and 
immunotherapies are gaining prominence and have given encouraging results against 
late-stage and aggressive cancers.  
 
Surgery 
Surgical resection of tumors has been practiced since 1600 BC and it is mentioned in 
ancient Indian and Egyptian medical records (6). Surgical excision of entire tumors and 
lymph nodes were commonly performed by surgeons Bilroth, Halstead and Handley 
with the invention of anesthesia during the 1800s (557).  Surgery is the first line of 
treatment for most cases of solid tumors and is performed for several reasons. Typically 
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it involves resection of the entire tumor mass along with some healthy tissue or even the 
affected organ and lymph nodes (lymphadenectomy). In some cases initial removal of 
part of the tumor is practiced (de-bulking or cytoreduction surgeries) in order to reduce 
the tumor to a manageable size for further treatment with chemotherapy or radiation. In 
addition surgery is required for diagnostic purposes to perform biopsies and ascertain the 
staging of the tumor to determine the best possible therapeutic approach. Surgery is also 
used for explorative purposes to assess the extent of tumor metastasis and the number of 
lymph nodes involved. Palliative surgeries are performed in certain cases in order to 
provide relief from distress caused due to tumor-related obstructions. Depending on the 
stage and the components involved surgical procedures for treatment of advanced 
colorectal cancer may vary.  
 
Surgical intervention for rectal cancer involves low anterior resection or abdominal 
perennial resection in combination with radiation and chemotherapy. Stage I rectal 
cancer is treated with surgical resection without chemoradiation. Surgical resection in 
combination with adjuvant or neo-adjuvant chemoradiation is preferred for stage II and 
III disease. Stage IV rectal cancer is treated by surgical bypass of local bowel 
obstruction as a palliative measure in combination with chemoradiation. For stage I and 
II colon cancers, surgery alone is sufficient with some stage II individuals requiring 
additional chemotherapy.(558). Adjuvant chemotherapy in combination with surgery is 
the preferred choice for stage III patients and improves survival (559, 560). A subset of 
stage IV colon cancer patients with resectable bowel disease and resectable isolated 
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hepatic and pulmonary metastases are tractable to surgical intervention. Transarterial 
chemo-embolization or radiofrequency ablation may be used in cases of unresectable 
liver metastases (561).  
 
Radical prostatectomy is used when prostate tumor growth is confined to the organ and 
the individual has a reasonable life expectancy with no other co-morbidities. Pelvic 
lymph node dissections (PLND) is commonly performed with radical prostatectomy 
however, it is not clear if removal of lymph nodes improves survival.  There are several 
types of radical prostatectomy such as retropubic, perineal and the more recent 
laproscopic and robotic radical prostatectomy. Retropubic is considered to be the most 
efficient and since it is time-tested and there is sufficient evidence demonstrating its 
superiority in cancer control and potency (562, 563). The only known disadvantage of 
this procedure is the blood loss. The perineal approach is used less due to the inability to 
perform pelvic lymphadenectomy, damage to anal-sphincter and bowel-related 
complications that arise from the procedure. Robotic and laproscopic techniques are 
relatively recent techniques and result in lower blood loss and improved visualization in 
the depths of the pelvis. Cancers that spread beyond the margins of the organs and 
invade seminal vesicles with no signs of metastases are termed locally advanced.  In 
such cases of prostate cancers radical prostatectomy is practiced in combination with 
adjuvant radiotherapy or neoadjuvant chemo-hormonal therapy. Local recurrence of 
prostate cancer following external beam radiotherapy or brachytherapy is treated by 
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salvage radical prostatectomy. This procedure is performed primarily for symptomatic 
relief and is not effective for cases of distal tumor metastasis (564). 
 
Radiotherapy 
Radiotherapy or radiation therapy is a commonly practiced treatment method that 
involves ionizing radiation to destroy malignant neoplastic cells. It is used for palliative 
and curative purposes and approximately 70% of cancer patients receive radiotherapy 
during their disease course (565). Radiation for therapy is used in different forms such as 
brachytherapy, external beam radiotherapy (EBRT) and unsealed sourced radiotherapy. 
Brachytherapy involves use of radioactive isotopes that are placed in the immediate 
vicinity of the cancerous tissue or often within the tumor tissue itself. The radioisotopes 
emit high doses of short range radiation which destroy the tumor tissue but have minimal 
effects on surrounding normal tissues (566, 567). It is a commonly employed treatment 
method for different kinds of tumors and is used in combination with chemotherapy and 
surgery. EBRT is performed by generating a beam of ionizing radiation using a linear 
accelerator which emits either high energy x-rays or gamma rays from radioisotopes 
such as cobalt-60. In order to ensure precise and effective delivery of radiation the 
shape, intensity, angle and direction of the beams can be altered depending on the 
location and size of the tumor (565-567). Unsealed source radiotherapy involves use of 
therapeutic radiopharmaceuticals which are radiolabeled molecules capable of 
transporting therapeutic doses of ionizing radiation to target sites in the body.  131I-
sodium iodide for thyroid cancer and 89Sr-strontium chloride and 32P-sodium phosphate 
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for metastasis associated bone pain are commonly used radiopharmaceuticals. Due to its 
specificity and ability to reach distant sites, use of radiopharmaceuticals is a preferred 
method of treatment over EBRT for cancer metastases that have widely disseminated 
(568). 
  
Radiation therapy is effective as an adjuvant treatment for individuals with advanced 
colon cancers that spread to neighboring organs and tissues. (565). In contrast to colon 
cancer which has a recurrence pattern on distant tissue sites, rectal cancer relapse occurs 
locally within the pelvis (569). This has led to use of radiation and chemotherapy as an 
adjuvant therapy after surgery for treatment of patients with stage 2-3 disease that have 
highest risk of locoregional recurrence. Chemotherapy operates as a radiosensitizer in 
the pelvis and works against metastases above the pelvis and recent studies indicate that 
chemotherapy before surgery gives encouraging results in a subset of patients with T3, 
T4 or node-positive rectal cancer in comparison to its use after surgery (570-573). 
  
Permanent seed implant (PSI) or EBRT are suitable therapeutic options for low-risk 
prostate cancer patients and effective control rates are attained when a single treatment 
method is employed (574). EBRT is highly efficacious in controlling low-risk disease 
and causes minimal side-effects. The radiation doses administered through EBRT at 
present are higher in comparison to what was used earlier since randomized trials 
demonstrate better biochemical control of the disease in terms of PSA stability with 
increasing doses of radiation (575-578). Doses > 70 gray (Gy) was considered unsafe 
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due to undesirable side-effects on the bladder and rectum; however, with better delivery 
systems it is now possible to administer doses ranging from 76-80 Gy with minimal 
toxic side-effects (565). Although the effectiveness and the mild nature of side-effects of 
EBRT are well documented, EBRT can also be inconvenient to the patients due to the 
daily treatments and the high cost involved (565, 579). PSI and brachytherapy are 
administered as single therapy for low-risk prostate cancer patients with prostate weights 
ranging from 50-60 grams. The final dose delivered to patients can range up to 145 Gy 
and hence the resulting toxicities are of a greater magnitude than EBRT (565). 
Intermediate and high-risk patients are treated with a combination of surgery, radiation 
and androgen-deprivation therapy. Randomized trials comparing the efficacy of 
combination therapy and radiation alone confirm the superiority of the former approach 
for patients with high and intermediate-risk (580). Administration of luteinizing 
hormone-releasing hormone agonists such as leuprolide or goserelin in combination with 
radiation therapy results in a synergistic effect on radiation induced cell death by 
promoting apoptosis. In addition intermediate and high-risk patients are also treated with 
intensity modulated radiotherapy (IMRT) combined with a brachytherapy (565).  
 
Chemotherapy 
Cytotoxic chemotherapeutic drugs that are commonly used as anti-cancer agents elicit 
their responses by alkylating nucleophilic functional groups, inhibiting metabolism, 
intercalating between DNA or RNA base pairs and inhibiting synthesis, interfering with 
topoisomerase II function and generating free oxygen radicals. Development of more 
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effective systemic chemotherapeutic agents has significantly improved the mean survival 
time in patients with metastatic colon cancer. 5-Flurouracil (5-FU) is the most 
commonly used systemic chemotherapy for treating advanced colorectal cancer. 5-FU is 
a fluoropyrimidine that interferes with DNA replication by inhibiting the enzyme 
thymidylate synthase that generates thymine, a nucleoside which is essential for DNA 
synthesis (581). Leucovorin, a reduced form of folate is normally administered in 
combination with 5-FU as a biomodulator to improve the binding between 5-FU and 
thymidylate synthase (582). It is employed as an adjuvant therapy for stage III colon 
cancer patients and stage II and III rectal cancer patients (558). The inability to detoxify 
fluoropyrimidines, due to dihydropyrimidine deficiency can lead to 5-FU toxicities such 
as neutropenia, stomatitis and diarrhea (561). There is increasing evidence to suggest 
that the DNA mismatch repair (MMR) function status of the tumor cells is important for 
the efficacy of 5-FU. DNA MMR machinery ensures the genome’s stability by repairing 
errors committed by DNA polymerase and MMR also identifies chemotherapeutic 
agents that intercalate into the DNA and induce death pathways in those cells (583-585). 
However, dysfunctional MMR machinery that fails to recognize the intercalated 
chemotherapeutic agent might not trigger cell deathand while 5-FU readily induces cell 
death in cancer cells with an intact MMR system and cells with a dysregulated DNA 
MMR were 28-fold more resistant to this drug.(584). Moreover, restoring the MMR 
function in 5-FU resistant cells enhances their susceptibility to this agent (586).  
Irinotecan is currently used in combination 5-FU as a first-line therapy for metastatic 
colon cancer, but is not beneficial in adjuvant therapy (558). Irinotecan falls under the 
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class of drugs that inhibit topoisomerase I, an enzyme that is involved in uncoiling of 
DNA before transcription and DNA replication. Irinotecan is metabolized into SN-38 by 
hepatic carboxylesterases and SN-38 is the active metabolite that inhibits topoisomerase 
I. Irinotecan as a single agent and in combination with 5-FU is shown to increase tumor 
shrinkage and improve survival in patients with advanced colorectal cancer by 2-3 
months (587, 588). Irinotecan is inactivated by uridine diphosphate 
glucuronosyltransferase 1A1 (UGT1A1) and individuals with a homozygous UGT1A1 
allele unable to effectively conjugate and detoxify irinotecan exhibit severe neutropenia 
(587-589). In addition other side effects of irinotecan treatment include alopecia, nausea, 
vomiting, diarrhea and bone marrow suppression (561, 590). 
 
Alkylating agents are another category of chemotherapeutic drugs commonly used to 
treat cancer. Oxaliplatin, a platinum derivative forms inter and intra DNA strand cross-
links thus preventing DNA replication and this eventually leads to cell death and 
oxaliplatin may also induce cell death by inhibiting the enzyme thymidylate synthase 
(558, 591, 592). Oxaliplatin alone is not effective for treating colon cancer and hence a 
combination of oxaliplatin, 5-FU and leucovorin, called FOLFOX is typically used (559, 
560).   Acute and chronic forms of neuropathy are the most common side effects 
observed during treatment with oxaliplatin besides rare kidney dysfunction and 
ototoxicity (591).  
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Symptomatic metastatic prostate cancer is typically treated by androgen deprivation, 
using LHRH agonists such as goserelin acetate (Zoladex) or leuprorelin acetate 
(Prostap), which simulate the effects of castration on testosterone levels and on prostate 
cancer response. These agents downregulate pituitary receptors leading to inhibition of 
release of follicle stimulation hormone (FSH) and lutinizing hormone (LH) and decrease 
production of testosterone in the testicular tissue (593, 594). Palliative care for hormone-
refractory prostate cancer (HRPC) patients is provided using cytotoxic chemotherapy, 
systemic isotope therapies and bisphosphonate therapy. Docetaxel in combination with 
prednisone is the most commonly used drug to treat HRPC and provides a significant 
survival advantage in these patients (595).  Docetaxel is a semi-synthetic analogue of 
paclitaxel (Taxol), which is an extract from the bark of the pacific yew tree, Taxus 
brevifolia. It causes cell cycle arrest and induces apoptosis by promoting microtubular 
polymerization and inhibiting disassembly of microtubules (596). Besides docetaxel, a 
combination of paclitaxel with estramustine or capecitabine has also produced 
encouraging results in HRPC patients (597). Platinum-based agents such as epirubicin 
and carboplatin in combination with 5-FU were not effective in majority of patients due 
to toxic side-effects however they were considered superior to single-agent cytotoxic 
treatments for patients with tolerance for combination chemotherapy (598). A third 
generation oral platinum-containing drug Satraplatin (JM-216) is effective in vitro 
against taxane-resistant cell lines has shown significant anti-tumor activity and low 
toxicity in combination with prednisone in a small phase III trial (599). 
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Targeted Therapy 
Targeted therapies unlike other conventional treatment strategies interfere with specific 
pathways, factors or receptors that are essential for tumor growth, survival and 
metastasis. In contrast to radiotherapy and chemotherapy that indiscriminately eliminate 
rapidly dividing cells, targeted therapy interacts with key factors that are present or 
highly expressed in cancer cells and absent in normal cells thus minimizing the side-
effects that are encountered during general systemic chemotherapies. 
 
Anti-Angiogenic Agents 
Several antiangiogenic agents have been approved and several others are currently in 
clinical trials. Bevacizumab, a monoclonal antibody raised against VEGF-A, was the 
first anti-angiogenic drug to be approved for metastatic colorectal cancer based on 
results obtained from a clinical trial conducted by Hurwitz et al. Although capable of 
interfering with angiogenesis Bevacizumab is not effective as a single agent and is 
approved for use in combination with standard chemotherapy as first-line treatment for 
metastatic colon cancer (600).  Bevacizumab elicits its responses by normalizing tumor 
blood vessel architecture and decreasing intratumoral hydrostatic pressure thus 
improving the delivery of anticancer agents to the tumor (601). Combinations of 
bevacizumab and chemotherapy have improved response rates and survival rates in 
metastatic colon cancer patients in both second-line and third-line therapy in most tested 
trials. According to recently reported data from the BRITE registry a significant increase 
in overall survival was observed in patients who continued bevacizumab throughout 
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treatment in comparison to those who discontinued bevacizumab (31.8 vs.19.9 months, 
HR 0.48, P <0.001) (602). However, in patients with previously untreated metastatic 
colon cancer no significant difference was observed between groups receiving a 
combination of bevacizumab and FOLFOX and those receiving FOLFOX alone 
although there was an increase in progression free survival (603). Side-effects observed 
in patients receiving bevacizumab are gastrointestinal perforation, arterial thromboses, 
myocardial infarctions, hypertension and strokes (604). There are several other 
angiogenic inhibitors that are currently being assessed for clinical efficacy including 
drugs such as vatalanib, sunitinib and aflibercept (a potent inhibitor of VEGF). 
Aflibercept is a recombinant fusion molecule of the human VEGF receptor extracellular 
domain. It has shown some promise as a single agent in a phase II trial in 51 patients 
with refractory metastatic colorectal cancer and its efficacy in combination with 
chemotherapy is currently being evaluated (605).  
 
Angiogenesis inhibitors such as bevacizumab, aflibercept and sunitib have been 
investigated for their efficacy in improving the survival rate and response rates in 
prostate cancer patients. Some of these drugs alone and in combination with 
chemotherapeutic agents have provided contrasting results while others have proven to 
be ineffective and discontinued (606-608). In addition several other angiogenesis 
inhibitors operating as immune modulators and multi-tyrosine kinase inhibitors are 
under development for treatment of HRPC. Tasquinimod is one such drug that has 
demonstrated improved progression free survival (7.6 versus 3.3 months) in HRPC 
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patients in a placebo-controlled phase II trial (609). It is an oral quinoline-3 carboxamide 
derivative that binds to an immune-modulatory protein, S1000A9 expressed on myeloid-
derived suppressor cells which are key promoters of angiogenesis and tumor growth 
(610, 611).  Similarly sorafenib is another molecule that is currently under clinical 
development and targets oncogenes such as c-raf, BRAF, VEGFR, platelet-derived 
growth factor receptor, Flt-3, c-KIT, and RET.  
 
Signal Transduction Pathway Inhibitors 
Tumor cell proliferation, invasion, migration and inhibition of apoptosis are regulated by 
numerous pathways involving key signaling molecules such as Ras-Raf-MAPK, PI3K-
Akt, protein kinase C and STAT. These different pathways stem from critical tyrosine 
kinase receptors and EGFR is the most important member of the class.  EGFR is targeted 
by either using monoclonal antibodies (mAb) that recognize EGFR or using small 
molecule inhibitors that inhibit its tyrosine kinase activity (612). Cetuximab and 
Panitumumab are two mAbs that are approved for therapeutic use against colon cancer 
(613, 614). Cetuximab inhibits cancer cell growth and survival by several mechanisms.  
It prevents receptor dimerization, which is an essential step for activation of the receptor 
and downstream signaling. It also reduces the expression of receptors on the cell surface 
by increasing internalization and degradation of receptors without activation. Cetuximab 
can also prevent any receptor-dependent DNA transcription by blocking the movement 
of receptor to the nucleus. In addition it also kills cells by antibody dependent cell 
mediated cytotoxicity (615). Evidence from recent clinical studies recommends K-Ras 
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testing prior to treating an individual with EGFR mAbs. Certain tumors have K-Ras 
mutations that enable them to remain constitutively active and be independent of EGFR 
signaling. In such scenarios blocking EGFR will not prevent downstream activation of 
Ras and its subsequent effectors and as a result the tumor might be refractory to the 
therapy. Hence it is recommended that the tumor be tested to determine if K-Ras is 
mutated or intact (616, 617). Farensyl transferase is an enzyme that operates downstream 
of Ras and drugs such as tipifarnib that inhibit the enzyme are currently being tested for 
their effectiveness in combination with anti-EGFR and anti-angiogenic agents (618). 
 
NOVEL GROUP OF THERAPEUTIC TARGETS 
It is a known fact that cancer is a highly complex disease. The data obtained from 
numerous clinical studies and in vitro experiments show that even targeted therapies for 
disrupting growth and survival of cancer cells are not straightforward. Although some 
mechanism-based drugs show some promise their beneficial therapeutic effects until 
now appear to be only modest. This can be attributed to the complex labyrinth-like 
signaling pathways and regulatory networks that allow cancer cells to grow and survive 
and inhibition of individual growth/survival-promoting and angiogenic pathways are not 
effective. The highly complex signaling in cancer cells enable them to function by 
relying on alternate pathways even if an individual signal transduction pathway is 
abrogated. Hence there is a need for therapeutic targets that can be more effectively 
targeted. To this effect our laboratory has focused on specificity protein (Sp) 
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transcription factors regulated expression of multiple genes that are important for cancer 
cell growth and survival and can be effectively targeted by various anti-cancer agents. 
 
Sp/KLF (Kruppel-like factor) Family of Transcription Factors 
Members of the Sp/KLF family have a highly conserved DNA binding domain that 
consists of three contiguously placed C2H2-type zinc fingers that are located at the C-
terminal region. Members of the family bind to GC boxes (GGGGCGGGG), 
GT/CACCC boxes (GGTGTGGGG) and basic transcription elements and regulate 
transcription of various genes (619-622). Although the DNA binding domain is 
conserved among members of the family their sequences in other domains are highly 
variable. Sp proteins exhibit a preference for GC-boxes over CACCC-boxes whereas 
KLFs have an increased binding affinity for GT-boxes over GC boxes (623-627). Sp/ 
KLFs are only homologous to Sp proteins in their C-terminal DNA binding domain. 
Sp/KLF members are categorized into various groups based on the sequence 
conservation in their N-termini; For example the Sp proteins have a glutamine rich 
domain, whereas GKLF and UKLF contain an acidic domain in their N-terminus. 
Similarly, FKLF and LKLF carry a proline-rich domain while UKLF and GKLF possess 
a serine-rich domain (628). (624, 628-630). As a result this can lead to variable 
transcriptional activity between SP/KLF members, with some being transcriptionally 
activating, others repressive and some exhibit both activities (cell-and-gene-dependent) 
(631).  
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Figure 13. Structural features of Sp proteins (632) 
 
 
Sp Proteins 
The Sp-family consists of 9 members (Sp1-9) and all Sp transcription factors carry a 
hallmark buttonhead (BTD) box CXCPXC N-terminal to the zinc fingers; although the 
function of the BTD box is not known, its presence in Drosophila and C.elegans Sp 
transcription factors suggests some physiological relevance. In addition all Sp 
transcription factors also carry a conserved amino acid stretch called the SP box at the 
N-terminus (633, 634). The genes encoding Sp-proteins are evolutionarily closely 
related and are linked to the homeobox gene cluster. Sp family members are grouped 
into two subsets with Sp1-4 (Figure 13) characterized by a glutamine-rich transactivation 
domain (TAD) and Sp5-9 forming the other subset which although structurally similar to 
other Sp members lacks the TAD. The four Sp-family members Sp1-4 have similar 
domain structures but sequence alignment of the C2H2 –type zinc finger domains shows 
that Sp1, Sp3 and Sp4 are more closely related to each other than to Sp2 (619, 634). 
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Structural studies on the zinc finger domains reveal that amino acids KHA, RER and 
RHK within the first, second and third zinc fingers respectively are all conserved in Sp1, 
Sp3 and Sp4 but not Sp2 proteins, where the critical histidine residue is substituted with 
a leucine (619, 635, 636). Hence, unlike other Sp proteins which bind GC-boxes the 
binding affinity of Sp2 is shifted to a GT-rich element within the T-cell receptor gene 5’ 
flanking region. In addition Sp2 contains only 1 TAD instead of 2 activation domains 
that are present on Sp1, Sp3 and Sp4 proteins (627). 
 
Sp Protein Expression in Tumor Tissue and its Role in Regulation of Critical Genes 
Evidence from studies conducted in this laboratory and several others indicate that Sp 
transcription factors play a crucial role in tumor growth, development and metastasis 
besides their involvement in normal development of tissues and organs (Figure 14). Sp1, 
Sp3 and Sp4 proteins are overexpressed in several cancer cell lines including colon, 
bladder, pancreatic, prostate, breast, thyroid and esophageal cancer cell lines (331, 637-
641). Wang et al. demonstrated that Sp1 levels were high in the nuclei of gastric tumor 
cells compared to the stroma or normal glandular epithelium within or surrounding the 
tumor where the levels of Sp1 protein were low or undetectable (284). Similarly, Sp1 
levels are high in pancreatic tumors compared to normal pancreas and Sp1 expression 
decreases with increasing age  (642). VEGF expression is regulated by Sp1 protein and a 
positive correlation between Sp1 and VEGF expression was observed in pancreatic and 
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Figure 14. Transcriptonal regulation of critical oncogenes by Sp transcription factors 
 
 
gastric cancer patients (643, 644). In addition these studies demonstrate that Sp1 is a 
negative prognostic factor for survival of pancreatic and gastric cancer patients (284-
286). Sp1 protein expression was also elevated in 11 out of 14 breast carcinoma while 
only 1 in 5 benign breast tumors displayed detectable levels of Sp1 protein (287). 
Similarly, Sp1 expression levels in the nuclear extracts of thyroid tumors was 
significantly elevated in comparison to corresponding normal tissues (288). Levels of 
Sp3 and Sp4 were not determined in cancer patient studies and their prognostic 
significance has not yet been determined. 
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There is growing evidence indicating that Sp family of transcription factors Sp1, Sp3 
and Sp4 are critical regulators of several genes that are essential for tumor growth, 
development, survival and metastasis (289). Several studies demonstrate that VEGF, and 
its receptors VEGR1 and VEGFR2 are important mediators of angiogenesis and these 
genes are regulated by Sp transcription factors through interactions with their GC-rich 
promoters (286, 290, 291, 335). RNA interference (RNAi) studies conducted in 
pancreatic cancer cells reveals that Sp1, Sp3 and Sp4 proteins are involved in VEGF, 
VEGFR1 and VEGFR2 expression and knockdown of Sp1, Sp3 and Sp4 by RNAi also 
affected pancreatic cancer cell growth and cell cycle progression with a decreased 
percentage of cells in G2/M and S and increased percentage of cells in G0/G1 phase. 
This was accompanied by increased expression of cyclin-dependent kinase inhibitor p27 
with Sp3 knockdown (326). In addition several studies have demonstrated the role of 
Sp1 in breast cancer cells in regulating key factors associated with growth and cell cycle 
progression (cyclin D1, E2F1, c-fos, transforming growth factor-), purine and 
pyrimidine synthesis, angiogenesis (VEGF) and survival (bcl-2) (327-330, 336, 337). 
RNAi studies in esophageal cancer cell lines reveal that hepatocyte growth factor 
receptor (c-MET) is also an Sp-regulated gene and other Sp-regulated genes important 
for cancer growth and development include, survivin, epidermal growth factor (EGFR), 
pituitary tumor-transforming gene 1 (PTTG-1) and the p65 subunit of NFB  (331-334).  
 
In addition to processes such as proliferation, angiogenesis and inflammation there is 
evidence to suggest that cancer cells manipulate mechanisms governing bioenergetics to 
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ensure growth and survival (549, 634). Enzymes involved in metabolism of glucose such 
as hexokinase, phosphofructokinase and pyruvate kinase are overexpressed in several 
cancer cell lines and tumors. Promoter analysis of the genes coding for these enzymes 
reveal that many of these genes also contain Sp binding sites and Sp proteins might be 
involved in the overexpression of some of the enzymes (645-649). 
 
Evidence from RNAi studies suggest that the cancer cell phenotype is dependent, in part, 
on Sp transcription factors and Sp regulated genes and this represents an example of 
“non-oncogenic addiction”. Sp proteins do not behave as classical oncogenes since they 
do not exhibit any somatic gene mutations and the heightened dependence of tumors on 
these transcription factors for regulating several important pathways suggests that Sp 
proteins are ideal therapeutic targets. Expression of Sp proteins is relatively high in 
cancer cells whereas normal cells have lower levels of these proteins particularly in adult 
tissues and hence drugs that specifically inhibit expression or induce degradation of Sp 
proteins constitute an important class of mechanism-based anticancer drugs. Moreover 
drugs that act against Sp proteins will coordinately downregulate several Sp-regulated 
genes responsible for cell proliferation, survival and angiogenesis many of which are 
themselves individual drug targets. In summary it is clear that drugs targeting Sp 
proteins are a viable and pragmatic therapeutic approach for treating multiple-tumor 
types. 
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Targeting Sp Transcription Factors 
Sp proteins and Sp-dependent pathways can be targeted by several approaches. Initial 
studies identified drugs that bound GC-rich DNA motifs, and these include mithramycin, 
hedamycin, thalidomide and daunomycin-derived bisanthracycline WP631. Drug 
interactions with GC-rich regions on the DNA decrease Sp1-DNA binding and blocking 
expression of Sp-regulated genes however these genes are accompanied by side-effects 
and inhibition of off-target genes (650-654). Oligodeoxynucleotides containing 
consensus GC-rich Sp1 binding sites (Sp1 decoys) are also promising agents that 
deactivate Sp-regulated genes by acting as decoys and binding Sp transcription factors 
and development of these reagents is in early stage (655-657).  
 
Research in this laboratory has focused on developing anticancer drugs that target 
critical pathways required for cancer growth, proliferation, survival, angiogenesis and 
metastasis by downregulation of Sp1, Sp3 and Sp4 protein expression. Targeting Sp 
proteins in several cancer cell lines and xenograft animal models using anti-cancer 
agents such as betulinic acid (BA), curcumin, arsenic trioxide, synthetic triterpenoids 
and NSAIDs decrease expression of key regulators of growth (EGFR, cyclin D1, c-
MET), survival (bcl-2, survivin), inflammation (NKB) and angiogenesis (VEGF, 
VEGFR1, VEGFR2) (639, 640, 658, 659). Multiple mechanistic pathways are involved 
in drug mediated downregulation of Sp proteins and these mechanisms are complex and 
dependent on the class of drugs and cancer cell line (Figure 15.). Drugs that induce 
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downregulation of Sp proteins mediate their responses either by inducing degradation 
(proteasome/caspase mediated) or transcriptional repression of Sp transcription factors. 
 
 
 
 
Figure 15. Downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes. 
 
 
Proteasome and Caspase Mediated Degradation of Sp Proteins  
Several classes of anti-cancer agents including non-steroidal anti-inflammatory drugs 
(NSAID), cyclooxygenase-2 (COX-2) inhibitors and triterpenoids elicit their anti-
carcinogenic effects by downregulating expression of Sp transcription factors via 
proteasome-dependent degradation. 
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COX-2 Inhibitors  
NSAIDs and related COX-2 inhibitors are anti-carcinogenic and their use is associated 
with decrease in the incidence and mortality of colon cancer (660), (661). Studies in our 
laboratory showed that COX-2 inhibitors such as celecoxib (Cel), nimesulide (NM) and 
NS-398 [NS; N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide] decreased Sp1 
and Sp4 but not Sp3 protein expression in SW480, RKO, HT-29 and DLD colon cancer 
cell lines. The COX-2 inhibitors did not affect Sp1 and Sp4 mRNA levels in SW480 
cells however, there was increased ubiquitination of Sp1 and Sp4 and this was inhibited 
by proteasome inhibitor, gliotoxin suggesting that Sp1 and Sp4  protein downregulation 
by COX2 inhibitors was proteasome dependent (637).  
 
Tolfenamic Acid 
Similarly, the effects of tolfenamic acid (TA), an NSAID, on Sp transcription factors 
have been extensively investigated in a variety of cancer cell lines. Treatment of 
pancreatic (Panc1 and L3.6pl) and rhabdomyosarcoma (RD and RH-30) cells with TA 
inhibited tumor growth and decreased Sp1, Sp3 and Sp4 levels and the mechanism of 
action of TA was cell context dependent. In Panc1 and RD cells TA-induced degradation 
of Sp proteins was reversed by treatment with a proteasome inhibitor, lactacystin, 
indicating that TA mediated downregulation of Sp1, Sp3 and Sp4 proteins was 
proteasome-dependent; however, these effects were not observed in RH-30 cells co-
treated with TA and proteasome inhibitors (662) (638). In contrast to pancreatic cancer 
cells, TA inhibited breast cancer cell proliferation and tumor growth in erbB2-
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overexpressing BTB474 and SKBR3 breast cancer cells and in athymic nude mouse 
model respectively with minimal effects on Sp protein levels. TA downregulated 
expression of erbB2 and transcription factors such as YY1 and AP-2 required for basal 
erbB2 expression (663). In addition TA treatment decreased proliferation in lung (A549 
and CRL58030), prostate (PC3) and esophageal (SEG-1 and BIC-1) cancer cell lines and 
inhibited c-Met expression through degradation of Sp proteins; however the mechanisms 
of Sp protein degradation was not fully understood (664-666).    
 
Betulinic Acid 
Betulinic acid (BA), a pentacyclic triterpene natural product also induced apoptosis and 
inhibited angiogenesis in cancer cells and tumors from multiple tissues. Treatment of 
LNCaP prostate and SW480 and RKO colon cancer cell lines with BA decreased 
expression of VEGF, survivin and several other oncogenic factors and these responses 
were mediated by downregulation of Sp1, Sp3 and Sp4 proteins. However the 
mechanism of action of BA on Sp proteins was cell context dependent. Co-treatment of 
LNCaP and SW480 cells with BA and proteasome inhibitor MG132 reversed the effects 
of BA, whereas the effects of BA were proteasome-independent in case of RKO cells 
(639, 667). A recent study investigated the effects of BA on Sp 1 transcription factor in 
lung tumors employing a bitransgenic mouse. BA inhibited lung tumor growth and 
decreased expression of Sp 1 protein levels. In the same study treatment of HeLa cells 
with BA increased sumoylation of Sp1 by inhibiting sentrin-specific protease-1 (SENP-
 118 
 
1) expression resulting in proteasome-dependent degradation of Sp1 transcription factor 
(668). 
 
Celastrol 
Celastrol (CSL), a naturally occurring triterpenoid acid is another anti-cancer drug that 
exhibits cell context dependent effects on Sp proteins. Studies conducted in our 
laboratory showed that CSL downregulates Sp transcription factors and Sp-dependent 
genes/proteins including fibroblast growth factor receptor -3 (FGFR3) by proteasome-
dependent degradation in case of KU7 bladder cancer cells whereas the mechanism of 
Sp protein downregulation in 253JB-V cells was proteasome-independent. Degradation 
of Sp proteins by CSL in 253JB-V bladder cancer cells was mediated by oxidative stress, 
which will be discussed in detail below (669).  
 
Curcumin 
The active ingredient of turmeric, curcumin, has been extensively investigated in our 
laboratory. Treatment of 253JB-V and KU7 bladder cancer cell lines with curcumin 
inhibited cancer cell growth, induced apoptosis and inhibited expression of pro-
oncogenic factors such as VEGF, VEGFR1 and survivin. These responses were 
accompanied by decreased levels of Sp1, Sp3 and Sp4 proteins and co-treatment with 
the proteasome inhibitor, MG132, inhibited curcumin induced degradation of Sp 
proteins and Sp dependent genes (640). 
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Aspirin 
Recent studies conducted in our laboratory indicate that caspases also play a role in 
degradation of Sp proteins. Caspases are cysteine dependent aspartate-directed proteases 
that play a vital role in the process of apoptosis. Treatment of colon cancer RKO, 
SW480, HT29 and HCT116 cell lines with aspirin inhibited growth and decreased Sp1, 
Sp3 and Sp4 protein and Sp-dependent genes. Aspirin mediated downregulation of Sp 
proteins and Sp dependent genes was blocked by co-treating colon cancer cells with the 
pan-caspase inhibitor Z-VAD-fmk. Moreover the caspase-dependent cleavage of Sp1, 
Sp3 and Sp4 was mediated by zinc ion sequestration by aspirin and the effects of aspirin 
on caspase-dependent Sp downregulation was blocked by co-treatment with zinc 
sulphate (670). 
 
Transcriptional Repression of Sp Proteins 
In addition to degradation of Sp transcription factors, certain drugs transcriptionally 
repress Sp1, Sp3 and Sp4 proteins and mRNA to elicit their anti-carcinogenic responses.  
 
Role of ROS in Drug Mediated Dowregulation of Sp Transcription Factors 
Studies in this laboratory have shown that several anti-cancer compounds mediate their 
effects via induction of oxidative stress and generation of reactive oxygen species 
(ROS). Arsenic trioxide inhibited cell proliferation and angiogenesis and induced 
apoptosis in several cancer cell lines including bladder, prostate, pancreas and colon 
cancer cells and these responses were cell context dependent (658). Treatment of KU7 
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bladder cancer cell lines with arsenic trioxide decreased cell proliferation and 
downregulated Sp1, Sp3 and Sp4 proteins and Sp-regulated gene products such as 
EGFR, VEGF, cyclin D1, survivin, and bcl-2. Arsenic trioxide-mediated downregulation 
of Sp proteins and Sp dependent genes was inhibited by co-treatment with antioxidants 
such as dithiothreitol (DTT) and glutathione (GSH) indicating that arsenic trioxide-
mediated downregulation of Sp proteins was ROS-dependent. However, these effects 
were not observed in 253JB-V bladder cancer cells (658). In contrast to these findings a 
previous study in promyelocytic leukemia cells treated with arsenic trioxide 
demonstrated decreased Sp1-DNA binding and this was associated with increased Sp1 
oxidation with no decrease in the levels of Sp1 protein (671).  
 
Curcumin and synthetic triterpenoids such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic 
acid (CDDO) and its methyl ester (CDDO-Me) also induced ROS and decreased 
mitochondrial membrane potential (MMP) in Panc1 and L3.6pl pancreatic cancer cells 
and treatment with antioxidants GSH and DTT inhibited ROS generation, prevented the 
loss of MMP and reversed the effects on downregulation of Sp1, Sp3 and Sp4 proteins 
and Sp dependent genes (672, 673). Similarly ethyl 2-((2,3 
bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094), a novel nitro-NSAID, ascorbic acid 
(vitamin C), curcumin and a synthetic analog of curcumin (3E,5E)-3,5-Bis(2,5-
dimethoxybenzylidene)-1-tbutoxycarbonylpiperidin-4-one (RL197) all decreased Sp 
proteins in SW480 and RKO colon cancer cells via ROS activation and antioxidants 
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inhibited the effects on Sp proteins and other responses including cell proliferation, 
induction of ROS and loss of MMP (674-676)  
 
Role of ZBTB10 and MiR27a in Drug Induced Downregulation of Sp Proteins 
ROS generation and loss of MMP is only one component of the mechanistic pathway 
involved in drug induced transcriptional repression of Sp transcription factors. A study 
investigating the transcriptional regulation of gastrin, a gastrointestinal tract growth 
factor discovered that a novel zinc finger and BTB domain containing 10 (ZBTB-
10/RIN ZF) protein that binds to the CACC cis-regulatory elements of the gastrin 
promoter and interferes with Sp1 binding and transactivation of the gastrin gene 
suggesting that ZBTB10 may function as an Sp1 repressor (677). Subsequent studies 
conducted in 2’-O-methyl RNA antisense miR-27a transfected SKBr3 cells revealed 
upregulation of ZBTB10 mRNA transcripts indicating that miR27a transcriptionally 
suppressed the expression of the Sp1 repressor, ZBTB10 (678). Hence, we hypothesized 
that overexpression of Sp transcription factors was due to transcriptional repression of 
ZBTB10 by miR27a (Figure 16).  
 
To this effect mRNA expression of miR27a, Sp1, Sp3, Sp4 and ZBTB10 was examined 
in six estrogen receptor (ER)-positive (ZR75, BT474, MCF7) and ER-negative (MDA-
MB435, MDA-MB231 and SKBR3) breast cancer cell lines. MiR-27a expression was 
observed in all the six breast cancer cells and the expression levels of Sp transcription 
factors were also high whereas only low levels of ZBTB10 mRNA were observed in the 
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breast cancer cell lines. Transfection of ER-negative MDA-MB-231 breast cancer cells 
with anti-sense miR-27a (as-miR-27a) increased ZBTB10 mRNA levels, decreased Sp 
proteins and Sp regulated proteins and also decreased the percentage of cells in S phase 
of the cell cycle. In addition, MDA-MB-231 cells transfected with GC-rich Sp1 and Sp3 
promoter constructs showed decreased luciferase activity following co-treatment with 
anti-sense miR-27a. In contrast Sp1, Sp3 and Sp4 expression was enhanced when MDA-
MB-231 cells were transfected with miR27a mimic. Furthermore, overexpression of 
ZBTB10 in these cell lines decreased Sp and Sp-dependent gene expression and 
increased number of cells in G0-G1 phase and decreased cell numbers in the S phase of 
the cell cycle (641). Therefore, results from these experiments established that targeting 
the oncogenic microRNA, miR-27a can facilitate induction of ZBTB10 expression 
which in turn can transcriptionally repress Sp proteins and Sp dependent genes by 
competitively binding to GC-rich sites on their promoter sequences (Figure 16). As 
mentioned above mitochondriotoxic drugs such as curcumin, CDDO-Me, CSL, BA and 
GT-094 induce ROS and this is accompanied by decreased miR-27a levels and induction 
of ZBTB10 which in turn results in downregulation of Sp proteins and Sp dependent 
genes and these responses can be blocked in cells co-treated with antioxidants (658, 672, 
675, 679). Similarly methyl 2-cyano-3,11-dioxo-18b-olean-1,12-dien-30-oate 
(CDODAMe), a triterpenoid also downregulates Sp proteins and Sp regulated gene 
products by inducing ZBTB10 and repressing miR-27a levels in SW480 and RKO colon 
cancer cells (680).  
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Figure 16. Mechanism of Downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes. 
 
 
Role of ZBTB4/MiR-20a/MiR-17-5-p Axis in Transcriptional Repression of Sp 
Proteins 
Recent studies investigating the role of human POK family members as transcriptional 
repressors showed that ZBTB4, another zinc finger and BTB domain containing protein 
binds to GC-rich sequences that bind Sp proteins (681). In addition, examining the 
Kaplan-Meier survival analysis of two publicly available breast cancer patient data sets 
revealed longer relapse-free survival in patients with high expression levels of ZBTB4 
whereas shorter relapse-free survival was observed in patients with low ZBTB4 
expression. Analysis of publicly available mRNA and miR data sets indicated that 
ZBTB4 can be negatively regulated by miR-17-5p and miR-20a which form part of the 
miR-17-92 cluster. MCF-7 cells transfected with 3`-UTR-ZBTB4-luc constructs showed 
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decreased luciferase activity following co-transfection with miR20a and miR17-5p 
mimics. Similarly, transfection with miR20a and miR17-5p mimics decreased ZBTB4 
protein expression in MCF7 breast cancer cells. In addition, MCF-7 and MDA-MB-231 
cells transfected with 3`-UTR-ZBTB4-luc followed by as-miR-20a and as-miR17-5p 
showed increased luciferase activity and increased expression of ZBTB4 protein. 
Furthermore, as-miR20a and ZBTB4 expression plasmid decreased luciferase activity in 
MCF-7 and MDA-MB231 cells transfected with Sp1 and Sp3 promoter-luciferase 
constructs. Similarly, knockdown of miR20a and overexpression of ZBTB4 in these 
breast cancer cell lines downregulated expression of Sp proteins and Sp regulated gene 
products. These results indicate that miR-20a enhances expression of Sp proteins by 
suppressing the Sp repressor ZBTB4 and targeting miR20a (antisense or drugs) enhances 
expression of ZBTB4 which in turn competes with Sp1 for GC-rich sites and 
downregulates Sp transcription factors and Sp dependent genes. Studies conducted in 
our laboratory show that drugs including CDODA-Me, curcumin, RL197 and CSL target 
Sp1, Sp3 and Sp4 proteins and Sp dependent genes by disrupting the ZBTB4/miR-
20a/miR-17-5-p axis in colon, prostate and bladder cancer cells (674, 682, 683).   
 
Besides ROS and proteasome-dependent degradation there is emerging evidence to 
suggest that some compounds inhibit Sp-transcription factors by inducing certain classes 
of phosphatases which will be discussed in detail in the following chapters. In addition 
recent evidence from this laboratory has indicated the involvement of cannabinoid (CB) 
receptors in downregulation of Sp proteins. Pre-treatment of BT474 and MDA-MB-453 
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breast cancer cells with CB receptor antagonists and small-interfering RNAs for CB 
receptors followed by treatment with BA inhibited BA mediated downregulation of Sp1, 
Sp3 and Sp4 proteins and other pro-oncogenic factors such as ErbB2, MAPK, Akt, YY1 
and AP2 in both cell lines. Similar effects were observed in MDA-MB-453 cells pre-
treated with the transient receptor potential cation channel subfamily V member 1/ 
Vanilloid receptor 1 antagonist, capsazepine followed by treatment with BA. This study 
also demonstrated for the first time that BA bound directly to both the CB1 and CB2 
receptors (684).  
 
Compound Cell lines Mechanism of Action 
Tolfenamic acid (638) Panc 1 Proteasome dependent degradation 
Tolfenamic acid (666) SEG-1, BIC-1 Not Determined 
Tolfenamic acid (663) BT474, SKBR3 No effect on Sp proteins 
Tolfenamic acid (664) A549, CRL5803 Not Determined 
Tolfenamic acid (665) PC3 Not Determined 
Tolfenamic acid (662) RH-30, RD Proteasome dependent degradation (RD) 
Betulinic acid (639) LNCaP Proteasome dependent degradation 
Betulinic acid (667) SW480 Proteasome dependent (SW480) 
Betulinic acid (667) RKO ROS and MMP, miR27a-ZBTB10 axis 
Betulinic acid (679) MDA-MB-231 miR27a-ZBTB10 axis 
Betulinic acid (684) BT474 CB receptor mediated, miR27a-ZBTB10 axis 
Betulinic acid (684) MDA-MB-453 CB and Vanilloid receptor, miR-27a-ZBTB10 axis 
Betulinic acid (685) HeLa Sumoylation, Proteasome dependent degradation (Sp1) 
Curcumin (640) 253JB-V, KU7 Proteasome dependent degradation 
 
Table 1. Mechanism of action of drugs that target Sp transcription factors. 
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Compound Cell lines Mechanism of Action 
Curcumin (673) Panc28, L3.6pl ROS and loss of MMP 
Curcumin (674) SW480, RKO 
ROS, MMP, miR27a-ZBTB10/miR20a-miR-17-5p-
ZBTB4 
RL197 (674) SW480, RKO 
ROS, MMP, miR27a-ZBTB10/miR20a-miR-17-5p-
ZBTB4 
CDODA-Me (680) SW480, RKO miR27a-ZBTB10 axis 
CDODA-Me (686) DU-145, PC3 miR-106b/93-ZBTB4 axis 
CDDO (672) Panc 1, L3.6pl Not Determined 
CDDO-Me (672) Panc 1, L3.6pl ROS, MMP, miR27a-ZBTB10 axis 
Celastrol (683) KU7 Proteasome dependent degradation 
Celastrol (669) 253JB-V ROS and miR27a-ZBTB10/mir20a-17-5p-ZBTB4 axis 
Nimesulfide (637) SW480, RKO, HT-29, DLD Proteasome dependent degradation (Sp1 and Sp4) 
GT-094 (675) SW480, RKO ROS and loss of MMP, miR27a-ZBTB10 axis 
Aspirin (670) SW480, RKO, HT-29, HCT116 Caspase mediate cleavage (RKO and SW480) 
Arsenic Trioxide (658) 253JB-V, KU7 ROS and loss of MMP in KU7 
Ascorbic Acid (676) RKO, SW480 ROS 
 
Table 1. Continued. 
 
 
CANNABINOIDS 
Cytotoxic anti-cancer agents effectively kill cancer cells but also target normal cells 
resulting in undesirable side effects and although these treatments may be beneficial for 
early stage cancers their effectiveness for treating advanced cases of cancer is low. More 
targeted therapies that focus on inhibiting activities of single molecules produce fewer 
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side effects and are far more specific than chemotherapy and radiation but their efficacy 
is also limited and can often be by-passed. Hence Sp proteins which regulate expression 
of multiple genes and pro-oncogenic pathways would appear to be ideal targets for 
development of mechanism based drugs and as indicated above the underlying 
mechanisms of action of several different classes of anticancer agents. 
 
Cannabinoids are being developed for cancer chemotherapy and have been approved for 
clinical trials (glioma) (687) and we hypothesize that an important underlying 
mechanism of action of cannabinoids is due to their downregulation of Sp transcription 
factors. 
 
A Bit of History 
The origin of the plant Cannabis is believed to be from the riverine valleys of Central 
Asia or from northern South Asia along the foothills of the Himalayas. It is the oldest 
psychotropic drug known to man and was first cultivated in China for fiber and seed 
production (688, 689). The medicinal properties of cannabis were first described by the 
Chinese emperor, Shen Nung in his compendium of Chinese medicinal herbs composed 
during 2737 BC (690). Cannabis then spread to India where it was referred to by the 
term “bhang” and was used for relieving anxiety. The analgesic, appetite stimulant, 
antiemetic, muscle relaxant and anticonvulsant properties of cannabis were discovered 
by the British physician and surgeon working in India, William O’ Shaughnessy in 1839. 
His observations introduced Europe and the Western hemisphere to the therapeutic uses 
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of this drug (688, 691). Later in 1854 cannabis was listed in the United State 
Dispensatory and was available in pharmacies of Western countries (662).  However, the 
use of cannabis was soon to be associated with causes of insanity, moral and intellectual 
deterioration, violence and various crimes. Hence in 1937 the US government introduced 
a Marijuana Tax Act under pressure from the Federal Bureau of Narcotics. This was 
followed by removal of cannabis from the United States Pharmacopeia, resulting in loss 
of its therapeutic legitimacy (692-694). Similarly, the 1971 Convention on Psychotropic 
Substances instituted by the United Nations was used by Britain and most European 
countries to ban cannabis (695). Currently cannabis is categorized as a Schedule I drug 
under the federal Controlled Substances Act of 1970 and is considered illegal for any 
purposes except FDA approved research programs (696). Medical cannabis is presently 
legal in twenty states and the District of Columbia in the US (697, 698). As of 
November 2012, recreational use of marijuana is legal in Washington and Colorado in 
the US (699). 
 
Cannabinoids and Cannabinoid Receptors 
The three main species of Cannabis are Cannabis sativa, Cannabis indica and Cannabis 
ruderalis (695). Cannabis contains more than 460 chemicals of which more than 60 of 
them are categorized under the class of plant-derived cannabinoids or phytocannabinoids 
(700). Delta-9-tetrahydrocannabinol (THC) is the main psychoactive ingredient of 
cannabis with delta-8-tetrahydrocannabinol (8THC), cannabinol (CBN), cannabidiol 
(CBD), cannabicyclol (CBL), cannabichromene (CBC) and cannbigerol (CBG) present 
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in smaller quantities (688, 701). The synthetic class of cannabinoids comprises of 
compounds structurally similar to phytocannabinoids and analogs that are structurally 
different from THC (702). The third class, endocannabinoids are a group of arachidonate 
based lipids such as anandamide (N-arachidonoylethanolamide, AEA) and 2-
arachidonoylglycerol (2-AG) that are synthesized within the body and are involved in 
various physiological processes (703). Cannabinoids elicit their responses by binding to 
cannabinoid receptors (CB) which are 7 transmembrane Gi/Go-coupled receptors. To 
this date two receptors have been identified namely CB1 and CB2 and they share 44% 
protein identity and exhibit different expression patterns and pharmacological properties 
(704-706). 
 
CB1 Receptors 
CB1 receptor is a G protein coupled receptor that contains seven transmembrane 
domains linked by three intracellular and extracellular loops, with the extracellular N-
terminal tail and the intracellular C-terminal tail (707). The CB1 receptor is a 473 
amino-acid long protein that can exist as homodimers and coexpression of other G-
protein-coupled receptors can give rise to heterodimers and oligomers (708, 709). CB1 
receptors are primarily expressed in areas of the central nervous system (CNS) that 
control motor activity (basal ganglia and cerebellum), memory and cognition (cortex and 
hippocampus), emotion (amygdala), sensory perception (thalamus), and autonomic and 
endocrine functions (hypothalamus, pons and medulla) (710). In addition they are also 
expressed in the peripheral nervous system and extraneural tissues such as testis, 
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vascular endothelium and spleen (711). They are abundantly distributed in the 
presynaptic terminals of the neurons, and to a lesser extent on the dendrites and soma of 
neurons (712, 713). Astrocytes, oligodendrocytes and neural stem cells also express low 
levels of CB1 receptors (714-716). CB1 receptors couple with the inhibitory Gi/o 
proteins and in some cases with the stimulatory Gs proteins to regulate signal 
transduction pathways, ion channels, enzymes generating cyclic nucleotide second 
messengers and kinases (706). The acute cognitive and intoxicating effects of THC are 
due to N-type channel blockade by CB1 receptors resulting in inhibition of synaptic 
transmission (717). The neuroprotective effects of cannabinoids can be attributed brain-
derived neurotrophic factor (BDNF) induced by increased activity of Erk resulting from 
activation of CB1 receptors (713). There is also evidence demonstrating the role of CB1 
receptor in stem cell fate and behavior and development of neuronal networks and 
functional synapses (716, 718). During neuropathological conditions the blood brain 
barrier gets disrupted resulting in infiltration of blood-derived leukocytes. CB1 receptors 
expressed in these blood cells are activated by cannabinoids that accumulate in the CNS 
and regulate inflammatory processes in the nervous tissue during such pathological 
conditions (719-721). Similarly, increased expression of cannabinoid receptors in 
diseases such as multiple sclerosis is considered to render a protective effect by reducing 
symptoms or suppressing disease progression (722). CB1 receptor levels are low in 
colorectal cancers due to increased DNA methylation of promoters and loss of CB1 
receptor expression in mice enhanced tumor proliferation in mouse models of colorectal 
cancer (723, 724). Prostate cancer cell express high levels of CB1 receptors and 
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treatment of prostate cancer cells with cannabinoid receptor agonists inhibits cell growth 
and induce apoptosis (725). In contrast breast cancer cells express low levels of CB1 
receptors and treatment with THC increased cell proliferation (726). 
 
CB2 Receptors 
The CB2 receptor contains 360 amino-acids with an N-terminus that is glycosylated and 
a C-terminus that is involved ligand-induced receptor desensitization (727). The CB2 
receptor amino acid sequence is less conserved across human and rodent species 
compared to the CB1 receptor (728). The non-conserved residues of CB2 receptor, S3.31 
and F5.46 confer CB1/CB2 receptor selectivity. Lipophilic groups bind to F5.46 residue 
that facilitates hydrogen bond formation with S3.31 resulting in a conformational change 
in the receptor structure leading to signal transduction (729). CB2 receptors are confined 
to the immune system in tissues of spleen, tonsils and lymph nodes and are primarily 
expressed in the leukocytes with B-cells displaying the highest levels and CD4+ T cells 
expressing the lowest levels of CB2 receptors. CB2 receptor expression is highly 
variable in natural killer (NK) cells, monocytes/macrophages, neutrophils and CD8+ T 
cells. The functional role of CB2 receptors was elucidated through experiments 
conducted in CB2 receptor knockout mice (705, 730). CB2 receptors are involved in 
modulation of immune responses and the anti-inflammatory properties of CBN such as 
inhibition of macrophage dependent antigen processing and T cell priming and induction 
of immune cell apoptosis is mediated by CB2 receptors (731-733). Most studies 
demonstrate absence of CB2 receptor expression in the brain (705, 719). Contrary to the 
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general belief that CB2 receptors are exclusive to the immune system, one study 
detected CB2 mRNA and protein in neurons located in the brain stem and is believed to 
regulate emesis (734). Pathological conditions can induce CB2 receptor expression. 
Prostate and colon cancer cells exhibit increased expression levels of CB2 receptor (723, 
725). Activated microglial cells from mouse models of multiple sclerosis and 
Alzheimer’s disease express high levels of CB2 receptors compared to resting microglial 
cells (735, 736). Cultured microglial cells, which are considered chronically activated 
also, express CB2 receptors on the protrusions (lamellapodia) involved in cell 
migrations. Like CB1 receptors, CB2 receptors are expressed in leukocytes and play a 
role in neuroinflammation by responding to cannabinoids that have accumulated as a 
result of disrupted blood brain barrier. CB2 receptors coupled with Gi/o proteins regulate 
secondary messengers, enzymes and signal transduction pathways. CB2 receptor 
activation can increase Erk activity for immune cell migration and regulation of gene 
expression of several genes (737).  
 
Other Receptors 
Experiments employing CB1-/- mice suggest existence of non CB1/CB2 receptors in 
neurons and their role in regulating synaptic transmission. In one set of experiments 
WIN 55,212-2, (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-
de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone, (WIN) and anandamide stimulated a 
novel receptor while 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-
methyloctan-2-yl)phenol (CP55,940), (6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-
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(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol (HU210) and THC 
were inactive; the stimulatory effects of WIN and  anadamide were not antagonized by 
CB1 receptor antagonist SR141716A indicating that the role of this receptor is distinct 
from CB1 and CB2 (738, 739). Studies examining the effects of WIN and CP55,940 on 
excitatory glutamatergic transmission and the analgesic efficacy of THC in spinal cord 
also suggested the expression of a novel receptor (740-743). Furthermore, certain 
cannabinoids induce hypotensive and vasodilatory responses in mesenteric vessels 
without activation of CB1, CB2 or TRPV1/vanilloid receptor (transient receptor 
potential cation channel subfamily V member 1) (744). The analgesic effects of 
palmitoylethanolamide (PEA), an AEA analog were blocked by a CB2 receptor 
antagonist SR144528 even though PEA does not bind to CB2 receptors, indicating the 
involvement of non-CB receptor-mediated anti-inflammatory effects of PEA (728, 745, 
746). A G protein coupled receptor GPR55 is believed to be the third cannabinoid 
receptor since THC, cannabidiol, anandamide, CP55,940 and SR141716A are able to 
bind and activate GPR55 (747). In addition lysophosphatidylinositol and its 2-
arachidonoyl derivative may be the endogenous ligands for GPR55 and activation of 
GPR55 results in induction of rhoA, cdc42 and rac1. It is also proposed that activation of 
GPR55 is responsible for the analgesic effects of PEA. GPR55 is coupled to G protein 
G13, a subunit of the fourth class of G protein alpha subunits that are not sensitive to 
pertussis toxin (706, 748-750). Another G protein receptor that is considered a 
cannabinoid receptor is GPR119 which is activated by anandamide and PEA and is 
highly expressed in pancreas and gastrointestinal tract (751-753). GPR18 may also be an 
 134 
 
abnormal cannabinoid receptor activated by AEA, abnormal cannabidiol, O-1602 and 
THC for processes such as microglial migration in the CNS (754, 755).  
 
The Endocannabinoid Signaling System 
CB1 and CB2 receptors are coupled to the Gi/o subtype of G protein and when activated 
can inhibit adenyl cyclase by releasing the Giisoforms (756). However, simultaneous 
activation of CB1 and dopamine D2 receptors due to heterodimerization can stimulate 2, 
4 and 7 isoforms of adenylate cyclase by releasing subunits (757, 758). Receptor 
dimerization also facilitates CB1 receptor coupling with Gq/11 subtypes of G protein 
leading to increased intracellular calcium in some neuron types treated with the synthetic 
cannabinoid WIN (759). Normally, neurotransmitters bind to ionotropic or metabotropic 
receptors when there is a surge in the cytosolic free Ca2+ levels. Endocannabinoids are 
synthesized in response to increased Ca2+ concentrations in postsynaptic neurons as 
membrane-bound precursors which are cleaved and released to bind to the presynaptic 
CB1 receptors (760). Cannabinoids bind to CB receptors and inhibit adenylate cyclase 
activity leading to decreased production of cyclic AMP (cAMP), which in turn leads to 
activation of K+ channels and inhibition of Ca2+ channels (761). Inhibition of Ca2+ 
channels inhibits release of neurotransmitters such as glutamate, dopamine and γ-
aminobutyric acid (GABA) in turn affecting processes such as learning, movement and 
memory respectively (Figure 17) (762). Several kinase pathways are activated by 
cannabinoid receptor signaling including p44/42 mitogen activated protein kinase, p38 
kinase, JUN-terminal kinase and phosphatidylinositol-3-kinase pathways (763-768). In  
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Figure 17.  A model of synaptic cannabinoid signaling  
 
 
addition activity of phosphatases such as protein phosphatase 2b (calcinuerin), mitogen-
activated protein kinase phosphatase-1 (MKP-1) are also regulated by CB1 receptors 
(769, 770). Some of these effects may be mediated through activation of G proteins 
whereas others function independently of G proteins via adaptor proteins (764, 771, 
772). 
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Endocannabinoids 
Endocannabinoids or endogenous cannabinoids are a group of eicosanoids that function 
as physiological ligands for cannabinoid receptors. They are arachidonate-based lipid 
messengers that are synthesized on demand and include compounds such as AEA, 2-AG, 
2-arachindonoyl glycerol ether (noladin ether), N-arachidonoyl-dopamine (NADA) and 
virodhamine (OAE) (Figure 18) (703, 773). AEA and 2-AG are endocannabinoids that 
have been studied extensively. AEA is both a full and partial CB1 receptor agonist 
depending on the tissue whereas it exhibits low affinity and can function as an antagonist 
of CB2 receptors (774). AEA is synthesized in the cells from the membrane lipid 
precursor N-arachidonoyl phosphatidylethanolamide (NAPE), which is generated by 
enzymatic transfer of arachidonic acid from the sn-1 position of phosphatidylcholine to 
the amide group of PE. NAPE then undergoes hydrolysis catalyzed by the enzyme 
phospholipase D to give rise to AEA (775-777).  In addition several studies indicate 
existence of parallel pathways for synthesis of AEA from NAPE. For example Sun and 
coworkers identified a secreted phospholipase 2 that hydrolyses N-acyl-PE to generate 
N-acyl-ethanolamides, including AEA in the stomach (778). Similarly, conversion of 
NAPE to phosphoanandamide and subsequent dephosphorylation by a phosphatase to 
form AEA was also reported (779).  
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Figure 18. Endocannabinoids, lipid messengers synthesized within the body (702) 
 
 
2-AG is derived from the intracellular secondary messenger diacylglycerol (DAG) 
which is generated from phosphoinositides or phosphatidic acid by the action of 
phospholipase C or phosphohydrolase respectively. DAG is then acted upon by DAG-
lipase to form 2-AG (780). Studies investigating the release of endocannabinoids under 
physiological conditions have revealed that AEA is released by depolarized neurons both 
Anandamide 
(AEA) 
2-Arachidonoyl glycerol (2-AG) 
2-arachindonoyl glycerol ether (noladin ether) N-arachidonoyl-dopamine 
(NADA)  
Virodhamine 
(OAE)  
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in vivo and in vitro (776, 781). However, there is no evidence demonstrating the release 
of 2-AG from depolarized neurons or under conditions in which AEA was released 
(781). Hence, it has been suggested that AEA functions as an intercellular signaling 
molecule while 2-AG is not released by neurons in the brain and may play a role in 
intracellular cannabinoid signaling (707). 
 
Intake and Metabolism of Endocannabinoids 
It is assumed that endocannabinoids are released into extracellular space from neurons 
through a transporter protein which is also involved in cellular uptake of cannabinoids. 
Evidence for this hypothesis stems from experiments that inhibit release of AEA by 
using transport blockers (782, 783). Endocannabinoids present in the extracellular space 
accumulate in neurons via Na+ and ATP -independent facilitated diffusion that occurs 
due to transmembrane concentration gradient (776, 784). Involvement of a transport 
protein in the uptake of AEA is also implied since AEA uptake is inhibited by N-(4-
hydroxy-phenyl) arachidonylamide (AM404) in rat cortical neurons and astrocytes 
(785). However, a specific transporter protein for the uptake of anandamide has not yet 
been cloned.  AEA is degraded in the cell by the enzyme fatty acid amide hydrolase 
(FAAH) into arachidonic acid and ethanolamine (786). Recent reports demonstrate 
inhibition of FAAH activity by AM404 in neuroblastoma cells suggesting that FAAH 
alone may be adequate for diffusion of AEA across the cell membrane (707). In contrast 
to these results experiments conducted in FAAH+/+ and FAAH-/- cells did not show a 
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difference in levels of AEA uptake implying that an FAAH-independent component in 
AEA uptake might indeed exist (787). 
  
2-AG is hydrolyzed by FAAH in vitro however, unaltered levels of 2-AG in wild-type 
and FAAH-/- mice brain suggests that 2-AG might not be the substrate of FAAH in vivo 
(787-789). 2-AG is metabolized by monoglyceride lipase (MGL) in vivo (790). 
 
Plant and Synthetic Cannabinoids  
THC is considered the most important ingredient of the hemp plant Cannabis sativa due 
to its high potency and abundance (791). 8-THC is another plant-derived cannabinoid 
that is equally active as THC but less abundant. CBN and CBD are two other 
phytocannabinoids that are present in abundant amounts but have weak and no 
cannabimimetic activity respectively (Figure 19) (711). Besides therapeutic applications, 
cannabinoids are commonly used for recreational purposes and according to government 
reports there are currently 14 million marijuana users in the US (792). Cannabis 
consumption can produce a state of euphoria and anxiety and these psychoactive effects 
are attributed to THC, the major component of the plant (793, 794). In addition to THC, 
cannabis plants also contain ingredients such as CBD that do not possess psychoactive 
properties. The ratio of non-psychoactive to psychoactive components in the plant is 
responsible for the varying degrees of cerebral high and anxiety experienced by 
individuals smoking different species of the plant. Cannabis indica has a 4-5 times 
higher CBD:THC ratio than Cannabis sativa and hence causes less anxiety. THC is an  
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Figure 19. Phytocannabinoids, active ingredients extracted from the plant cannabis sativa (702) 
 
agonist of the cannabinoid receptor and causes anxiety whereas CBD is a 5-HT1A 
receptor agonist that elicits an anxiolytic effect and higher levels of CBD suppress the 
anxiogenic effects of THC. Hence, Cannabis sativa is preferred for daytime use as 
medical cannabis due to its cerebral “high” while Cannabis indica is favored for night 
time use as a therapeutic owing to its sedative effects (795).  
 
Synthetic cannabinoids are classified into different families (Figure 20). The classical 
cannabinoid analogues are structurally related to THC and include (-) HU-210, Nabilone  
Delta-9-tetrahydrocannabinol (Δ
9
-THC) Cannabinol (CBN) 
Cannabidiol (CBD) Ajulemic acid 
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Figure 20. Synthetic cannabinoids (A) Classical, (B) Non-classical, (C) Amino-alkly-indole derivatives 
and (D) Eicosanoids (702) 
(-) HU-210 Nabilone (+) HU-211 
CP-55,940 CP-55,244 CP-47,497 
 
 
R-(+)-WIN55212
 
JWH-015 L-768242 
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and (+) HU-211. While some of them display cannabinoid receptor activity others do not 
show any affinity to receptors. Non-classical cannabinoid analogues include compounds 
that are structurally related to CP-55,940. These compounds are structurally different 
from THC and do not possess the characteristic tetrahydropyran ring. The third class of 
synthetic cannabinoids is aminoalkylindole derivates that resemble the lead compound 
WIN 55,212-2. Their structures are different from THC but elicit responses similar to 
THC and other plant-derived cannabinoids. The last set of synthetic cannabinoids 
constitutes eicosanoids that are structurally-related to endocannabinoids (702, 796, 797). 
Synthetic cannabinoids have been used to investigate the structure activity relationship  
among all cannabinoids and for determining various structural elements required for 
activity. In addition these compounds serve as templates for designing more effective 
drugs for various conditions (798). Some synthetic cannabinoids such as Nabilone are 
available as an anti-emetic, appetite stimulant and analgesic and several other synthetic 
cannabinoids are marketed in the form of psychoactive designer drugs for recreational 
purposes (670, 799) . However, the recent signing of the Synthetic Drug Abuse 
Prevention Act of 2012 into law has placed several cannabinoids including JWH-
018, JWH-073, CP-47,497, JWH-200, and cannabicyclohexanol on Schedule I of 
Controlled Substances Act and they are illegal to possess or use in the US (800). 
 
Therapeutic Applications 
The therapeutic applications of cannabinoids have been known since the early 1970s and 
there is sufficient evidence from animal studies and clinical trials to support the 
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beneficial effects of cannabinoids for several conditions including cancer patients 
undergoing chemotherapy (711). 
 
Anti-emetic 
Nausea and vomiting are the most common side-effects observed in individuals 
receiving chemotherapy. Clinical trials conducted with THC, synthetic cannabinoids and 
cannabinoid smoking during the 1970s and 1980s demonstrated anti-emetic potencies 
comparable to dopamine D2-receptor antagonists prochlorperazine, domperidone and 
metoclopramide. Moreover patients indicated a clear preference for cannabinoids over 
conventional anti-emetics in this study (662, 670, 801). THC (dronabinol [Marinol]) and 
its synthetic analogue LY109514 (nabilone [Cesamet]) are currently available as oral 
medications in the form of capsules and are approved for treating nausea and emesis 
associated with cancer chemotherapy.  In addition cannabinoids are more effective in 
controlling nausea and vomiting in patients during the delayed phase of chemotherapy 
compared to modern anti-emetics, such as 5-HT3-receptor antagonist ondansetron and 
the selective substance P/neurokinin-1-receptor antagonist aprepitant (711). The anti-
emetic effects of cannabinoids can be attributed to inhibition of gastrointestinal (GI) 
tract motility by binding to CB1 receptors located on the myentric and submucosal 
plexus of the GI tract and blocking the release of acetylcholine in these areas. In addition 
CB1 receptors are expressed on the dorsal-vagal complex of the brainstem that controls 
the vomiting reflex and cannabinoid receptor binding in this region may also contribute 
to the anti-emetic effect (802). 
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Appetite Stimulation 
Lack of appetite (anorexia) and weight loss are commonly observed in a large proportion 
of patients with advance cancer. Anorexia can result in a wasting syndrome known as 
cachexia and is characterized by weight loss, muscle atrophy, fatigue and weakness and 
this is an important risk factor for morbidity and mortality in cancer (803). Several 
studies have demonstrated appetite stimulatory effects of THC and related cannabinoids 
in AIDS and cancer patients when administered in low doses that do not result in side-
effects (804). CB1 receptors and endocannabinoids present in the hypothalamus control 
food intake and blocking CB1 receptors or decreasing the levels of endocannabinoids 
can induce weight loss and decrease appetite. Dronabinol is currently prescribed for 
AIDS patients as an appetite stimulant at a dosage range of 2.5-5.0 mg/day. In addition 
several Phase II and Phase III clinical trials provide evidence supporting the appetite-
stimulating effect of THC at 5.0 mg/day in advanced cancer patients (670, 805, 806). 
 
Analgesic Effects 
Patients suffering from cancer frequently experience moderate to severe pain and it 
worsens in cases of metastatic or advanced-stage cancer (711). Cannabinoids inhibit 
nociception by activating CB1 receptors in the thalamus, periaqueductal grey matter and 
rostral ventromedial medulla of the brain, dorsal horn of the spinal cord and dorsal root 
ganglia of the nerve terminals (807, 808). Similarly, peripherally located CB2 receptors 
elicit analgesic responses by inhibiting mediators of pain and inflammation (745, 807). 
Results from four Phase III clinical trials using THC and two first-generation synthetic 
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cannabinoid derivatives show a similar analgesic potency compared to a moderate opioid 
analgesic, codeine (809, 810). 
 
Cannabinoids and Cancer 
The anti-cancer effects of cannabis compounds were first reported by Munson and 
coworkers in 1975 showing that oral THC inhibited lung-adenocarcinoma cell growth in 
vitro and tumor growth in mouse tumor xenograft (811). Despite the encouraging results 
from these experiments, further research on the anti-tumor activities of cannabinoids was 
not carried out until the 1990s.  Studies conducted in several laboratories demonstrate 
the anti-proliferative effects of various classes of cannabinoids including 
phytocannabinoids (THC, cannabidiol), synthetic cannabinoids (WIN, HU-210) and 
endocannabinoids (AEA, 2-AG) in a variety of tumor cell lines (812). Furthermore, 
xenograft studies in nude mice show that cannabinoids inhibit tumor growth in lung 
carcinomas, gliomas, thyroid epitheliomas, skin carcinomas and lymphomas (711). 
Several mechanisms have been proposed to explain the anti-cancer properties of 
cannabinoids.  
 
The effects of cannabinoids on cancer cells are cell context dependent and the 
mechanisms involved are complex. As mentioned earlier cannabinoids stimulate a 
multitude of signaling pathways such as MAPK, ERK JNK and p38 MAPK that are 
involved in cell growth and differentiation. Similarly, cannabinoids also play a role in 
induction of PI3K-AKT survival pathways. In contrast to these findings several studies 
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demonstrate suppression of ERK and AKT signaling and induction of apoptosis by 
cannabinoids (813).  
 
Ceramide is a lipid second messenger involved in induction of apoptosis and cell cycle 
arrest, formed as a result of sphingomyelin breakdown (814, 815). Cannabinoids initiate 
apoptosis by regulating sphingomyelin metabolism and in turn increasing levels of 
ceramide which is proapoptotic in cancer cells (816). This mechanism is cannabinoid 
receptor-dependent but does not involve G-proteins and is mediated via an adaptor 
protein, factor associated with neutral spingomyelinase activation (FAN) (772). In 
addition to generating ceramide by breakdown of sphingomyelin, CB receptor activation 
can also lead to de novo synthesis of ceramide (817, 818). Mechanisms of cannabinoid-
induced apoptosis via the ceramide pathway are best illustrated using glioma cells as the 
model (817, 819). Treatment of glioma cells with cannabinoids increase ceramide levels 
leading to activation of RAF1-MEK-ERK and inhibition of AKT signal transduction 
pathways (817, 818). ERK activation induces cell proliferation; however, prolonged 
activation of ERK results in cell-cycle arrest and cell death. Moreover, the anti-cancer 
effects of cannabinoids also depend on ceramide levels. Two peaks of ceramide 
generation with different kinetics are observed in glioma cells following cannabinoid 
receptor activation and the second peak of ceramide generation governs ERK activation 
and apoptotic effects of cannabinoids (817, 818, 820, 821) . Similar effects are observed 
in prostate cancer cell lines where blocking de novo ceramide synthesis inhibits 
cannabinoid mediated cell death (562). Cell cycle arrest at G1-S transition due to 
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activation of CB1 receptors in breast cancer cell lines is attributed to inhibition of 
cAMP-protein kinase A (PKA) pathway. PKA inactivation results in RAF1 activation 
leading to prolonged ERK stimulation and inhibition of cell growth via suppression of 
prolactin receptor and high-affinity neurotrophin TRK receptor (563, 687, 822). 
Cannabinoid receptor-mediated inhibition of cell proliferation in pheochromocytoma, 
skin carcinoma and prostate carcinoma cells occurs via deregulation of growth factor 
receptor signaling (562, 663, 813). Cannabinoids inhibit angiogenesis by blocking 
expression of VEGF and other pro-angiogenic cytokines and also inhibit of matrix 
metalloproteinase-2 (MMP-2) expression in lung tumor xenografts in vivo (663, 664, 
671).  
 
Most conventional therapies invariably result in deleterious side effects since they 
indiscriminately target both normal and cancer cells. Cannabinoids on the other hand are 
toxic to cancer cells culture and tumors in mice and rats with minimal effects on normal 
tissues. Some studies even demonstrate a protective effect of cannabinoids on normal 
cells of astroglial and oligodendroglial lineages (715, 768). The reported anti-
proliferative and protective effects of cannabinoids are primarily associated with 
ceramide levels and the AKT survival pathway (817, 818). The second peak of ceramide 
generation represents de novo synthesis of ceramide and this is responsible for inducing 
apoptosis by inhibiting AKT signaling. However, this second peak is absent in normal 
astrocytes and cells that are resistant to cannabinoid mediated apoptosis although they 
express functional CB receptors (817, 820). Hence it is apparent that in glioma cells 
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cannabinoids activate the CB receptor to generate ceramide to inhibit cell survival 
pathways while in normal cells activation of CB receptors stimulate AKT pathway and 
prevent ceramide mediated AKT inhibition (768, 818). Similar phenomena are observed 
in thyroid epithelioma and skin carcinoma cells where cannabinoids selectively inhibit 
tumor cells and do not affect their non-transformed counterparts (663, 676). 
 
 In contrast high concentrations of cannabinoids can induce apoptosis in non-
transformed monocytes, macrophages and lymphocytes leading to defective host anti-
tumor responses due to deficiency of  cytokines such as interferons- and interleukin-12 
(665, 669). Nevertheless, long-term surveys of HIV-positive patients do not show any 
correlation between cannabis smoking or dronabinol use and average T-cell count or 
AIDS progression (662, 670).  
The first and only clinical trial to this date investigating the anti-tumor responses of 
cannabinoids was conducted by Guzman et al in 2006. The effects of THC were 
investigated in 9 patients suffering from recurrent glioblastoma multiforme by 
intratumoral administration of THC. Delivery of the drug was achieved without any 
apparent psychoactive effects. THC inhibited tumor cell proliferation in vitro and 
decreased tumor cell Ki67 immunostaining in two patients (687). 
 
Cannabinoids are well tolerated by mice and rats in animal studies and several grams per 
kilograms of body weight of THC are required to cause lethality in animals. In contrast 
to many anticancer agents and other drugs fatalities due to cannabis consumption in 
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humans have not been reported (680). Prolonged administration of high doses of THC in 
mice and rats did not result in any marked histopathological changes in the brain or other 
organs and THC increased survival and lowered the incidence of primary tumors (823). 
Similarly, no alterations in physiological and neurological blood parameters were 
observed in cannabis smokers or individuals receiving long-term cannabinoid treatment 
(662, 670, 680). However, the most commonly associated side-effects that limit the use 
of cannabinoids in therapy are the psychoactive effects even though they are well within 
the accepted range. Employing drugs that specifically bind to CB2 receptors can 
significantly reduce the psychotropic effects observed due to CB1 receptor activation. 
Alternatively, it has been suggested that the use of non-psychotropic compounds such as 
CBD, dexanabinol and ajulemic acid which inhibit glioma cell growth in vitro and in 
vivo may also be viable cannabinoid-based anticancer agents (682, 683, 686). Drugs that 
inhibit degradation of endocannabinoids and significantly increase levels of 
endocannabinoids at tumor sites have also proven successful as inhibitors of tumor 
growth with minimal psychotropic effects (679).  
 
Data from clinical trials and animal experiments indicate that cannabinoids are effective 
anti-cancer agents and relatively safe compared to conventional chemotherapeutics. 
However, their mechanisms of action are highly complex and not fully understood and 
there is also evidence for both receptor dependent and independent pathways. Several 
studies show that cannabinoids induce many of the same responses/pathways observed 
for anticancer agents that target degradation or suppression of Sp transcription factors. 
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For example, treatment of LNCaP cells with WIN decreased expression of VEGF and 
caused downregulation of cyclins D1, D2, E (632, 725). Similarly, WIN treated non-
melanoma skin tumors displayed impaired tumor vascularization accompanied by 
decreased levels of VEGF and inhibition of EGFR function (663). In addition an APC 
(Min/+) mouse study reveals that loss or inhibition of CB1 receptor promotes intestinal 
adenoma growth and activation of CB1 receptors inhibit tumor growth by 
downregulation of the antiapoptotic protein survivin (724). Studies investigating the 
effects of cannabinoids such as WIN, JWH-133 and AEA on glioma cells have also 
shown inhibition of VEGF and the receptor VEGFR2 (824).  
 
Therefore we hypothesize that the anticancer activity of CBs is due, in part, to 
downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes and this will be investigated in 
the proposed research. Results of these studies will facilitate more targeted clinical 
applications of CBs alone or in combination therapies. 
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CHAPTER II  
INDUCTION OF APOPTOSIS BY CANNABINOIDS IN PROSTATE 
AND COLON CANCER CELLS IS PHOSPHATASE-DEPENDENT* 
 
INTRODUCTION 
The anticancer activities of phytochemicals and their synthetic derivatives is complex 
and dependent on tumor-type; however, several studies show that an important 
component of their activity is associated with induction of specific phosphatases which 
in turn inhibit kinase signaling pathways that are overexpressed in many tumors.  For 
example, several phytochemical anticancer agents including betulinic acid and other 
polycyclic terpenoids inhibit STAT3 activation and this has been linked to induction of 
the protein tyrosine phosphatase SHP-1 (825-831).  Curcumin, resveratrol and calcitriol 
(vitamin D analog) also induce the dual specificity phosphatase mitogen-activated 
protein kinase phosphatase 5 (MKP5) mRNA levels in prostate cancer cell lines (832, 
833) and this response has been linked to inhibition of the p38 stress kinase activity. 
 
Cannabinoids have long been used for ameliorating the debilitating effects of cytotoxic 
anticancer drugs; however, these compounds also exhibit antitumorigenic activity  
 
 
 
*Reprinted with permission from “Induction of apoptosis by cannabinoids in prostate 
and colon cancer cells is phosphatase-dependent” by Sreevalsan S, Joseph S, Jutooru 
I, Chadalapaka G, Safe SH, 2011. Anticancer Res, 31 (11) 3799-3807, Copyright [2011] 
by Anticancer Research: International Journal of Cancer Research and Treatment. 
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against multiple tumor types (711, 824, 833-835) and cannabinoids are already in 
clinical trials for treatment of brain tumors (e.g. gliomas). The mechanisms of action of 
cannabinoids are complex and dependent on ligand structure and cell context, and the 
effects are both receptor (CB1 and/or CB2)-dependent and -independent. Like many 
other phytochemical anticancer agents, cannabinoids induce growth inhibitory, pro-
apoptotic and antimetastatic responses which are accompanied by modulation of several 
kinase activities (660, 724, 725, 836-844), and we hypothesized that cannabinoids may 
also induce phosphatases.  This paper demonstrates that the synthetic cannabinoid WIN-
55,212-2 (WIN) and cannabidiol (CBD) induced expression of several phosphatase 
mRNAs in LNCaP and SW480 cells and the phosphatase inhibitor sodium orthovanadate 
(SOV) inhibited WIN- and CBD-induced apoptosis in colon and prostate cancer cells.  
However, knockdown of the cannabinoid (CB) receptors (CB1 and CB2) showed that 
induction of apoptosis by CBD but not WIN was receptor-dependent. 
 
MATERIALS AND METHODS 
Chemicals, Antibodies, Plasmids, and Reagents  
WIN was purchased from Tocris Bioscience.  Cannabidiol was kindly provided by Dr. 
Norbert. E. Kaminski (Michigan State University, East Lansing, MI).  Tyrosine 
phosphatase inhibitor, SOV, was purchased from Calbiochem.  Cleaved poly (ADP-
ribose) polymerase (PARP), phospho-c-jun N-terminal kinase (pJNK) and JNK 
antibodies were obtained from Cell Signaling.  -Actin antibody was purchased from 
Sigma-Aldrich.  Antibodies for phospho-Akt, Akt, phospho-extracellular-signal-
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regulated kinases (pERK), ERK, phospho-ErbB-2, ErbB-2, phospho-P38, P38, and 
phospho-signal transducer and activator of transcription 3 (STAT3) were purchased 
from Santa Cruz Biotechnology.  Chemiluminescence reagents for western blot imaging 
were purchased from Millipore.  RPMI and DMEM media were purchased from Sigma. 
 
Cell Culture  
Human LNCaP prostate carcinoma cells were obtained from American Type Culture 
Collection.  Human SW480 colon carcinoma cell line were provided by Dr Stanley 
Hamilton (M.D. Anderson Cancer Center, Houston, TX).  LNCaP cells were maintained 
in RPMI 1640 medium supplemented with 10% fetal bovine serum and 100X antibiotic 
antimycotic solution.  SW480 cells were maintained in DMEM/F-12 supplemented with 
5% fetal bovine serum and 100X antibiotic antimycotic solution.  Cells were maintained 
at 37C in the presence of 5% CO2. 
 
Cell Proliferation Assay  
Prostate and colon cancer cells (3 x 104 per well) were plated in 12-well plates and 
allowed to attach for 24 hr.  The medium was then changed to DMEM/Ham's F-12 
medium without phenol red containing 2.5% charcoal-stripped FBS, and either vehicle 
(DMSO) or different concentrations of compounds were added. Cells were then 
trypsinized and counted after 24, 48 and 72 hr using a Coulter Z1 cell counter.  Each 
experiment was done in triplicate, and results are expressed as means ± SE for each set 
of experiments. 
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Western Blot Analyses  
Prostate and colon cancer cells were seeded in DMEM/Ham's F-12 medium.  After 24 
hr, cells were treated with either vehicle (DMSO) or WIN and CBD for 48 and 24 hr, 
respectively, or pretreated with SOV (0.25 mM and 0.5 mM) for 40 min and then treated 
with WIN and CBD.  Cells were lysed with high salt buffer and subjected to SDS-PAGE 
and immunoblotting for cleaved PARP, CB1, CB2 and cleaved caspase 3 proteins as 
described previously (845).    
 
Real-Time PCR  
Prostate and colon cancer cells were seeded and after 24 hr, were treated with either 
vehicle (DMSO) or WIN and CBD for 24 hr.  Total RNA was isolated using the RNeasy 
Protect Mini kit according to the manufacturer's protocol.  cDNA was prepared and 
subjected to real-time PCR analysis as described previously (845).  MKP-1(forward-5'-
CTCCATGCTCCTTGAGAGGAGAAATGC-3'; reverse-5'-
GGTAGGTATGTCAAGCATGAAGAG-3)', MKP-2 (forward 5'-
TACAAGTGCATCCCAGTGGA-3'; reverse 5'-CCCGTTTCTTCATCATCAGG-3'), c-
PacP (forward 5'-TCTCAGTGGTGCCGCATCTA-3'; reverse 5'-
CAGGGTGTGAGGATGGCAA-3'), s-PacP (forward 5'-
GGCAGATGATGCTTTGAGAACA-3'; reverse 5'-TCATCCAAAGCCCATTTTCC-
3'), PTEN (forward 5'-CGAACTGGTGTAATGATATGT-3'; reverse 5'-
CATGAACTTGTCTTCCCGT-3'), DEP-1 (forward 5'-
TCGTTCGTGACTACATGAAGCA-3'; reverse 5'-CCCCAGCACTGCAATGC-3'), 
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SHP-1 (forward 5'-AATGCGTCCCATACTGGCCCGA-3'; reverse 5'-
CCCGCAGTTGGTCACAGAGT-3'), PTP1B (forward 5'-
TCCTACCTGGCTGTGATCGAG-3'; reverse 5'-CCTTCCACTGATCCTGCACTG-3'), 
PP2A (forward 5'-GTTGGGAGGTGGCAGTGAG-3'; reverse 5'-
AAACACTGGCCTCTGGTGTC-3') primers were acquired from Sigma.  MKP-5 
(forward 5'-GCTCAGGACCTGGACACCAT-3'; reverse 5'-
GGAAGATGAGTGGTGACGTTGAT-3'); primers were acquired from IDT.  Values 
for each gene were normalized to expression levels of TATA-binding protein. 
 
siRNA Interference Assay 
LNCaP and SW480 cells were seeded (1 × 105 per well) in six-well plates in 
DMEM/Ham's F-12 medium supplemented with 2.5% charcoal-stripped FBS without 
antibiotic and left to attach for 24 hr.  The CB1 and CB2 knockdown (iCB1 and iCB2) 
along with iLamin as control was done using Lipofectamine 2000 reagent according to 
the manufacturer's instructions.  Small inhibitory RNAs were purchased from Sigma-
Aldrich. 
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Table 2. List of the symbols, names and synonyms of genes discussed in this study. 
 
 
RESULTS 
WIN and CBD Induce Apoptosis and Inhibit Proliferation of LNCaP and SW480 
Cells 
Results summarized in Figures 21A and 21B show that WIN and CBD inhibited LNCaP 
cell growth, and IC50 values for half-maximal growth inhibition after 2 days were 5.1 and 
10.0 М and, after 3 days, were 4.59 and 9.43 М, respectively.  Similar results were 
observed in SW480 cells (Figs. 21C and 21D); IC50 values (for days 2 and 3) were 3.3 
and 3.5 М for WIN and 5.95 and 5.06 М for CBD.  The concentration-dependent 
effects of CBD on cell proliferation were observed within 24 hr after treatment, whereas 
the growth inhibitory effects of WIN were somewhat delayed in both cell lines.  WIN 
and CBD also induced a time-dependent increase in PARP cleavage, a marker of 
Symbol Name Synonyms 
DUSP1 Dual specificity phosphatase 1 MKP1 
DUSP4 Dual specificity phosphatase 4 MKP2 
DUSP6 Dual specificity phosphatase 6 MKP3 
DUSP10 Dual specificity phosphatase 10 MKP5 
ACPP Prostatic acid phosphatase, cellular and serum cPAcP, sPAcP 
ERBB2 Human epiderman growth factor receptor-2 HER2 
PTEN Phosphatase and tensin homolog PTEN 
PTPRJ Protein tyrosine phosphatase, receptor type, J DEP1 
PTPN6 Protein tyrosine phosphatase, non-receptor type 6 SHP1 
PTPN1 Protein tyrosine phosphatase, non-receptor type 1 PTP1B 
PPP2R4 Protein phosphatase 2A activator, regulatory subunit 4 PP2A 
STAT3 Signal transducer and activator of transcription 3 STAT3 
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apoptosis, in LNCaP and SW480 (Fig. 22) cells.  Maximal induction by CBD was 
observed within 12 hr after treatment in both cell lines, whereas WIN-induced PARP 
cleavage was maximal after 24 hr. 
 
 
Figure 21. Effects of cannabinoids on LNCaP and SW480 cell proliferation.  Concentration-dependent 
effects of WIN and CBD on LNCaP (A, B) and SW480 (C, D) cell proliferation.  Cells were treated with 
DMSO and 2.5-7.5 M of WIN and 5-15 M of CBD for 72 hr.  Cells were counted as described in 
Materials and Methods.  Results are expressed as mean ± S.E. for three replicate determinations for each 
treatment group, and significantly (p<0.05) decreased proliferation is indicated (*).  Proliferation of cells 
treated with DMSO (solvent control) was set at 100%.  -Actin served as a loading control for all Western 
blots.   
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Figure 22.  Induction of apoptosis by WIN and CBD.  Time-dependent effects of WIN and CBD on 
cleaved PARP expression in LNCaP (A, B) and SW480 (C, D) cells.  Cells were treated with DMSO, 7.5 
M WIN (12, 24 and 48 hr) and 15 M CBD (12, 18, and 24 hr), and cPARP expression was determined 
by western blot analysis of whole cell lysates as described in Materials and Methods.   
 
 
WIN and CBD Induce Phosphatases in LNCaP and SW480 Cells 
Figure 23 summarizes the effects of WIN and CBD on induction of phosphatase mRNA 
levels in LNCaP cells.  WIN induced MKP-1 and MKP-5 and CBD induced MKP-1, 
MKP-2 and MKP-5 mRNAs after 24 hr.  Similar results were observed at earlier time 
points, and WIN also induced MKP-2 after 48 hr (data not shown).  In contrast, none of 
the selected protein tyrosine phosphatases were induced by WIN or CBD in LNCaP  
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Figure 23.  Effects of WIN and CBD on phosphatase mRNA levels in LNCaP cells.  Induction by WIN 
(A, B) and CBD (C, D).  Cells were treated with DMSO, 7.5 M WIN and 15 M CBD for 24 hr, and 
MKP-1, MKP-2, MKP-5, s-PAcP, c-PAcP, PTP1b, PP2A, DEP-1 and SHP-1 mRNA levels were 
determined by real time PCR as described in the Materials and Methods.  Results are expressed as mean ± 
S.E. for 3 replicate experiments and significant (p<0.05) increases are indicated (*).   
 
 
cells.  In SW480 cells, WIN did not induce the dual specificity phosphatases but induced 
s-PacP and SHP-1 after treatment for 24 hr (Fig. 24); however, after 48 hr, induction of 
c-PacP, MKP-1 and MKP-5 by WIN were also observed (data not shown).  CBD 
induced MKP-1, MKP-5, s-PacP, p-PacP and SHP-1 in SW480 cells after treatment for 
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24 hr.  These results demonstrate that like other anticancer agents, cannabinoids induce 
expression of several dual specificity phosphatase and protein tyrosine phosphatase 
mRNAs, and current studies are focused on the induction and/or activation of individual 
phosphatase proteins and their functions in cancer cells. 
 
 
 
Figure 24.  Effects of WIN and CBD on phosphatase mRNA levels in SW480 cells.  Induction by WIN 
(A, B) and CBD (C, D).  Cells were treated with DMSO, 7.5 M WIN and 15 M CBD for 24 hr, and 
MKP-1, MKP-2, MKP-5, s-PAcP, c-PAcP, PTP1b, PP2A, DEP-1 and SHP-1 mRNA levels were 
determined by real time PCR as described in the Materials and Methods.  Results are expressed as mean ± 
S.E. for 3 replicate experiments and significant (p<0.05) increases are indicated (*).  
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The effects of WIN- and CBD-induced phosphatases on dephosphorylation of 
p42/44MAPK, pAKT, pSTAT3, pJNK, pErbB2, and pP38MAPK were investigated in 
LNCaP and SW480 cells and with few exceptions, the data were difficult to interpret 
since both phospho and total kinase protein levels were decreased simultaneously 
(Figure 25).  This suggested that cannabinoid-induced phosphatases decreased multiple 
kinase activities but also activated other pathways that affect expression of their 
corresponding proteins (total).  The mechanisms associated with decreased kinase 
proteins are currently being investigated. 
 
WIN- and CBD-Induced Apoptosis is Phosphatase-Dependent:  Role of CB 
Receptors is Ligand-Dependent 
Preliminary studies on the effects of phosphatase inhibitor cocktails and their 
components on CBD- and WIN-induced growth inhibition and apoptosis showed that 
SOV was the most effective inhibitor and this was consistent with CBD- and WIN-
dependent induction of dual-specificity and protein tyrosine phosphatases which are 
inhibited by SOV.  WIN and CBD induced PARP cleavage as early as 12 hr after 
treatment, and PARP cleavage induced by WIN and CBD persisted for 48 and 24 hr, 
respectively (Fig. 23).  Since near maximal induction of PARP cleavage by WIN and 
CBD was observed after treatment of SW480 and LNCaP cells for 24 or 12 hr, 
respectively, and these time points were used for investigating the effects of SOV on 
WIN- and CBD-induced PARP cleavage.  Cells were treated with the cannabinoids 
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Figure 25. Effects of WIN and CBD on phospho and total kinase proteins in LNCaP (A, B) and SW480 
(C, D) cells. Cells were treated with varying concentrations of WIN (2.5, 5 or 7.5 μM) and CBD (5, 10 or 
15 μM) for 48 and 24 hr, respectively, and whole cell lysates were analyzed by western blot analysis as 
described in Materials and Methods. β-Actin served as a loading control for all western blots. 
 
 
 
 
 
 
 
A B 
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Figure 25. Continued 
 
alone and in combination with SOV.  The phosphatase inhibitor SOV significantly 
decreased WIN- and CBD-induced PARP cleavage in LNCaP (Fig. 26A) and SW480 
(Fig. 26B) cells, demonstrating that the CBD- and WIN-induced phosphatase activities 
play an important role in the pro-apoptotic activity of these compounds. Receptor-
dependent and -independent induction of apoptosis by WIN and CBD was investigated 
in LNCaP and SW480 cells treated with the cannabinoids alone or after transfection with 
small inhibitory RNAs (siRNAs) targeting CB1 and CB2 receptors.  CBD-induced 
C D 
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PARP and caspase-3 cleavage in LNCaP cells was inhibited after knockdown of the CB2 
receptor (Fig. 26C), whereas after CB1 receptor knockdown, CBD-induced caspase 
activation was partially inhibited but PARP cleavage was not  
 
 
 
Figure 26.  Effects of phosphatase inhibitor and cannabinoid receptor knockdown on cannabinoid-
mediated induction of cPARP by WIN and CBD in LNCaP and SW480 cells.  Effects of phosphatase 
inhibitor sodium orthovanadate (SOV) on cannabinoid-induced PARP cleavage in LNCaP (A) and SW480 
(B) cells.  Cells were pre-treated with SOV followed by treatment with WIN and CBD for 24 and 12 hr, 
respectively, and whole cell lysates were analyzed by western blot analysis as described in Materials and 
Methods.  -Actin served as a loading control for all western blots.  Effects of cannabinoids and CB1 and 
CB2 receptor knockdown by RNA interference in LNCaP (C) and SW480 (D) cells.  Cells were 
transfected with siRNAs against CB1 and CB2 receptors followed by treatment with CBD for 12 hr and 
whole cell lysates were examined for expression of cPARP, cleaved caspase3, and CB1 and CB2 receptor 
proteins were determined by western blot analysis as indicated in the Materials and Methods.  -Actin 
served as a loading control for all Western blot analyses. 
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Figure 26.  Continued 
 
 
affected. In SW480 cells, both CB1 and CB2 receptor knockdown inhibited CBD-
induced PARP cleavage and caspase-3 activation (cleavage) (Fig. 26D).  In contrast, 
WIN-induced apoptosis and caspase-3 cleavage was unaffected by knockdown of CB1 
or CB2 receptors in LNCaP or SW480 cells (data not shown).  Thus, the pro-apoptotic 
activities of WIN and CBD were phosphatase-dependent in both cell lines but 
 166 
 
cannibinoid receptor-independent and -dependent, respectively, in LNCaP and SW480 
cells. 
 
DISCUSSION 
Cannabinoids have emerged as an important new class of anticancer drugs that bind 
cannabinoid receptors and activate several downstream pathways leading to inhibition of 
cancer cell proliferation, and induction of apoptosis (711, 824, 834, 835).  Their 
mechanisms of action are complex and dependent on cell context and ligand structure 
and there are examples of cannabinoid-mediated activities that are receptor-dependent 
and –independent (660, 724, 725, 836-843).  Several studies show that cannabinoids 
such as WIN, ΔTHC and CBD modulate kinase activities in cancer cell lines and this 
includes inhibition of membrane-bound and intracellular kinases resulting in their 
dephosphorylation.  The mechanisms associated with cannabinoid-induced inactivation 
of kinases is unknown; however, several different classes of anticancer drugs induce 
dual specificity and protein tyrosine phosphatases which selectively inactivate phospho-
kinases that play a role in cancer cell growth and survival (825-832, 846-852). 
 
Previous studies on the effects of cannabinoids on activated phospho-kinases are highly 
variable in various cancer cell lines and dependent on the structure of the cannabinoid 
and cell context. WIN inhibited growth and induced apoptosis in LNCaP cells and this 
was due in part to sustained phosphorylation of p42/44 MAPK and decreased p-AKT 
expression (842).  The phytochemical ΔTHC inhibited growth and induced apoptosis in 
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SW480 cells and this was accompanied by decreased expression of phospho-p42/p44 
MAPK and phospho-AKT (840). 
 
Although the reported effects of cannabinoids on phospho-kinases were highly variable 
among different cell lines, we observed that WIN and CBD induced expression of 
several dual specificity and protein tyrosine phosphatase mRNAs in LNCaP and SW480 
cells (Figs. 23 and 24).  Selection of the phosphatases was based on their putative 
anticarcinogenic activities and on previous reports showing that dual specificity and 
protein tyrosine phosphatases were induced by several phytochemical anticancer agents 
including curcumin, resveratrol, ursolic acid, betulinic acid, guaiane sesquiterpenoids, 
guggulsterone, epigallocatechin-3-gallate and retinoic acid (825-832, 846-852).  
Previous studies with these compounds primarily focused on induction of a single 
phosphatase gene, whereas results of this study showed that WIN and CBD induced 
multiple and overlapping phosphatase mRNAs (Figs. 23 and 24).  WIN and CBD 
induced MKP-1 and MKP-5 after treatment for 24 hr in LNCaP cells, whereas MKP-2 
induction by CBD and WIN was time-dependent (24 and 48 hr, respectively) (Fig. 23).   
 
In SW480 cells, the pattern of phosphatase induction by WIN and CBD differed after 
treatment for 24 hr primarily due to induction of MKP-1 by CBD and not WIN (Fig. 24); 
however, after 48 hr, WIN also induced MKP-1 (data not shown).  Since both CB 
receptor antagonists alone induced phosphatase mRNAs (data not shown), the role of the 
CB receptor in mediating induction of individual phosphatase mRNAs was not further 
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investigated.  In addition, the effects of CBD- and WIN-dependent induction of dual 
specificity and protein tyrosine phosphatases gene expression on dephosphorylation of 
phospho-kinase proteins was confounded by the parallel decrease of most phospho-
kinase and total kinase proteins (Fig. 25).  It was apparent in SW480 cells that WIN 
dramatically decreased AKT phosphorylation without decreasing total AKT protein and 
this was comparable to the effects reported for ΔTHC in SW480 cells (840).  The only 
other consistent observation was that WIN and CBD enhanced phosphorylation of the 
p38 stress protein kinase in both cell lines (Fig. 25).  These results demonstrate that 
WIN-/CBD-induced phosphatases may play a role in kinase inactivation in SW480 and 
RKO cells; however, these results were confounded by the parallel decrease in kinase 
proteins, and the mechanisms of the latter response are currently being investigated. 
 
CBD and WIN also inhibited LNCaP and SW480 cell growth (Fig. 21) and induced 
apoptosis (Fig. 22) in both cell lines, and induction of apoptosis by cannabinoids is an 
important element of their anticancer activity (830-833).  Induction of caspase-
dependent PARP cleavage was used as an indicator of apoptosis and it was clear that 
both WIN and CBD induced PARP cleavage in LNCaP and SW480 cells (Fig. 22) and 
this is consistent with cannabinoid-induced apoptosis in many other cancer cell lines 
(660, 711, 724, 725, 824, 834-843).  Moreover, we also observed that WIN-/CBD-
induced PARP cleavage was dramatically decreased in cells cotreated with the 
phosphatase inhibitor SOV (Figs. 26A and 26B), indicating that cannabinoid-induced 
phosphatases played a role in the induction of SW480 and LNCaP cell death.  It should 
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be noted that although induction of PARP cleavage by WIN is maximal after 24 hr, there 
was significant induction within 12 hr in LNCaP and SW480 cells (Fig. 22).  In contrast, 
induction of phosphatase mRNA levels after treatment with WIN for 12 hr is relatively 
low in SW480 cells, whereas modest but significant induction was observed in LNCaP 
cells (data not shown).  These results suggest that other “proapoptotic” phosphatases 
may also be induced or activated by WIN and CBD and these are currently being 
investigated.  CB1 and CB2 receptor knockdown by RNAi was used to determine the 
role of the CB receptors in mediating CB- and WIN-induced proapoptotic activity 
(cleavage of PARP and caspase 3) and the results demonstrate that the effects of WIN 
were CB receptor-independent, whereas CBD-induced apoptosis was CB receptor-
dependent (Fig. 26C and 26D). 
 
In summary, this study shows for the first time that cannabinoids induced several 
phosphatase mRNAs in LNCaP and SW480 cells and this was consistent with induction 
of phosphatases by other phytochemical anticancer drugs (825-832, 846-852).  The 
direct effects of phosphatase induction on decreased phospho-kinase proteins was 
confounded by a parallel decrease in most (total) kinase proteins.  This response may 
also be important for the anticancer activities of WIN and CBD and is currently being 
investigated.  Previous studies have reported induction of MKP-1 and MKP-3 by 
cannabinoids in microglial cells and this resulted in inactivation of MAPK; however, 
effects on apoptosis were not determined (769, 853).  The results obtained using the 
phosphatase inhibitor SOV demonstrate that induction of apoptosis by WIN and CBD 
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was significantly blocked by the phosphatase inhibitor SOV, and this represents a novel 
proapoptotic pathway induced by cannabinoids.  Current studies are focused on 
identification of specific proapoptotic phosphatases and their mechanisms of induction 
or activation by cannabinoids. 
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CHAPTER III  
THE CANNABINOID WIN 55,212-2 DECREASES SPECIFICITY 
PROTEIN (SP) TRANSCRIPTION FACTORS AND THE 
ONCOGENIC CAP PROTEIN EIF4E IN COLON CANCER CELLS 
 
INTRODUCTION 
There are three major classes of cannabinoids which include plant-derived compounds 
such as Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), endogenous 
cannabinoids (anandamide and 2-arachidonylglycerol), and synthetic compounds that 
mimic the effects of cannabinoids (773, 834).  Cannabinoids bind the CB1 and CB2 
receptors which are differentially expressed in some but not all tissues, and there is also 
evidence that some cannabinoids also interact with other G-protein coupled receptors 
(GPCR) including the receptor transient receptor potential vanilloid type 1 (TRPV1) and 
GPR55 (747, 854, 855).  THC is the main psychoactive cannabinoid found in the 
marijuana plant Cannabis sativa L; however, in addition to the psychoactive effects of 
THC, endocannabinoids and synthetic cannabinoids also play a role in energy 
metabolism, pain and inflammation, cardiovascular, musculoskeletal and respiratory 
disorders, and cancer, and opportunities for cannabinoid-based pharmacotherapies are 
extensive (773). 
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The anticancer activities of cannabinoids have been known for over 3 decades, and 
clinical trials for treatment of gliomas with cannabinoids have been reported (674).  
Cannabinoids inhibit growth, induce apoptosis, and exhibit antimetastatic and 
antiangiogenic activities in multiple cancer cell lines and inhibit tumor growth in in vivo 
mouse models (711, 824, 835, 856).  The effects of cannabinoids are complex and 
dependent on ligand structure and cell context, and the responses can also be CB (CB1 
and/or CB2) receptor-dependent or -independent (711, 824, 835, 856).  For example, the 
synthetic mixed CB1 and CB2 receptor agonist 2,3-dihydro-5-methyl-3-([mor-
pholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 
55, 212-2 (WIN)] inhibited gastric cancer cell growth and decreased VEGF expression 
and these responses were blocked in cells cotreated with WIN plus CB receptor 
antagonists (844), and similar CB receptor-dependent responses were observed in mantle 
cell lymphoma (857).  In contrast, WIN induced phosphatase-dependent apoptosis in 
SW480 colon and LNCaP prostate cancer cells and these responses were inhibited by the 
phosphatase inhibitor sodium orthovanadate (SOV) but not by CB receptor antagonists 
or by CB receptor knockdown (858).  
 
Treatment of cancer cells with cannabinoids activates or inactivates various kinases, 
ceramide synthesis and ceramide-mediated proapoptotic and stress-related genes, and 
downregulates expression of epidermal growth factor receptor (EGFR), survivin, cyclin 
D1, bcl-2 and vascular endothelial growth factor (VEGF) (562, 671, 725, 836, 838, 840, 
844, 857-860).  Previous RNA interference studies have shown that these genes are also 
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regulated by one or more of the specificity protein (Sp) transcription factors Sp1, Sp3 
and Sp4 which are overexpressed in colon and other cancer cell lines and tumors (641, 
672, 673, 861-865).  Therefore, we hypothesized that the anticancer activity of 
cannabinoids such as WIN in colon cancer cells may also be due, in part, to 
downregulation of Sp proteins and this could also be related to the reported induction of 
phosphatases by cannabinoids in these cells (858).  Results of this study show that WIN 
induced protein phosphatase 2A (PP2A)-dependent downregulation of Sp1, Sp3, Sp4 
and Sp-regulated gene products including the pro-oncogenic cap protein eIF4e in colon 
cancer cells.  These responses were CB receptor-independent and involved disruption of 
microRNA-27a (miR-27a)-mediated suppression of the zinc finger transcriptional 
repressor ZBTB10 which acts as an Sp repressor (641, 672, 684, 865). 
 
MATERIALS AND METHODS 
Chemicals, Antibodies, and Reagents  
WIN 55,212-2 mesylate (1038), AM251 (1117) and AM630 (1120) were purchased 
from Tocris Bioscience (Ellisville, MO, USA).  Tyrosine phosphatase inhibitor, sodium 
orthovanadate, was purchased from Calbiochem (La Jolla, CA, USA).  Dithiothreitol 
(DTT) was obtained from Boehringer Mannheim Corp, (Indianapolis, IN).  Gliotoxin 
was kindly provided by Dr. Alan Taylor (National Research Council of Canada, Halifax, 
NS, Canada).  p-EIF4e (S209), eIF4e (9742S) and Cleaved poly (ADP-ribose) 
polymerase (PARP) (9541) antibodies were obtained from Cell Signaling (Danvers, 
MA).  Lactacystin, glutathione (GSH) and antibodies for -Actin (A1978), CB1 (C1233) 
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and CB2 (WH0001269M1) receptors were purchased from Sigma-Aldrich (St. Louis, 
MO, USA).  Antibodies for EGFR (1005), Sp3 (D-20) and Sp4 (V-20) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA).  PP2A Immunoprecipitation 
Phosphatase Assay Kit (17-313), Immobilon Western Chemiluminescent HRP substrate 
(WBKLS0500) and antibodies for Sp1 (07-645) and PP2A (05421) were purchased from 
EMD Millipore (Billerica, MA, USA).  Cyclin D1 (2261-1) and survivin (2463-1) 
antibodies were purchased from Epitomics (Burlingame, CA).  VEGFR1 (ab32152) 
antibody was purchased from Abcam (Cambridge, MA).  Antibody for VEGF (209-403-
B99) was purchased from Rockland Antibodies and Assays (Gilbertsville, PA).  
ZBTB10 (A303 258A) antibody was purchased from Bethyl Laboratories (Montgomery, 
TX).  Apoptotic, Necrotic and Healthy Cells Quantification Kit (30018) was purchased 
from Biotium (Hayward, CA).  In situ cell death detection POD kit (11684817910) was 
obtained from Roche (Mannhelm, Germany).  Dulbecco’s Modified Eagle Medium 
(DMEM) was obtained from Sigma (St. Louis, MO). 
 
Cell Lines 
Human SW480 colon carcinoma cell line was provided by Dr. Stanley Hamilton (M.D. 
Anderson Cancer Center, Houston, TX).  RKO and HT-29 colon carcinoma cell lines 
were obtained from ATCC (Manassas, VA).  Cells were purchased more than 6 months 
ago and were not further tested or authenticated by the authors.  Cells were maintained at 
37C in the presence of 5% CO2 as described (858). 
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Cell Proliferation Assay 
Colon cancer cells (1 x 105 per well) were seeded in 12-well plates and allowed to attach 
for 24 hr.  The medium was then changed to DMEM/Ham's F-12 medium containing 
2.5% charcoal-stripped FBS, and either vehicle (DMSO) or varying concentrations of 
WIN was added.  Cells were then trypsinized and counted after 24 and 48 hr using a 
Coulter Z1 cell counter (Sykesville, MD).  Each experiment was performed in triplicate, 
and results were expressed as means  SE for each set of experiments. 
 
Annexin V Staining Assay 
SW480 and RKO cells were seeded in 2 well Nunc Lab-tek chambered coverglass plates 
from Thermo Scientific (Waltham, MA) and were allowed to attach for 24 hr.  The 
medium was then changed to DMEM/Ham’s F-12 medium containing 2.5% charcoal-
stripped FBS, and either DMSO or WIN was added.  Cells were stained after 9 hr with 
FITC-Annexin-V, propidium iodide and DAPI dyes according to the manufacturer’s 
protocol and were visualized under EVOS fl, fluorescence microscope, from Advanced 
Microscopy Group (Bothell, WA) using a multiband filter set for FITC, rhodamine and 
DAPI.  The proportion of apoptotic cells was determined by the amount of green 
fluorescence observed. 
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Terminal Deoxyribonucleotide Transferase-Mediated Nick-End Labeling (TUNEL) 
Assay    
HT-29 (7 × 104) were seeded in four-chambered glass slides and left overnight to attach.  
After treatment with WIN for 48 hr, the in situ cell death detection POD kit was used for 
the terminal deoxyribonucleotide transferase-mediated nick-end labeling (TUNEL) assay 
according to the manufacturer’s protocol.  The percentage of apoptotic cells was 
determined by counting stained cells from eight fields, each containing 50 cells. 
 
Western Blot Analyses 
Colon cancer cells were seeded in DMEM/Ham's F-12 medium and were allowed to 
attach for 24 hr.  Cells were treated with either DMSO or WIN for indicated time periods 
or pretreated with the proteasome inhibitors, antioxidants, phosphatase inhibitors and 
cannabinoid receptor antagonists, and then treated with WIN.  Cells were lysed and 
analyzed by western blots as described (858). 
 
Small Inhibitory RNAs (siRNA) Interference Assay 
Colon cancer cells were seeded (2 x 105 per well) in six-well plates in DMEM/Ham’s F-
12 medium supplemented with 2.5% charcoal stripped FBS without antibiotics and left 
to attach for 24 hr.  siRNAs specific for CB1 and CB2 receptors, PP2A and ZBTB10 
along with iLamin/iGL2 as control were transfected using Lipofectamine 2000 reagent 
according to the manufacturer’s protocol. Small interfering RNAs for CB1 and CB2 
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receptors, PP2A and ZBTB10 were obtained from Sigma (St. Louis, MO).  
Lipofectamine 2000 was purchased from Life Technologies (Grand Island, NY). 
 
Quantitative Real-Time PCR 
SW480 colon cancer cells were plated (2 x 105) and left to attach for 24 hr.  Cells were 
treated with either vehicle or CBD for 24 hr.  MicroRNA was isolated using the mirVana 
miRNA isolation kit from Ambion-Life Technologies (Grand Island, NY) according to 
the manufacturer’s protocol. cDNA was prepared using the Taqman MicroRNA Reverse 
Transcription kit and was subjected to quantitative real-time PCR with specific primers 
for miR27a using the Taqman Universal PCR Master Mix from Applied Biosystems 
Quantification of miRNA (RNU6B and miRNA-27a) was done using the Taqman 
miRNA kit (Applied Biosystems) according to the manufacturer's protocol in the 
CFX384 Real-Time PCR Detection System from Biorad (Hercules, CA). U6 small 
nuclear RNA was used as a control to determine relative miRNA expression. Primers for 
RNU6B and miR27a were purchased from Applied Biosystems. Total RNA was isolated 
using the RNeasy Protect Mini kit (Qiagen) according to the manufacturer's protocol. 
RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen) 
according to the manufacturer's protocol. PCR was carried out with the SYBR Green 
PCR Master Mix from Applied Biosystems on a CFX384 Real-Time PCR Detection 
System from Biorad (Hercules, CA) using 0.5 μmol/L of each primer and 1 μL cDNA 
template in each 10 μL reaction. TATA binding protein (TBP) was used as an exogenous 
control to compare the relative amount of target gene in different samples. The PCR 
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profile was as follows: one cycle of 95°C for 10 min, then 40 cycles of 95°C for 15 s and 
60°C for 1 min. The comparative CT method was used for relative quantitation of 
samples.  Primers were purchased from Sigma (St. Louis, MO). 
 
The following primers were used: 
TBP, forward, 5′-TGCACAGGAGCCAAGAGTGAA-3′;  
TBP, reverse, 5′-CACATCACAGCTCCCCACCA-3′ 
ZBTB10 (F): 5′-GCTGGATAGTAGTTATGTTGC-3′ 
ZBTB10 (R): 5′-CTGAGTGGTTTGATGGACAGA-3′ 
 
PP2A Phosphatase Assay 
Cells were seeded (3 x 105) and left to attach for 24 hr.  Cells were treated with DMSO, 
okadaic acid, and 5 and 7.5 M WIN.  Cells were harvested and lysed using the high salt 
lysis buffer.  The lysates were then subjected to buffer exchange using the Zeba Desalt 
Spin Columns (8981) from Thermo Scientific to eliminate any contaminating phosphates 
that could skew the experimental results.  The lysates were then immunoprecipitated 
with anti-PP2A, C subunit, antibody and were incubated in a mixture of diluted 
phosphopeptide and serine/threonine assay buffer for 10 min at 30C in a shaking 
incubator.  The phosphatase activity was determined by addition of malachite green dye 
and comparing the absorbance between controls and treatment at 650 nm in a plate 
reader. 
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RESULTS 
Treatment of SW480, RKO and HT-29 colon cancer cells with 2.5, 5.0 and 7.5 M WIN 
for 24 or 48 hr significantly inhibited cell proliferation at the two higher concentrations 
(Fig. 27A – 27C).  In addition, WIN also induced Annexin V staining in SW480 and 
RKO cells within 9 hr after treatment, indicating rapid induction of early apoptosis, 
whereas Annexin V was not induced in HT-29 cells at the early time point (data not 
shown).  In contrast, TUNEL staining was increased in HT-29 cells treated with WIN for 
48 hr, indicating differences between the timing of WIN-induced apoptosis in 
SW480/RKO vs. HT-29 cells.  Figure 27D shows that treatment with WIN for 48 hr also 
induced PARP cleavage in all three colon cancer cell lines as previously reported for 
WIN in SW480 cells (858). 
  
WIN-induced growth inhibition and apoptosis was also accompanied by decreased 
expression of growth promoting (EGFR, cyclin D1) and survival (survivin) genes 
products in SW480, RKO and HT29 cells (Fig. 28A).  Treatment of SW480, RKO and 
HT29 cells with 2.5 – 7.5 M WIN decreased levels of VEGF and VEGFR1 protein in 
the 3 cell lines, although the effects in HT-29 cells were less than observed in the other 
two cell lines (Fig. 28B).  Treatment of SW480, RKO and HT-29 cells with 2.5, 5.0 or 
7.5 M WIN for 48 hr decreased expression of Sp1, Sp3 and Sp4 proteins as indicated 
by quantitation of the band intensities (relative to -actin) (Fig. 28C).   
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Figure 27.  WIN inhibits colon cancer cell growth, induces apoptosis and PARP cleavage.  SW480 (A), 
RKO (B) and HT-29 (C) cells were treated with DMSO and 2.5-7.5 M WIN for 24 and 48 hr and 
counted, or treated with DMSO and 7.5 M of WIN for 9 hr (A and B) and 48 hr (C) and effects on 
Annexin V (SW480 and RKO) and TUNEL (HT-29) staining was determined.  Results are expressed as 
means  SE for at least three separate determinations, and significant (p < 0.05) induction (*) or inhibition 
(**) by WIN is indicated.  (D) Cells were treated with DMSO and 2.5-7.5 M of WIN for 48 hr and whole 
cell lysates were examined for expression of cleaved PARP by western blots.  -Actin served as a loading 
control for all western blots. 
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Figure 27.  Continued 
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Figure 28.  WIN downregulates Sp-regulated proliferative, survival (A) and angiogenic (B) gene products 
and Sp proteins (C) in SW480, RKO and HT-29 cells. Cells were treated with 2.5-7.5 M of WIN for 48 
hr, whole cell lysates were analyzed by western blots, and expression of Sp1, Sp3 and Sp4 protein was 
quantitated (C) relative to -actin (levels in the DMSO group were set at 1.0). 
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This is the first example of a synthetic cannabinoid decreasing expression of Sp proteins 
and Sp-regulated gene products in cancer cells; however, we have recently reported that 
betulinic acid (BA), a triterpenoid compound that also decreases Sp1, Sp3 and Sp4 
protein levels in multiple cancer cell lines, exhibits CB receptor agonist activity (684). 
 
Drug-induced downregulation of Sp transcription factors has been linked to activation of 
proteasomes or induction of ROS (638, 639, 667, 672, 675).  Using SW480 cells as a 
model, we show that WIN-induced downregulation of Sp1, Sp3 and Sp4 was not 
reversed in cells cotreated with WIN plus the proteasome inhibitors lactacystin or 
gliotoxin (Fig. 29A).  Moreover, treatment of SW480 cells with WIN in combination 
with the antioxidants DTT or GSH also did not inhibit WIN-induced downregulation of 
Sp1, Sp3 or Sp4 proteins (Fig. 29B) and this contrasted the effects of BA and GT-094 (a 
nitro-NSAID) in the same cell line (667, 675).  The CB1 and CB2 receptor antagonists 
AM251 and AM560 had minimal effects on Sp protein expression and, in combination 
with WIN, did not inhibit WIN-induced downregulation of Sp1, Sp3 or Sp4 proteins 
(Fig. 29C). Moreover, similar results were observed in SW480 cells after knockdown of 
the CB1 (iCB1) or the CB2 (iCB2) receptor by RNA interference (Fig. 29D), 
demonstrating that the effects of WIN on downregulation of Sp transcription factors was 
CB receptor-independent. 
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Figure 29.  Effects of proteasome inhibitors, antioxidants, cannabinoid receptor antagonists, and 
cannabinoid receptor knockdown on WIN-mediated downregulation of Sp proteins.  SW480 cells were 
pre-treated with lactacystin (10 M) or gliotoxin (3 M) (A), DTT (1 mM) or GSH (5 mM) (B), AM251 
(4 M) and AM630 (5 M) (C) for 45 min followed by treatment with 7.5 M of WIN for 48 hr, and 
whole cell lysates were analyzed by western blots.  (D)  Cells were transfected with siRNAs against CB1 
and CB2 receptors, followed by treatment with WIN for 48 hr, and whole cell lysates were analyzed by 
western blots.   
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WIN induced several phosphatase mRNAs in SW480 cells and the phosphatase inhibitor 
sodium orthovanadate (SOV) partially blocked WIN-induced PARP cleavage (858) and, 
therefore, we investigated the effects of SOV on WIN-induced downregulation of Sp1, 
Sp3 and Sp4 proteins using SW480 cells as a model.  Figure 30A shows that WIN-
induced downregulation of Sp1, Sp3 and Sp4 was reversed after cotreatment with SOV 
and these results are consistent with the inhibition of WIN-induced PARP cleavage by 
SOV (858) since knockdown of Sp1 (by RNAi) also enhances PARP cleavage (672).  A 
recent study showed that -tocopherol succinate-induced downregulation of Sp1 in 
prostate cancer cells was PP2A-dependent (866) and western blot analysis of whole cell 
lysates from SW480 cells transfected with a non-specific oligonucleotide (iCtrl) or a 
specific oligonucleotide that targets PP2A (iPP2A) and treated with 7.5 M WIN or 
DMSO showed that WIN-mediated downregulation of Sp1, Sp3 and Sp4 proteins was 
significantly attenuated in cells transfected with iPP2A (Fig. 30B).  Similar results were 
also observed in RKO cells with some differences in the relative effectiveness of PP2A 
knockdown (Fig. 33A).  PP2A knockdown also attenuated WIN-induced downregulation 
of cyclin D1 and VEGFR1 but had minimal effect on EGFR protein levels (Fig. 30C), 
suggesting that decreased expression of EGFR in SW480 cells treated with WIN was 
phosphatase- and Sp-independent. 
 
We also used an in vitro assay to confirm that WIN induced PP2A activity since 
previous studies did not observe induction of PP2A mRNA levels in SW480 cells treated 
with WIN (858).  PP2A activity in SW480 was measured using the PP2A  
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Figure 30.   Effects of phosphatase inhibition on WIN-dependent downregulation of Sp proteins and Sp-
regulated gene products.  (A)  Cells were pre-treated with 0.35 mM SOV for 45 min followed by treatment 
with 7.5 M of WIN for 48 hr, and whole cell lysates were analyzed by western blots.  Cells were 
transfected with siRNA against phosphatase PP2A (iPP2A), followed by treatment with WIN for 48 hr, 
and whole cell lysates were examined for expression of Sp1, Sp3, Sp4 and PP2A proteins (B) and Sp-
regulated gene products (C) by western blot analysis.  (D) Cells were treated with DMSO, 5 and 7.5 M of 
WIN, and PP2A activity was determined in the absence and presence of the phosphatase inhibitor okadaic 
acid.  Results are expressed as means  SE for at least three separate determinations, and significant (p < 
0.05) induction (*) or inhibition (**) by okadaic acid is indicated.  Lysates used for phosphatase assay 
were analyzed by western blots to determine expression of PP2A protein. 
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Figure 30. Continued 
B. 
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Immunoprecipitation Phosphatase Assay Kit from Millipore.  Treatment of SW480 cells 
with 7.5 M WIN induced an approximate 30% increase in PP2A activity and this was 
comparable to the induction of PP2A phosphatase activity reported by Kickstein et al. 
(867).  Figure 30D shows that 10 nM okadaic acid significantly inhibited PP2A activity 
in SW480 cells (positive control).  Cell lysates used for the phosphatase activity assays 
were then subjected to western blot analysis and probed with PP2A antibody to confirm 
the presence of PP2A in the cell lysates (Fig. 30D). 
 
PP2A decreases expression of the phosphorylated form of the pro-oncogenic cap protein 
eIF4E (868) (p-eIF4E) and therefore the time-dependent effects of 7.5 M WIN on 
expression of Sp1, Sp3, Sp4, p-eIF4E and eIF4E proteins were investigated (Fig. 31A).  
Sp1, Sp4 and Sp3 (high molecular weight forms) expression was significantly decreased 
after 12 hr, whereas the lower molecular weight forms of Sp3 were more slowly 
decreased over the 48 hr period.  p-eIF4E and eIF4E proteins were significantly 
decreased within 12 hr after treatment with WIN and continued to decrease (over 48 hr); 
the decrease of eIF4E (total protein) was more gradual than observed for the phospho-
protein.  Treatment of SW480 cells with WIN alone or in combination with SOV 
showed that the phosphatase inhibitor blocked WIN-induced effects on p-eIF4E and 
eIF4E, but not PP2A (Fig. 31B), demonstrating that WIN-induced downregulation of p-
eIF4E, eIF4E, Sp1, Sp3 and Sp4 was phosphatase dependent.  The role of PP2A in this 
process was investigated by RNAi, and WIN-mediated repression of p-eIF4E and eIF4E 
(total) proteins was significantly inhibited by knockdown of PP2A (Fig. 31C), 
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demonstrating a role for PP2A in mediating downregulation of eIF4E and peIF4E and 
this parallels results observed for phosphatase-dependent downregulation of Sp 
transcription factors (Fig. 30), suggesting possible cross-regulation of eIF4E and Sp 
transcription factors.  Knockdown of Sp1 (iSp1), Sp3 (iSp3) and Sp4 (iSp4) in SW480 
cells resulted in specific knockdown of these transcription factors, and iSp1 and to a 
lesser extent iSp3 also decreased eIF4E protein expression (Fig. 31D), whereas Sp4 
knockdown had minimal effects, suggesting that in SW480 cells eIF4E expression is 
primarily regulated by Sp1.  In contrast, knockdown of eIF4E by RNAi decreased 
expression of the targeted protein and slightly increased expression of Sp1, Sp3 or Sp4 
proteins, suggesting that cross-regulation between Sp transcription factors and eIF4E is 
unidirectional.  A comparable experiment was carried out in RKO cells; iSp1, iSp3 and 
iSp4 decreased eIF4E protein expression and the combination of all 3 oligonucleotides 
caused a marked decrease of eIF4E protein (Fig. 33B), indicating that eIF4E is an Sp-
regulated gene in colon cancer cells. 
 
Drug-induced proteasome-independent downregulation of Sp1, Sp3 and Sp4 has been 
related to transcriptional repression due to downregulation of miR-27a and miR-
20a/miR-17-5p which regulate the "Sp repressors" ZBTB10 and ZBTB4 (641, 869).  
Treatment of SW480 cell with 7.5 M WIN induced ZBTB10 protein within 12 hr and 
induction was high after 24 hr but markedly decreased after 36 and 48 hr (Fig. 32A).  In 
contrast, induction of ZBTB4 protein was not observed (data not shown).  
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Figure 31.  Effects of WIN and Sp protein knockdown on total and phospho-eIF4E in SW480 cells.  (A)  
Cells were treated with DMSO or 7.5 M WIN for 12, 18, 24, 36 and 48 hr, and whole cell lysates were 
analyzed by western blots.   Cells were pretreated with SOV for 45 min (B) or transfected with siRNA 
against PP2A (C), followed by treatment with WIN for 48 hr, and whole cell lysates were analyzed by 
western blots.  (D) SW480 cells were transfected with various siRNA and whole cell lysates were 
analyzed for expression of Sp proteins and eIF4E by western blots. 
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Figure 31. Continued 
 
 
SW480 cells were treated with 7.5 M WIN and also transfected with iGL2 (control) or 
iPP2A oligonucleotides, and the induction of ZBTB10 in the control cells was 
significantly decreased after knockdown of PP2A (Fig. 32B).  In a parallel experiment, 
WIN also decreased expression of miR-27a after treatment for 24 or 48 hr and, after 
knockdown of PP2A by RNAi, downregulation of miR-27a by WIN was attenuated (Fig.  
32C). The role of WIN-induced ZBTB10 on suppression of Sp proteins was confirmed 
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in SW480 cells treated with WIN and transfected with iGL2 (control) or iZBTB10 
oligonucleotides in an RNAi assay; knockdown of ZBTB10 inhibited downregulation of 
Sp1, Sp3 and Sp4 by WIN (Fig. 32D).  We observed that WIN also induced ZBTB10 in 
RKO cells and this response was attenuated in cells transfected with iPP2A (RNAi), and 
knockdown of ZBTB10 by RNA also inhibited WIN-mediated suppression of Sp1, Sp3 
and Sp4 proteins in RKO cells (Figs. 33C and 33D).  These results demonstrate that 
WIN-mediated downregulation of Sp proteins in SW480 cells is due to induction of 
PP2A and PP2A-dependent disruption of the miR-27a:ZBTB10 which results in 
induction of ZBTB10 and ZBTB10-dependent repression of Sp proteins and Sp-
regulated genes. 
 
DISCUSSION 
Sp1, Sp3 and Sp4 proteins are highly expressed in multiple cancer cell lines and tumors, 
whereas levels of these transcription factors are low to non-detectable in non-tumor 
tissue (672, 673, 863-865) and these observations are consistent with reports that Sp1 
expression in rodent and human tissues decreases with age (870, 871).  The pro-
oncogenic activity of Sp proteins is primarily due to Sp-regulated genes which include 
several that play pivotal roles in cancer cell proliferation [cyclin D1, c-Met, epidermal 
growth factor (EGFR)], survival (survivin, bcl-2), angiogenesis [vascular endothelial  
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Figure 32.  WIN modulates miR27a and ZBTB10 expression.  (A) SW480 cells were treated with DMSO 
or 7.5 M of WIN for 12, 18, 24, 36 and 48 hr, and whole cell lysates were analyzed for ZBTB10 protein 
by western blots.  SW480 cells were transfected with siRNA against PP2A, followed by treatment with 7.5 
M WIN for 24 and 48 hr.  Whole cell lysates were analyzed by western blot analysis for ZBTB10 
expression (B) and miR27a levels (C) were determined by qPCR as described in the Materials and 
Methods.  (D) SW480 cells were transfected with siRNA against ZBTB10 followed by treatment with 7.5 
M WIN for 24 and 48 hr, and whole cell lysates were analyzed by western blots.  Results for RNA 
expression are expressed as means  SE for at least three separate determinations, and significant (p < 
0.05) inhibition (*) by WIN is indicated and reversal of these effects by iPP2A (**) are indicated. 
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Figure 32.  Continued 
 
 
growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2)], and inflammation 
(NFB, p65).  Thus, Sp transcription factors are an excellent example of non-oncogene 
addiction by cancer cells (307) and therefore an important target for mechanism-based 
anticancer drugs.  Reports from different laboratories have identified diverse agents that 
decrease expression of Sp transcription factors and these include various phytochemical 
anticancer compounds including BA and their synthetic analogs, NSAIDs, bortezimob, 
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-tocopherol succinate, arsenic trioxide and other ROS inducers (638, 639, 641, 667, 
672, 673, 675, 684, 863-866, 872). 
 
 
 
Figure 33. Effects of phosphatase inhibition in RKO cells.  (A) SW480 cells were transfected with siRNA 
against phosphatase PP2A (iPP2A), followed by treatment with WIN for 48 hr, and whole cell lysates 
were examined for expression of Sp1, Sp3 and Sp4. (B) RKO cells were transfected with various siRNA 
and whole cell lysates were analyzed for expression of Sp proteins and eIF4E by western blots. (C) Cells 
were transfected with siRNA against PP2A, followed by treatment with 7.5 M WIN for 24 hr.  Whole 
cell lysates were analyzed by western blot analysis for ZBTB10 expression. (D) RKO cells were 
transfected with shRNA against ZBTB10 followed by treatment with 7.5 M WIN and whole cell lysates 
were analyzed by western blots.  
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Figure 33. Continued 
 
 
BA decreases expression of Sp1, Sp3 and Sp4 in prostate, colon, bladder and breast 
cancer cell lines (639, 667, 684, 864).  Results illustrated in Figures 27 and 28 confirm 
that the cannabinoid WIN also inhibited growth and induced apoptosis in SW480, RKO 
and HT-29 colon cancer cells and downregulated Sp1, Sp3, Sp4 and Sp-regulated genes.  
Since knockdown of Sp1 or multiple Sp transcription factors alone in cancer cells 
inhibits growth and induces apoptosis (672, 673, 863, 864) , then the anticancer activity 
of WIN is due, in part, to downregulation of Sp proteins.  However, in contrast to BA 
and other agents that downregulate Sp transcription factors, WIN-induced Sp 
downregulation was proteasome- and ROS-independent and knockdown or inhibition of 
CB1 or CB2 receptors did not affect this response in SW480 cells (Fig. 29).  The 
receptor-independent effects of WIN were consistent with previous studies showing that 
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the anticancer activity of WIN was both receptor-dependent and -independent (844, 857, 
858). 
 
We recently reported that WIN-induced apoptosis in SW480 and LNCaP cells is 
inhibited by the phosphatase inhibitor SOV but not by CB receptor knockdown and WIN 
also induces multiple phosphatase mRNAs (858).  These results, coupled with a report 
that PP2A plays a role in -tocopherol succinate-induced downregulation of Sp1 in 
prostate cancer cells (866) prompted us to investigate the effects of SOV and PP2A 
knockdown on WIN-induced repression of Sp proteins.  Both SOV and PP2A 
knockdown attenuated WIN-mediated downregulation of Sp1, Sp3, Sp4 and Sp-
regulated gene products (Fig. 30), confirming a role for PP2A and possibly other 
identified phosphatases in mediating the anticancer activities of WIN. An important 
proteasome-independent pathway for drug-induced downregulation of Sp1, Sp3 and Sp4 
involves induction of the transcriptional repressors ZBTB10 and ZBTB4 which exhibit 
low expression in cancer cell lines due to their regulation (repression) by miR-27a and 
miR-20a/miR-17-5p, respectively (638, 639, 641, 667, 675, 684, 866-869).  WIN did not 
induce ZBTB4 in SW480 cells; however, a time-dependent induction of ZBTB10 
protein was observed (Fig. 32A) and this response was abrogated after knockdown of 
PP2A (Fig. 32B), and these results were paralleled by PP2A-dependent repression of 
miR-27a (Fig. 32C).  Moreover, since knockdown of ZBTB10 by RNAi blocks WIN-
mediated downregulation of Sp1, Sp3 and Sp4 proteins (Fig. 32D) and since miR-27a 
antagomirs and ZBTB10 expression decrease Sp protein expression in colon cancer cells 
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(872), it is clear that disruption of miR-27a:ZBTB10 is critical for the observed 
responses.  The mechanism of PP2A-mediated effects on miR-27a:ZBTB10 are 
unknown and are currently being investigated. 
 
The induction of PP2A activity by WIN suggested that WIN may also regulate 
phosphorylation of the important cap protein eIF4E since it has been reported that PP2A 
dephosphorylates p-eIF4E which has been characterized as a pro-oncogenic phospho-
protein (868).  WIN clearly decreased expression of p-eIF4E; however, this was 
unexpectedly accompanied by downregulation of eIF4E (total protein).  Since eIF4E and 
Sp transcription factors regulate expression of several genes in common (e.g. cyclin D1 
and VEGF), we used RNAi to show for the first time that eIF4E is an Sp-regulated gene 
in colon cancer cells (Fig. 31D).  This observation extends the number of pro-oncogenic 
factors that are regulated by Sp1, Sp3 and Sp4 in cancer cells emphasizing the potential 
clinical applications of drugs that target Sp proteins. 
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CHAPTER IV 
CANNABIDIOL (CBD) INHIBITS GROWTH OF COLON CANCER 
CELLS THROUGH PHOSPHATASE DEPENDENT 
DOWNREGULATION OF SPECIFICITY PROTEINS 
 
INTRODUCTION 
Cannabinoids (CB) define a growing class of structurally-diverse compounds which 
include a large number terpenoid-phenolic phytochemicals isolated from cannabis sativa 
and related species, synthetic compounds that interact with the CB receptors and 
endogenous or endocannabinoids (516, 773, 873). Although the psychoactive 
phytochemicals such as Δ9-tetrahydrocannabinol (Δ9-THC) have been investigated for 
their mood-altering properties, there has been extensive research and clinical 
applications for the use of CBs in treating multiple diseases including cancer (685, 711, 
824, 835, 856, 873). Initial clinical applications of psychoactive CBs in cancer 
chemotherapy has been to attenuate the emesis, wasting and pain that accompanies many 
different cancers; however in 1975 it was reported by Munson and coworkers that 
several CBs exhibit anticancer activity against Lewis lung adenocarcinoma cells 
(811)(10). Subsequent studies in several laboratories show that most classes of CBs 
exhibit anticancer activity against a wide spectrum of cancer cell lines in vitro and also 
in in vivo models (685, 711, 824, 835, 856). 
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Among the phytochemical cannabinoids one of the non-psychoactive compounds, 
cannabidiol (CBD) has been extensively investigated as an anticancer agent in many 
different cancer cell lines and shows potential for clinical applications (638, 639, 660, 
661, 664, 677, 678, 681, 841-843, 858, 874-885). A recent review by Massi and 
coworkers (685)highlighted many of the CBD-induced responses in  cancer cell lines 
and these included inhibition of cell growth and survival, decreased migration and/or 
invasion, antiangiogenic activity and cell death (apoptosis and  autophagy). Not all of 
these responses were observed in any single study however, it was evident that the 
activity of CBD was consistent with that of many other phytochemical-derived 
anticancer agents and clinically used chemotherapeutic drugs. CBD also modulated 
several pathways and expression of genes which were consistent with CBD-induced 
anticancer activities. For example, CBD induced caspase and polyADPribose 
polymerase (PARP) cleavage [markers of apoptosis (858, 875, 877, 884)] induced 
reactive oxygen species (ROS) in some cancer cells (677, 685, 843), decrease Id-1 
expression (plays a role on invasion) (881), upregulated tissue inhibitor of matrix 
metalloproteinases1 (TIMP-1) (invasion) which was dependent on induction of p38 and 
p44/42 mitogen-activated protein kinases (660).  Previous studies have focused on 
different pathways/genes and cannot be directly compared; however, it was apparent 
from various CB receptor  inhibition studies that the overall mechanisms of action of 
CBD  were highly variable and cell context-dependent (685). For example in HeLa and 
lung cancer cells the CBD-induced downregulation of TIMP-1 or decreased invasion 
was significantly inhibited by CB1 and CB2 receptor antagonist, the vanilloid receptor 
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antagonist (capsazepine) and inhibitors of p38 and p42/42 (660). In contrast, a recent 
report showed that decreased viability of A549 and H460 lung cancer cells after 
treatment with CBD was not affected by CB1, CB2 and vanilloid receptor antagonist but 
was significantly blocked by cotreatment with the cycloxygenase-2  COX-2 inhibitor 
NS398 and or the peroxisome proliferator-activated receptorγ (PPARγ) inhibitor  
GW9662 (885). 
 
Studies in the laboratory reported that CBD-induced apoptosis in LNCaP and SW480 
colon cancer cells and this response was attenuated after cotreatment with the 
phosphatase inhibitor sodium orthovanadate (SOV). We also observed induction of 
several phosphatase mRNAs (858). In this study we have investigated the anticancer 
activity of CBD in RKO and SW480 colon cancer cell lines and demonstrate that CBD 
inhibits growth and induces apoptosis. We also observed that CBD decreased expression 
of several growth promoting [cyclin D1 and epidermal growth factor receptor (EGFR)], 
survival (survivin) and angiogenic [vascular endothelial growth factor (VEGF) and its 
receptor (VEGFR1)] gene products. In previous studies we have observed that these 
proteins are regulated by specificity protein (Sp) transcriptions factors Sp1, Sp3 and Sp4 
that are overexpressed in colon and other cancer cell lines (638-641, 865, 872, 886) and 
in this study we also demonstrated that CBD downregulated Sp1, Sp3 and Sp4 proteins. 
CBD also downregulated microRNA-27a (miR27-a) induced the Sp repressor ZBTB10 
however the mechanisms of this response are unknown and are currently being 
investigated. 
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MATERIALS AND METHODS 
Chemicals, Antibodies, and Reagents 
Cannabidiol, Lactacystin, glutathione (GSH) and antibody for -Actin (A1978) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  AM251 (1117) and AM630 
(1120) were purchased from Tocris Bioscience (Ellisville, MO, USA).  Tyrosine 
phosphatase inhibitor, sodium orthovanadate, was purchased from Calbiochem (La Jolla, 
CA, USA).  Dithiothreitol (DTT) was obtained from Boehringer Mannheim Corp, 
(Indianapolis, IN).  Gliotoxin was kindly provided by Dr. Alan Taylor (National 
Research Council of Canada, Halifax, NS, Canada).  Cleaved poly (ADP-ribose) 
polymerase (PARP) (9541) antibody was obtained from Cell Signaling (Danvers, MA).  
Antibodies for EGFR (1005), Sp3 (D-20) and Sp4 (V-20) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).  Immobilon Western Chemiluminescent HRP 
substrate (WBKLS0500) and antibodies for Sp1 (07-645) and CXCR4 (AB1846) and 
PP2A (05421) were purchased from EMD Millipore (Billerica, MA, USA).  Cyclin D1 
(2261-1) and survivin (2463-1) antibodies were purchased from Epitomics (Burlingame, 
CA).  VEGFR1 (ab32152) antibody was purchased from Abcam (Cambridge, MA).  
Antibody for VEGF (209-403-B99) was purchased from Rockland Antibodies and 
Assays (Gilbertsville, PA).  ZBTB10 (A303 258A) antibody was purchased from Bethyl 
Laboratories (Montgomery, TX).  Apoptotic, Necrotic and Healthy Cells Quantification 
Kit (30018) was purchased from Biotium (Hayward, CA).  Dulbecco’s Modified Eagle 
Medium (DMEM) and real-time PCR primers for TATA binding protein (TBP) and 
ZBTB10 were obtained from Sigma (St. Louis, MO).  MicroRNA isolation kit mirVana 
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was obtained from Ambion-life technologies (Grand Island, NY). Primers for RNU6B 
and miR27a were purchased from Applied Biosystems. 
 
Cell Lines   
Human SW480 colon carcinoma cell line was provided by Dr. Stanley Hamilton (M.D. 
Anderson Cancer Center, Houston, TX).  RKO colon carcinoma cell line was obtained 
from ATCC (Manassas, VA).  Cells were purchased more than 6 months ago and were 
not further tested or authenticated by the authors.  Cells were maintained at 37C in the 
presence of 5% CO2 as described (858). 
 
Cell Proliferation Assay 
Colon cancer cells (1 x 105 per well) were seeded in 12-well plates and allowed to attach 
for 24 hr.  The medium was then changed to DMEM/Ham's F-12 medium containing 
2.5% charcoal-stripped FBS, and either vehicle (DMSO or ethanol) or varying 
concentrations of CBD was added.  Cells were then trypsinized and counted after 24 and 
48 hr using a Coulter Z1 cell counter (Sykesville, MD).  Each experiment was performed 
in triplicate, and results were expressed as means  SE for each set of experiments. 
 
Annexin V Staining Assay 
SW480 and RKO cells were seeded in 2 well Nunc Lab-tek chambered coverglass plates 
from Thermo Scientific (Waltham, MA) and were allowed to attach for 24 hr.  The 
medium was then changed to DMEM/Ham’s F-12 medium containing 2.5% charcoal-
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stripped FBS, and either vehicle or CBD was added.  Cells were stained after 9 hr with 
FITC-Annexin-V, propidium iodide and DAPI dyes according to the manufacturer’s 
protocol and were visualized under EVOS fl, fluorescence microscope, from Advanced 
Microscopy Group (Bothell, WA) using a multiband filter set for FITC, rhodamine and 
DAPI.  The proportion of apoptotic cells was determined by the amount of green 
fluorescence observed. 
 
Western Blot Analyses 
Colon cancer cells were seeded in DMEM/Ham's F-12 medium and were allowed to 
attach for 24 hr.  Cells were treated with either vehicle or CBD for indicated time 
periods or pretreated with the proteasome inhibitors, antioxidants, phosphatase inhibitors 
ceramide synthase inhibitors and cannabinoid receptor antagonists, and then treated with 
CBD.  Cells were lysed and analyzed by western blots as described (858). 
 
Small Inhibitory RNAs (siRNA) Interference Assay 
Colon cancer cells were seeded (2 x 105 per well) in six-well plates in DMEM/Ham’s F-
12 medium supplemented with 2.5% charcoal stripped FBS without antibiotics and left 
to attach for 24 hr.  siRNAs specific for CB1 and CB2 receptors, PP2A, MKP-1 and 
MKP-5 along with iLamin/iGL2 as control were transfected using Lipofectamine 2000 
reagent according to the manufacturer’s protocol (Ref). Small interfering RNAs for CB1 
and CB2 receptors, MKP-5, MKP-1 and PP2A were obtained from Sigma (St. Louis, 
MO).  Lipofectamine 2000 was purchased from Life Technologies (Grand Island, NY). 
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Quantitative Real-Time PCR 
SW480 colon cancer cells were plated (2 x 105) and left to attach for 24 hr.  Cells were 
treated with either vehicle or CBD for 24 hr.  MicroRNA was isolated using the mirVana 
miRNA isolation kit from Ambion-Life Technologies (Grand Island, NY) according to 
the manufacturer’s protocol. cDNA was prepared using the Taqman MicroRNA Reverse 
Transcription kit and was subjected to quantitative real-time PCR with specific primers 
for miR27a using the Taqman Universal PCR Master Mix from Applied Biosystems 
Quantification of miRNA (RNU6B and miRNA-27a) was done using the Taqman 
miRNA kit (Applied Biosystems) according to the manufacturer's protocol in the 
CFX384 Real-Time PCR Detection System from Biorad (Hercules, CA). U6 small 
nuclear RNA was used as a control to determine relative miRNA expression. Total RNA 
was isolated using the RNeasy Protect Mini kit (Qiagen) according to the manufacturer's 
protocol. RNA was reverse transcribed using Superscript II reverse transcriptase 
(Invitrogen) according to the manufacturer's protocol. PCR was carried out with the 
SYBR Green PCR Master Mix from Applied Biosystems on an ABI 7500 Fast Real-
Time PCR System (PE Applied Biosystems) using 0.5 μmol/L of each primer and 2 μL 
cDNA template in each 25 μL reaction. TATA binding protein (TBP) was used as an 
exogenous control to compare the relative amount of target gene in different samples. 
The PCR profile was as follows: one cycle of 95°C for 10 min, then 40 cycles of 95°C 
for 15 s and 60°C for 1 min. The comparative CT method was used for relative 
quantitation of samples.   
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The following primers were used: 
TBP, forward, 5′-TGCACAGGAGCCAAGAGTGAA-3′;  
TBP, reverse, 5′-CACATCACAGCTCCCCACCA-3′ 
ZBTB10 (F): 5′-GCTGGATAGTAGTTATGTTGC-3′ 
ZBTB10 (R): 5′-CTGAGTGGTTTGATGGACAGA-3′ 
 
RESULTS 
RKO and SW480 colon cancer cells were initially used as models for this study, RKO 
cells express wild-type Ras and p53; in contrast SW480 cells express mutated forms of 
Ras (K12Val) and p53 (Arg 273 His). Treatment of both cell lines with  (DMSO or 
ethanol) (control), 5, 10 or 15 µM CBD decreased cell growth and IC50 values after 
treatment for 24 hr were 5.08 and 13.65 µM for SW480 and RKO cells respectively (Fig. 
34A). Longer term treatment with CBD demonstrate that the minimum effective 
concentrations for growth inhibition were 5 and 10 µM for SW480 and RKO cells 
respectively indicating the enhance sensitivity of the former cell line to the growth 
inhibitory effects of CBD. Subsequent studies were focused on early events induced by 
CBD in these cell lines and therefore higher concentrations of CBD (10 – 15 µM) were 
used. Results in Figure 34B show that treatment with 15 µM CBD for 9 hr  induced 
annexin V staining in SW480 and RKO cells and this was also accompanied by 
enhanced cleaved PARP (Fig. 34C) indicating that CBD induced apoptosis in both cell 
lines. 
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We also examined the effects of CBD on prototypical gene products associated with cell 
growth, survival and angiogenesis and observed that CBD decreased expression of 
  
 
Figure 34. CBD inhibits colon cancer cell growth, induces apoptosis and PARP cleavage.  (A) SW480 
and RKO cells were treated with DMSO or ethanol and 5-15 M CBD for 24, 48 and 72 hr and counted, 
or (B) treated with DMSO or ethanol and 15 M of CBD for 9 hr and effects on Annexin V (SW480 and 
RKO) staining was determined.  Results are expressed as means  SE for at least three separate 
determinations, and significant (p < 0.05) induction (*) or inhibition (**) by CBD is indicated.  (C) Cells 
were treated with DMSO or ethanol and 5-15 M of CBD for 24 hr and whole cell lysates were examined 
for expression of cleaved PARP by western blots.  -Actin served as a loading control for all western 
blots. 
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Figure 34. Continued 
 
 
EGFR, cyclin D1 and survivin proteins (Fig. 35A) and also decreased expression of the 
angiogenic proteins VEGF and VEGFR1 proteins (Fig. 35B). Previous studies with 
betulinic acid (BA) which is a newly discovered cannabinoid (684) showed that BA also 
downregulated the same set of genes and this was due to decreased expression of Sp1, 
Sp3 and Sp4 proteins in SW480 and RKO cells (Fig. 35C) and this is consistent with 
decreased expression of Sp-regulated gene products (Figs. 35A and 35B). Moreover, 
silencing of Sp1, Sp3 and Sp4 by RNAi in SW480 cells (Fig. 35D) also shows that one 
or more of these genes regulates cyclin D1 and EGFR and also apoptosis (cleaved 
PARP). 
 
Previous studies with BA demonstrated that the CB receptors were involved in 
repression of Sp-TFs (684);  in contrast, CBD-induced downregulation of Sp1, Sp3 and 
Sp4 was not inhibited in SW480 (Fig. 36A) or RKO (Fig. 36B) cells cotreated with the 
CB1 and CB2 receptor antagonists AM251 and AM630 respectively. Moreover, we also 
confirmed by combined knockdown of the CB1 and CB2 receptors  in SW480 (Fig. 
36C) and RKO (Fig. 36D) cells that these receptor were not involved in the effects of 
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CBD on Sp TFs. Previous studies show that the effects of CBs may also involve other 
pathways  and this includes induction of ceramide (proapoptotic) and ROS (677, 843); 
the latter  response has previously been linked to downregulation of Sp1, Sp3 and Sp4  
 
 
 
Figure 35. CBD downregulates Sp-regulated proliferative, survival (A) and angiogenic (B) gene products 
and Sp proteins (C) in SW480 and RKO cells. Cells were treated with 5-20 M of CBD for 24 hr, (D) 
cells were transfected with Sp1,Sp3 and Sp4 siRNAs  and whole cell lysates were analyzed by western 
blots. 
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Figure 35. Continued 
 
 
through ROS-dependent downregulation of miR-27a and induction of the Sp repressor, 
ZBTB10 (672, 675, 872, 887). Using SW480 cells as a model we observed that the 
ceramide synthase inhibitors fumonisin B1 or ISP1 (Fig. 37A) or the antioxidants DTT 
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or GSH (Fig. 37B) did not inhibit the effects of CBD on repression of Sp1, Sp3 and Sp4. 
Moreover, the proteasome inhibitors gliotoxin and lactacystin do not inhibit CBD-
induced effects on Sp1, Sp3 and Sp4 (Fig. 37C) and therefore this degradation pathway 
which plays a role in drug-induced Sp degradation in some cancer cells (638-640) is not 
activated by CBD in SW480 cells. 
 
 
Figure 36. Effects of cannabinoid receptor antagonists, and cannabinoid receptor knockdown on CBD-
mediated downregulation of Sp proteins.  SW480 (A) and RKO (B) cells were pre-treated with AM251 (4 
M) and AM630 (5 M) for 45 min followed by treatment with 15 M of CBD for 24 hr, and whole cell 
lysates were analyzed by western blots. SW480 (C) and RKO (D) cells were transfected with siRNAs 
against CB1 and CB2 receptors, followed by treatment with CBD for 24 hr, and whole cell lysates were 
analyzed by western blots.   
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Figure 36. Continued 
 
 
 
Figure 37. Effects of ceramide synthase inhibitors, antioxidants and proteasome inhibitors on CBD-
mediated downregulation of Sp proteins.  SW480 cells were pre-treated with fumonisin B1 (10 μM), ISP1 
(5 μM) (A), DTT (1 mM) or GSH (5 mM) (B), lactacystin (10 M) or gliotoxin (3 M) (C) for 45 min 
followed by treatment with 15 M of CBD for 24 hr, and whole cell lysates were analyzed by western 
blots.   
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Figure 37. Continued 
 
In previous studies we showed that CBD-induced apoptosis in LNCap and SW480 cells 
was attenuated by the phosphatase inhibitor SOV (858) and results in Figure 38A show 
that SOV significantly inhibited downregulation of Sp1, Sp3 and Sp4 by CBD in SW480 
cells. CBD induces MKP-1 and MKP-5 in colon cancer cells (858) and both 
phosphatases have previously been linked to downregulation of Sp1 (832, 888); 
however, results in Figure 38B show that silencing of MKP-1 or MKP-5  does not alter 
CB-mediated effects on Sp1, Sp3 or Sp4 (Fig. 38B). Moreover, silencing of PP2A also 
does not affect this response (Fig. 38C) even though this phosphatase plays a role in 
WIN-mediated repression of Sp proteins in the same cell line (see Chapter III). We also 
observed that CBD induces expression of the Sp repressor ZBTB10 mRNA and protein 
(Fig. 38D) and suppresses levels of microRNA miR27a in SW480 cells and this is 
consistent with the effects of CBD on Sp1, Sp3 and Sp4 protein expression since 
previous studies show that ZBTB10 is regulated by miR27a and overexpression of 
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ZBTB10 or miR-27a antagomirs downregulate Sp proteins in colon cancer cells (872). 
Current studies are focused on the pathways linking induction of phosphatases by CBD 
to the subsequent induction of ZBTB10. 
 
 
 
Figure 38. Effects of phosphatase inhibition on CBD-dependent downregulation of Sp proteins and CBD-
dependent modulation of miR27a and ZBTB10 expression. (A)  Cells were pre-treated with 0.35 mM 
SOV for 45 min followed by treatment with 15 M of CBD for 24 hr, and whole cell lysates were 
analyzed by western blots.  Cells were transfected with siRNA against phosphatase MKP-1 (iMKP1) and 
MKP-5 (iMKP5) (B) and PP2A (iPP2A) (C), followed by treatment with CBD for 24 hr and whole cell 
lysates were examined for expression of Sp1, Sp3, Sp4 and MKP-1 and MKP-5 proteins, (D) SW480 cells 
were treated with DMSO or 15 M of CBD for 4, 8, 12, 18 and 24 hr, and whole cell lysates were 
analyzed for ZBTB10 protein by western blots. Cells were treated with DMSO or ethanol and 10-15 µM 
of CBD for 24 hr and ZBTB10 expression and miR27a levels were determined by qPCR as described in 
the Materials and Methods. Results for RNA expression are expressed as means  SE for at least three 
separate determinations, and significant (p < 0.05) inhibition (**) and induction (*) by CBD are indicated. 
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Figure 38. Continued 
B 
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DISCUSSION 
CBs are emerging as an important class of anticancer agents that target multiple pro-
oncogenic pathways. Results obtained using Δ9THC and other putative CB receptor 
agonists demonstrate that many of the critical pathways and genes that are modulated by 
CBs are CB1 and CB2 receptor-dependent. For example, Δ9THC induces stress 
responses in cancer cells and this includes stress-regulated proteins (p8) and other stress 
markers which result in the induction of apoptosis (836, 859). Induction of p8 by Δ9THC 
is partially blocked by CB1 and CB2 receptor antagonists and also by ceramide synthase 
inhibitors indicating an important role for ceramide in activating the stress pathways. 
Studies in this laboratory have been examining the anticancer activities of several 
phytochemicals and their derivatives as anticancer agents and one of these compounds, 
the naturally-occurring triterpenoid BA inhibits growth of multiple cancer cell lines in 
vitro and tumors in vivo (639, 667, 684, 836). Our results show that BA decreased 
expression of Sp1, Sp3 and Sp4 and pro-oncogenic Sp-regulated genes in prostate, colon 
and breast cancer cells. Subsequent studies showed that BA competitively bound the 
CB1 and CB2 receptors and in colon and breast cancer cells BA-mediated repression of 
Sp TFs was CB receptor-dependent and in colon cancer cells induction of ROS by BA 
also contributed to decreased expression of Sp TFs (667, 684). 
 
These observations suggested that an important underlying mechanism of action of CBs 
may be due to downregulation of Sp1, Sp3, Sp4 and Sp regulated genes and we initiated 
studies on the synthetic CB WIN 55, 212-2 and CBD in colon cancer cells. Both 
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compounds induced apoptosis in LNCaP and SW480 cells and these effects were 
inhibited after cotreatment with the phosphatase inhibitor SOV (858). In this study we 
observed that like BA, CBD decreased expression of Sp1, Sp3, Sp4 and several pro-
oncogenic Sp-regulated genes (Fig. 35). These results are consistent with the growth 
inhibitory and pro-apoptotic effects of CBD (Fig. 34); moreover silencing of Sp1, Sp3 
and Sp4 by RNA interference confirmed that one or more of these proteins regulated 
expression of cyclin D1 and EGFR and induce expression of cleaved PARP, a marker of 
apoptosis (Fig. 35D). 
 
Previous studies on the mechanisms of drug-induced downregulation of Sp TFs have 
identified two major pathways, namely induction of caspases or proteasomes (638, 639, 
889) that degrade Sp proteins or a mechanism which involves transcriptional repression 
of Sp TFs and Sp-regulated genes (667, 672, 675, 887). This latter pathway has been 
characterized for drugs that induce ROS and this response is both drug and cell context 
dependent. For example, curcumin induced ROS-dependent repression of Sp proteins in 
pancreatic cancer cells (887) but proteasome dependent degradation in bladder cancer 
cells (640). Although the mechanism of ROS-mediated repression of Sp1, Sp3 and Sp4 
is not fully understood, it has been shown that ROS induces ZBTB10 or another Sp 
repressor ZBTB4 through downregulation of miR-27a or miR-20a/miR-17-5p 
respectively (672, 887). Both ZBTB10 and ZBTB4 are transcriptional repressors that 
competitively bind and displace Sp proteins from GC-rich cis-elements and this results 
in decreased gene expression (641, 890). Results obtained in this study  show that CBD 
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does not induce Sp degradation through activation of proteasomes  (Fig.37C) and 
cotreatment of colon cancer cells with CBD plus antioxidants (DTT or GSH) does not 
block Sp downregulation (Fig. 37B). In contrast, we observed that CBD induced the 
transcriptional repressor ZBTB10 and decreased levels of miR27a (Fig. 38D) and 
current studies are investigating the role of CBD-induced phosphatases in mediating 
repression of Sp1, Sp3 and Sp4 and in the induction of ZBTB10. Thus CBD represents 
another cannabinoid (in addition to BA) that acts, in part, as an anticancer agent through 
repression of Sp proteins. These data exhibit some overlap with results of ongoing 
studies using the synthetic CB WIN-55, 212-2 which also induces phosphatase-
dependent repression of Sp1, Sp3 and Sp4 through CB receptor-independent pathways 
however, the effects of WIN are PP2A-dependent. It will be important to determine the 
prevalence of this mechanism for other CBs in various cancer cell lines since this will 
facilitate clinical development of CBs for treatment of cancer in combination with other 
anticancer drugs. 
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CHAPTER V 
 1,1-BIS(3'-INDOLYL)-1-(P-BROMOPHENYL)METHANE AND 
RELATED COMPOUNDS REPRESS SURVIVIN AND DECREASE 
-RADIATION-INDUCED SURVIVIN IN COLON AND 
PANCREATIC CANCER CELLS* 
 
INTRODUCTION 
Survivin is a 16.5 kDa protein and a member of the inhibitor of apoptosis (IAP) family 
of proteins that suppress caspase-3, caspase-7 and caspase-9 and thereby inhibits both 
the extrinsic and intrinsic apoptotic pathways (891-893).  In addition to the anti-
apoptotic activity of survivin, this protein also acts as a subunit of the chromosomal 
passenger complex and plays a role in cell division and cell cycle control (894).  
Survivin expression in normal tissues is variable (895-899); however, several studies 
show that survivin is more highly expressed in precancerous and tumor tissue derived 
from most solid tumors and hematological malignancies (893, 895, 900, 901).  
Intuitively, overexpression of survivin and other IAPs is not unexpected since cancer 
cells and tumors typically exhibit deregulated proliferative and survival pathways.   
 
 
 
*Reprinted with permission from “1,1-bis(3'-indolyl)-1-(p-bromophenyl)methane and 
related compounds repress survivin and decrease -radiation-induced survivin in colon 
and pancreatic cancer cells” by Sreevalsan S, Jutooru I, Chadalapaka G, Safe SH, 2009. 
Int J Oncol, 35 (5) 1191-1199, Copyright [2009] by: International Journal of Oncology. 
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High levels of survivin expression in cancer cells are due, in part, to several factors 
which regulate survivin at the transcriptional and posttranscriptional level.  For example, 
several cancer cell lines overexpress specificity protein (Sp) transcription factors Sp1, 
Sp3 and Sp4 which in turn increase survivin expression through interaction with GC-rich 
cis-elements in the survivin promoter (863, 902, 903).  Nuclear factor kappa B (NFB) 
is overexpressed in multiple tumor types and in some leukemia cell lines, expression of 
survivin is regulated by NFB (904).  In other leukemia cell lines, Krüppel-like factor 5 
(KLF5) upregulates survivin expression and inhibits p53 which mediates suppression of 
survivin (905, 906). 
 
Several studies report that survivin overexpression is a negative prognostic factor for 
cancer patient survival (893, 907-911).  For example, increased nuclear (but not 
cytosolic) survivin expression was associated with a decreased overall survival for breast 
cancer patients (907).  Survivin expression in tumors is not only a negative prognostic 
factor, but expression of this gene has also been linked to drug resistance associated with 
chemotherapy and radiotherapy (912-919).  Resistance to antiandrogen and cis-platin 
therapy for treatment of prostate cancer is mediated by survivin (912, 913) and taxol 
resistance has also been linked to induction of survivin in cancer cell lines and tumors 
(914, 915).  Radiotherapy is important for treating several types of tumors and 
radioresistance is related, in part, to induction of survivin in tumors undergoing 
radiotherapy (916-919).  These observations suggest that survivin may be an important 
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chemotherapeutic target for cancer chemotherapy and agents that decrease survivin 
expression could also serve to ameliorate drug- and radiotherapy-resistant tumors in  
which survivin expression is increased. 
 
Research in this laboratory has identified a series of 1,1-bis(3'-indolyl)-1-(p-substituted 
phenyl) methanes (C-DIMs) that inhibit pancreatic, colon, prostate, bladder and breast 
cancer cell and tumor growth (920-925).  C-DIMs containing p-phenyl, p-t-butyl and p-
trifluoromethyl substituents activate peroxisome proliferator-activated receptor  
(PPAR) (920-923), whereas p-methoxy and unsubstituted C-DIMs activate the orphan 
receptor Nur77 (924, 925).  Other receptor-inactive C-DIMs including 1,1-bis(3'-
indolyl)-1-(p-bromophenyl)methane (DIM-C-pPhBr) and the corresponding 2,2'-
dimethyl derivative (2,2'-diMeDIM-C-pPhBr) also induce apoptosis in cancer cells 
through activation of ER stress (926, 927).  In this study, we demonstrate that DIM-C-
pPhBr and 2,2'-diMeDIM-C-pPhBr decrease survivin expression in pancreatic and colon 
cancer cells and in combination with radiotherapy, these compounds decrease 
radioresistance and inhibit radiation-induced survivin expression. 
 
MATERIALS AND METHODS 
Chemicals, Antibodies, Plasmids, and Reagents 
C-DIMs were synthesized in this laboratory from the condensation of indole or 
substituted indole plus a substituted benzaldehyde derivative and confirmed by gas 
chromatography-mass spectrometry as described previously (920, 926, 927).  Cleaved 
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poly (ADP-ribose) polymerase (PARP) antibody was obtained from Cell Signaling 
(Danvers, MA).  Survivin antibody was purchased from R and D Systems (Minneapolis, 
MN); -actin antibodies were purchased from Sigma-Aldrich (St. Louis, MO); and 
proteasome inhibitor MG132 was purchased from Calbiochem (San Diego, CA).  The 
pSurvivin-269 constructs containing survivin promoter inserts (positions -269 to +49) 
linked to luciferase reporter gene was kindly provided by Dr. M. Zhou (Emory 
University, Atlanta, GA).  Reporter lysis buffer and luciferase reagent for luciferase 
studies were purchased from Promega (Madison, WI).  -Galactosidase (-gal) reagent 
was obtained from Tropix (Bedford, MA).  Lipofectamine reagent was supplied by 
Invitrogen (Carlsbad, CA).  Western lightning chemiluminescence reagent was from 
Perkin Elmer Life Sciences (Boston, MA). 
 
Cell Lines 
SW480 human colon carcinoma cell lines were provided by Dr. Stanley Hamilton (M.D. 
Anderson Cancer Center, Houston, TX).  Panc28 cell line was a generous gift from Dr. 
Paul Chiao, The University of Texas M.D. Anderson Cancer Center (Houston, TX).  
Human pancreatic Panc1 cancer cell line were obtained from the American Type Culture 
Collection (Manassas, VA).  The L3.6pl cell line was developed at The University of 
Texas M.D. Anderson Cancer Center.  Cell lines were maintained in DMEM/F-12 
(Sigma, St. Louis, MO) supplemented with 2.2% sodium bicarbonate, 2.2% bovine 
serum albumin, 5% fetal bovine serum, and 10 ml/L of 100X antibiotic antimycotic 
solution (Sigma).  Cells were maintained at 37C in the presence of 5% CO2. 
 223 
 
 
Cell Proliferation Assay 
Pancreatic and colon cancer cells (3 x 104 per well) were plated in 12-well plates and 
allowed to attach for 24 hr.  The medium was then changed to DMEM/Ham’s F-12 
medium containing 2.5% charcoal-stripped FBS, and either vehicle (DMSO) or different 
concentrations of the compound were added.  Cells were then trypsinized and counted 
after 24 hr using a Coulter Z1 cell counter.  Each experiment was done in triplicate, and 
results were expressed as means  SE for each set of experiments. 
 
Transfection and Luciferase Assay 
Colon cancer cells were plated in 12-well plates at 1x105 per well in DMEM/Ham’s F-
12 media supplemented with 2.5% charcoal-stripped FBS.  After 16 to 20 hr, reporter 
gene constructs [i.e. pSurvivin-269 (0.04 Ag) and -gal (0.04 Ag)] were transfected by 
Lipofectamine (Invitrogen) according to the manufacturer’s protocol.  Five hr after 
transfection, the transfection mix was replaced with complete media containing either 
vehicle (DMSO) or the indicated compound for 20 to 22 hr.  Cells were then lysed with 
100 L of 1X reporter lysis buffer, and 30 L of cell extract were used for luciferase and 
-gal assays.  Lumicount was used to quantitate luciferase and -gal activities, and the 
luciferase activities were normalized to -gal activity. 
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Western Blots 
Colon and pancreatic cancer cells were seeded in DMEM:Ham's F-12 medium.  Twenty-
four hr later, cells were treated with either vehicle (DMSO) or the indicated compounds 
for 24 hr or pretreated with the proteasome inhibitor, MG132 (10 M) for 1 hr and then 
treated with the compounds.  Cells were lysed using high-salt buffer and Protease 
Inhibitor Cocktail.  Protein lysates were separated on 12% SDS-PAGE 120 V for 4 hr.  
Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes by wet 
electroblotting and the membranes were incubated with primary antibody.  After 
washing with TBST, the PVDF membrane was incubated with secondary antibody in 5% 
TBST-Blotto and the membrane was washed with TBST for 10 min, incubated with 
chemiluminescence substrate for 1 min, and exposed to Kodak autoradiography film. 
 
Irradiation 
Colon and pancreatic cancer cells were plated and exposed to varying doses of -
radiation generated from a Theratron 80 cobalt-60 teletherapy machine (Atomic Energy 
of Canada) with a dose rate of 80.166 cGy/minute (same as 0.8016 Gray per minute or 
80.166 rads/minute), for a 30x30 cm field, at a source-surface distance of 80 cm.  The 
irradiated cells were then treated with the indicated compounds after 8 hr, and cells were 
counted or lysates were obtained after the indicated treatment times. 
 
 
 
 225 
 
Real-Time PCR   
Total RNA was isolated using the RNeasy Protect Mini kit (QIAGEN, Valencia, CA) 
according to the manufacturer's protocol.  RNA was eluted with 30 L of RNase-free 
water and stored at -80C.  RNA was reverse-transcribed using Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer's protocol.  cDNA was prepared 
from the SW480 colon and Panc28 pancreatic cancer cell lines at different time intervals 
using a combination of oligodeoxythymidylic acid and dNTP mix (Applied Biosystems, 
Foster City, CA) and Superscript II (Invitrogen).  Survivin primers (forward 5'-ATG 
GCC GAG GCT GGC TTC ATC-3'; reverse 5'-ACG GCG CAC TTT CTT CGC AGT 
T-3') were acquired from IDT (Skokie, IL).  Each PCR was carried out in triplicate in a 
20-L volume using SYBR Green Master mix (Applied Biosystems) for 15 min at 95C 
for initial denaturing, followed by 40 cycles of 95C for 30 sec and 60C for 1 min in the 
ABI Prism 7500 sequence detection system (Applied Biosystems).  Values for each gene 
were normalized to expression levels of TATA-binding protein (TBP). 
 
RESULTS 
Treatment of colon and pancreatic cancer cells with DIM-C-pPhBr or 2,2'-diMeDIM-C-
pPhBr induces apoptosis and ER stress (926, 927) and results in Figure 39A show that 
after treatment of SW480 cells with these compounds for 24 hr, there was significant 
concentration-dependent decrease in cell proliferation.  Both C-DIMs decreased cell 
numbers at concentrations of 10 or 15 M and at a concentration of 5 M, DIM-C-
pPhBr also inhibited SW480 cell growth, whereas 2,2'-diMeDIM-C-pPhBr was inactive.  
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Figures 39B and 39C show that both compounds also induce caspase-dependent PARP 
cleavage (15 and 20 M) and at these same concentrations there was a parallel decrease 
in survivin expression in SW480 cells.  In addition, we also observed that both C-DIM 
compounds decreased survivin mRNA expression after treatment for 24 hr (Fig. 39D). 
 
 
 
Figure 39.  Effects of C-DIMs on SW480 cell proliferation and expression of survivin and cleaved PARP.  
Concentration-dependent effects on cell proliferation (A) and survivin and c-parp protein expression (B 
and C).  Cells were treated with DMSO and different concentrations of DIM-C-pPhBr or 2,2'-diMeDIM-
C-pPhBr for 24 hr.  Cells were counted (A) or whole cell lysates were analyzed by western blots as 
described in the Materials and Methods.  (D) Survivin mRNA levels.  Cells were treated with DMSO or 
10-20 M of C-DIM compounds, and survivin mRNA levels were determined by real time PCR as 
described in the Materials and Methods.  A significantly (p < 0.05) decreased response is indicated (*).  -
Actin served as a loading control for all western blots in Figures 39 –27. 
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Figure 39. Continued 
 
 
 
Figure 40. Effects of C-DIMs on Panc28 cell proliferation and expression of survivin and c-parp. 
Concentration-dependent effects on cell proliferation (A) and survivin and c-parp protein expression (B 
and C). Cells were treated with DMSO and different concentrations of DIM-C-pPhBr or 2,2'-diMeDIM-C-
pPhBr for 24 h. Cells were counted (A) or whole cell lysates were analyzed by Western blot analyses aals 
as described in Materials and methods. (D) Survivin mRNA levels. Cells were treated with DMSO or 10-
20 μM of C-DIM compounds, and survivin mRNA levels were determined by real-time PCR as described 
in Materials and methods. *A significantly (p<0.05) decreased response is indicated. 
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Figure 40. Continued 
 
DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr also inhibited Panc28 pancreatic cancer cell 
growth (Fig. 40A) and significant inhibition was observed at concentrations of 15-20 
µm.  DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr also induced PARP cleavage and 
decreased survivin protein levels in Panc28 cells (Figs. 40B and 40C) and this was also 
accompanied by decreased survivin mRNA levels.  All of these responses were observed 
after treatment of SW480 or Panc28 cells for 24 hr.  IC50 values for growth inhibition 
after treatment with DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr were 10.8 and 8.3 M 
(SW480) and 9.4 and 8.8 M (Panc28), respectively. 
 
We also investigated the time dependent effects of DIM-C-pPhBr and 2,2'-diMeDIM-C-
pPhBr on survivin protein and cleaved PARP expression using a relatively high 
concentration (20 M) of both compounds in order to determine differences between the 
temporal expression of both proteins.  In SW480 cells, 20 M DIM-C-pPhBr and 2,2'-
diMeDIM-C-pPhBr decreased levels of survivin protein within 2 hr after treatment, 
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whereas cleaved PARP protein was observed only after treatment for 12 hr (Figs. 41A 
and 41B).  Similar results were observed in Panc28 cells (Fig. 41C and 41D); however, 
the extent of survivin degradation after treatment for 2 hr was lower in Panc28 compared 
to SW480 cells.  These results show that there was a lag between the loss of survivin and 
induction of cleaved PARP in both cell lines. 
 
   
 
Figure 41.  Time course effects of DIM-C-pPhBr (20 M) and 2,2'-diMeDIM-C-pPhBr (20 M) on 
survivin and c-parp expression.  SW480 cells were treated with DIM-C-pPhBr (A) or 2,2'-diMeDIM-C-
pPhBr (B) and Panc28 cells were treated with DIM-C-pPhBr (C) or 2,2-diMeDIM-C-pPhBr (D) for 2, 12 
or 24 hr.  DMSO treatment served as a vehicle control.  Whole cell lysates were analyzed by western blots 
as described in the Materials and Methods.   
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Figure 41. Continued 
 
Figures 42A and 42B illustrate the effects of 20 M DIM-C-pPhBr and 2,2'-diMeDIM-
C-pPhBr on survivin mRNA levels in SW480 and Panc28 cells.  Both compounds either 
had no effect or induced survivin mRNA levels after treatment of SW480 or Panc28 
cells for 2 hr; significant inhibition of survivin mRNA levels was observed in SW480 
and Panc28 cells after 12 hr; however, the magnitude of survivin mRNA repression was 
more pronounced in the colon cancer cells.  Thus, the effects of DIM-C-pPhBr and 2,2'-
diMeDIM-C-pPhBr on survivin mRNA levels were observed at later time points 
compared to the rapid downregulation (within 2 hr) of survivin protein (Fig. 41). 
 
We also confirmed that DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr decreased luciferase 
activity in SW480 cells transfected with pSurvivin-269, a construct containing the -269 
to +49 region of the survivin promoter (Fig. 42C).  Results were not obtained in Panc28 
cells due to low transfection efficiencies in this cell line.  Since DIM-C-pPhBr and 2,2'-
diMeDim-C-pPhBr decreased survivin protein but not mRNA levels within 2 hr after 
treatment, we investigated the effects of these compounds alone and in combination with  
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Figure 42.  C-DIM-dependent effects on survivin expression.  Changes in survivin mRNA expression in 
SW480 (A) and Panc28 (B) cells.  Cells were treated with 20 M DIM-C-pPhBr or 2,2'-diMeDIM-C-
pPhBr for 24 hr, and survivin mRNA levels were determined by real time PCR as described in the 
Materials and Methods.  (C) Effects on the survivin promoter.  SW480 cells were transfected with 
pSurvivin(269) and treated with DMSO or the C-DIM compounds.  Luciferase activity was determined as 
described in the Materials and Methods.  (D) Effects of MG132. SW480 cells were treated with DMSO, 
C-DIM compounds alone (20 M), 10 M MG132, or a combination of C-DIMs plus MG132 for 4 hr.  
Whole cell lysates were analyzed by western blots as described in the Materials and Methods.  
Significantly (p < 0.05) decrease mRNA levels or luciferase activity (compared to DMSO) is indicated (*). 
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Figure 43.  Effects of -radiation on cell proliferation and survivin expression.  SW480 (A) and Panc28 
(B) cell growth and expression of survivin in SW480 (C) and Panc28 (D) cells.  Cells were treated with 
DMSO (control) and irradiated with 2, 5 or 10 Gy for 24 or 48 hr, and cell number and survivin protein 
expression (from whole cell lysates) were determined as described in the Materials and Methods. 
 
the proteasome inhibitor MG132 after treatment of SW480 cells for 4 hr (Fig. 42D).  The 
results show that C-DIM-dependent downregulation of survivin protein was partially 
reversed by the proteasome inhibitor, suggesting that activation of proteasomes 
contributed to the early decrease in survivin expression. 
 
 
 233 
 
 
 
Figure 44.  Interactions of -radiation and C-DIMs.  (A) Effects of C-DIM on -radiation-induced survivin 
protein expression.  Cells were treated with DMSO, C-DIMs (20 M), radiation (10 Gy), or C-DIMs plus 
radiation for 24 hr.  Whole cell lysates were analyzed by western blots as described in the Materials and 
Methods.  Effects of C-DIMs and radiation on proliferation of SW480 (B) and Panc28 cells (C).  Cells 
were treated with DMSO, C-DIMs and radiation as described in (A), and cell numbers were determined as 
described in the Materials and Methods.  (D) Concentration-dependent effects of C-DIMs on -radiation-
induced survivin protein expression.  SW480 cells were treated with DMSO; 5, 10 or 15 M DIM-C-
pPhBr or 2,2'-diMeDIM-C-pPhBr alone; or in combination with -radiation for 24 hr.  Whole cell lysates 
were analyzed by western blots as described in the Materials and Methods. 
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Figure 44. Continued 
 
 
 
 
Figure 45.  Effects of -radiation on growth of Panc1 (A) and L3.6pl (B) pancreatic cancer cells and 
expression of survivin in Panc1 (C) and L3.6pl (D) cells.  Experiments were performed as described in the 
Materials and Methods.  -Actin was used as a protein loading control.  
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Since DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr inhibit survivin protein expression, the 
interactions of these compounds with radiotherapy were investigated.  Figure 43A 
illustrates the effects of -radiation on proliferation of SW480 cells.  Cells were 
administered doses of 2, 5 and 10 Gy using a Theatron 80 cobalt-60 teletherapy 
instrument and the effects of radiation on cell growth were determined after 24 and 48 
hr. This cell line was responsive to radiation-induced inhibition of cell growth and after 
24 hr, significant inhibition was observed using 5 and 10 Gy (but not 2 Gy) and all three 
doses of radiation inhibited cell growth after 48 hr.  Using a similar protocol, -radiation 
also inhibited Panc28 cell proliferation (Fig. 43B); however, this cell line was clearly 
more resistant to radiotherapy than SW480 cells over this time period and significant 
growth inhibition was observed only after 24 hr.  The effects of -radiation on survivin 
expression were also investigated in SW480 (Fig. 43C) and Panc28 (Fig. 43D) cells and 
in both cell lines, 5 and 10 Gy induced survivin expression after radiation for 24 hr, 
whereas induction of survivin was either decreased or not observed after 48 hr.  -
Radiation also induced survivin and decreased proliferation of Panc1 and L3.6pl 
pancreatic cells and both cell lines were more responsive than Panc28 cells to the 
antiproliferative activity of -radiation (Fig. 45). 
 
The combined effects of -radiation and C-DIM compounds on survivin expression are 
summarized in Figures 44A and 44B.  Treatment of SW480 cells with 20 M DIM-C-
pPhBr or 2,2'-diMeDIM-C-pPhBr for 24 hr showed that the C-DIMs alone decreased 
survivin, -radiation alone increased survivin and C-DIMs in combination with radiation 
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decreased radiation-induced survivin expression.  Similar effects were observed on cell 
numbers in SW480 or Panc28 cells (Fig. 44C); however, the high concentrations (20 
M) of the C-DIM alone significantly decreased cell proliferation so that the interactions 
with -radiation were not apparent.  We also examined the effects of lower 
concentrations of DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr (5, 10 and 15 M) on 
inhibition of -radiation-induced induction of survivin in SW480 cells (Fig. 44D).  
Inhibition was only observed using 15 M concentrations of C-DIMs and these 
concentrations alone also decreased levels of survivin protein.  These results 
demonstrate that combinations of C-DIMs plus -radiation decrease radiation-induced 
survivin which plays a role in radioresistance. 
 
DISCUSSION 
Overexpression of survivin in cancer cell lines and tumors coupled with the negative 
prognostic significance of this gene for the survival of patients with some tumors has 
heightened interest in survivin as a potential drug target (893, 895, 901).  It is also 
important to evaluate the effects of both old and new drugs on survivin expression since 
it has been demonstrated that increased expression of survivin by taxol-like drugs and 
radiotherapy can lead to therapy resistance (914-919).  Several reports show that diverse 
drugs can downregulate survivin expression and these include:  vitamin D3 and related 
analogs in leukemia and breast cancer cells (928); PPAR agonists in breast cancer cells 
(929); doxorubicin, histone deacetylase inhibitors and lovastatin (an inhibitor of 3-
hydroxy-3-methylglutaryl coenzyme A reductase) in colon cancer cells (930-932); 
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cyclooxygenase-2 inhibitors in glioblastoma and pancreatic cancer cells (933) and -
tocotrienol in human embryonic kidney A93 cells (934).  The mechanisms of survivin 
downregulation by these drugs are dependent on cell context. 
 
Previous studies in this laboratory showed that PPAR-active C-DIMs downregulate 
survivin expression in MDA-MB-231 breast cancer cells after prolonged treatment; 
however, this was not accompanied by apoptosis (922).  In contrast, DIM induced 
growth inhibition, apoptosis and downregulated survivin expression in MDA-MB-231 
cells (935). DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr do not activate PPAR or Nur77 
but induced apoptosis in colon and pancreatic cancer cells, and activation of apoptosis 
by these compounds was due, in part, to ER stress-dependent upregulation of death 
receptor 5 (926, 927).  In this study, we used these same compounds to investigate their 
effect on survivin expression in colon and pancreatic cancer cells and their potential 
interactions with -radiation.  Like many other anticancer agents, C-DIMs potentially 
activate multiple pathways and we focused on some of the early responses induced by 
these compounds within 24 hr after treatment.  Concentration-dependent studies indicate 
that 10-20 M DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr decrease survivin protein 
expression in SW480 and Panc28 cells (Figs. 39 and 40) and this is accompanied by 
caspase-dependent PARP cleavage.  Using a relatively high concentration (20 M) of 
the C-DIM compounds demonstrates that survivin downregulation occurs within 2 hr 
after treatment in both SW480 and Panc28 cells (Fig. 41), whereas in the same 
experiment PARP cleavage is not observed until a later time point.  This does not 
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necessarily completely uncouple loss of survivin with induction of caspase-dependent 
PARP cleavage but indicates at least that this rapid downregulation of survivin is not 
paralleled by PARP cleavage.  Interestingly, we also observed that rapid downregulation 
of survivin protein in SW480 and Panc28 cells treated with DIM-C-pPhBr or 2,2'-
diMeDIM-C-pPhBr was not accompanied by decreased survivin mRNA levels after 2 hr 
since decreased transcription was not observed until 12-24 hr after treatment in both cell 
lines (Fig. 42).  Moreover, the proteasome inhibitor MG132 blocked C-DIM-induced 
downregulation of survivin protein after treatment of SW480 cells for 4 hr (Fig. 42D).  
These results suggest that the C-DIM compounds downregulate survivin expression by 
both transcription-independent and -dependent pathways, and current studies are focused 
on the mechanisms associated with activation of these pathways by C-DIMs. 
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CHAPTER VI  
SUMMARY 
 
We hypothesized that the anticancer activity of cannabinoids (CBs) was linked to 
induction of phosphatases. The effects of cannabidiol (CBD) and the synthetic 
cannabinoid WIN-55,212 (WIN) on LNCaP (prostate) and SW480 (colon) cancer cell 
proliferation were determined by cell counting; apoptosis was determined by cleavage of 
poly(ADP)ribose polymerase (PARP) and caspase-3 (western blots), and phosphatase 
mRNAs were determined by real-time PCR.  The role of phosphatases and CB receptors 
in mediating CBD- and WIN-induced apoptosis was determined by inhibition and 
receptor knockdown. CBD and WIN inhibited LNCaP and SW480 cell growth and 
induced expression of several phosphatase mRNAs, and the phosphatase inhibitor 
sodium orthovanadate significantly inhibited cannabinoid-induced PARP cleavage in 
both cell lines, whereas only CBD-induced apoptosis was CB1 and CB2 receptor-
dependent. CB receptor agonists induce phosphatases and phosphatase-dependent 
apoptosis in cancer cell lines; however, the role of the CB receptor in mediating this 
response is ligand-dependent. 
 
Cannabinoids (CBs) are currently in clinical trials for treatment of gliomas, and both 
plant-derived and synthetic CBs, such as the synthetic-mixed CB1 and CB2 receptor 
agonist 2,3-dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-ben-
zoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2  (WIN)], inhibit growth of 
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multiple cancer cell lines via receptor-dependent and -independent pathways.  In this 
study, WIN inhibited RKO, HT-29 and SW480 cell growth, induced apoptosis, and 
downregulated expression of survivin, cyclin D1, epidermal growth factor receptor 
(EGFR), vascular endothelial growth factor (VEGF) and its receptor (VEGFR1).  WIN 
also decreased expression of specificity protein (Sp) transcription factors Sp1, Sp3 and 
Sp4, and this is consistent with the observed downregulation of the aforementioned Sp-
regulated genes.  In addition, we also observed by RNA interference (RNAi) that the 
oncogenic cap protein eIF4E was an Sp-regulated gene also downregulated by WIN in 
colon cancer cells.  WIN-mediated repression of Sp proteins was not affected by CB 
receptor antagonists or by knockdown of the receptor but was attenuated by the 
phosphatase inhibitor sodium orthovanadate or by knockdown of protein phosphate 2A 
(PP2A).  WIN-mediated repression of Sp1, Sp3 and Sp4 was due to PP2A-dependent 
downregulation of microRNA-27a (miR-27a) and induction of miR-27a-regulated 
ZBTB10 which has previously been characterized as an "Sp repressor".  The results 
demonstrate that the anticancer activity of the widely used synthetic cannabinoid WIN is 
due, in part, to PP2A-dependent disruption of miR-27a:ZBTB10 and ZBTB10-mediated 
repression of Sp transcription factors and Sp-regulated genes including eIF4E. 
 
Cannabidiol (CBD) is a non-psychotropic phytocannabinoid present in the plant 
cannabis sativa. In addition to its use in treating cancer-related pain, nausea and reduced 
appetite, CBD is a promising anticancer agent that modulates kinase activities and other 
growth inhibitory, pro-apoptotic, antiangiogenic and antimetastatic pathways. In this 
 241 
 
study 5-15 μM CBD inhibited cell proliferation, induced annexin V staining and PARP 
cleavage in SW480 and RKO colon cancer cells. Treatment of SW480 and RKO cells 
with CBD also downregulated gene products associated with cell proliferation (EGFR, 
cyclin D1), angiogenesis (VEGF, VEGFR1) and cancer cell survival (survivin). RNA 
interference studies employing siRNAs for Sp1, Sp3 and Sp4 demonstrated that some of 
these genes such as cyclin D1 and EGFR are regulated by Sp proteins and concentrations 
at which CBD downregulated Sp-dependent genes also inhibited Sp1, Sp3 and Sp4. Co-
treatment of SW480 cells with CB receptor antagonists AM251 and AM630 or siRNAs 
against CB1 and CB2 receptors did not reverse the effects of CBD on Sp transcription 
factors indicating that CBD-mediated repression of Sp proteins was CB receptor 
independent. Moreover, CBD-dependent downregulation of Sp proteins was not affected 
by ceramide synthase inhibitors, proteasome inhibitors or antioxidants but was reversed 
by the phosphatase inhibitor sodium orthovanadate. Knockdown of dual specificity 
phosphatases MKP-1 and MKP-5 or serine threonine phosphatase PP2a did not affect 
block the effects of CBD on Sp1, Sp3 and Sp4 and ongoing studies in the laboratory are 
focused on identifying the phosphatases involved in the anticancer effects of CBD. In 
addition CBD repressed levels of microRNA 27a and induced protein expression of the 
Sp repressor ZBTB10 which is regulated by miR-27a and these results indicate that CBD 
acts in part as an anti-cancer agent through downregulation of Sp proteins. 
 
1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane (DIM-C-pPhBr) and the 2,2'-dimethyl 
analog (2,2'-diMeDIM-C-pPhBr) inhibit proliferation and induce apoptosis in SW480 
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colon and Panc28 pancreatic cancer cells.  In this study, treatment with 10-20 M 
concentrations of these compounds for 24 hr induced cleaved PARP and decreased 
survivin protein and mRNA expression in both cell lines.  However, results of time 
course studies show that DIM-C-pPhBr and 2,2'-diMeDIM-C-pPhBr decrease survivin 
protein within 2 hr after treatment, whereas survivin mRNA levels were decreased only 
at later time points indicating activation of transcription-independent and -dependent 
pathways for downregulation of survivin.  In addition, we also observed that -radiation 
inhibited pancreatic and colon cancer cell growth and this was associated with enhanced 
expression of survivin after 24 (SW480) or 24 and 48 (Panc28) hr and correlated with 
previous studies on the role of survivin in radiation-resistance.  However, in cells 
cotreated with -radiation plus DIM-C-pPhBr or 2,2'-diMeDIM-C-pPhBr, induction of 
survivin by -radiation was inhibited after cotreatment with both compounds, suggesting 
applications for these drugs in combination cancer chemotherapy with -radiation. 
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